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Licé Yulieth González-Angulo 
 
Background 
There are 9.4 million new active TB cases each year and nearly 5,000 TB deaths occur 
every day—mostly in the developing world. Poor and vulnerable groups are at greater risk of 
infection with M. tuberculosis, compared to the general population. Overcrowded living or 
working conditions, poor nutrition, and co-morbidities such as HIV/AIDS, increase the annual 
risk of TB infection and development of TB disease. TB can be controlled by preventing 
infection, and by early treatment of active disease. Rapid identification of sources of infection, 
early diagnostic evaluation, and completion of treatment, have been described as key elements 
for effective TB control. TB control efforts have focused on new diagnostics to identify patients 
with TB, new shorter anti-tuberculosis drug regimens, and innovative infection control 
technologies to reduce the risk of TB exposure. However, many of these advances are not 
readily implemented in resource-constrained settings, where most TB cases occur. 
New effective and field-adapted interventions are needed to improve TB programme 
outcomes. Two projects, which focus on breaking the cycle of TB transmission in developing 
country settings, are reported. First, we evaluate the diagnostic yield of sputum induction, a 















confirmation of TB, and which contributes to the prompt identification of paucibacillary TB 
cases; second, we evaluate how knowledge of TB and acceptability of patient-specific infection 
control measures compares between patients suspected with TB who lack TB education and 
patients with TB, who have received TB education; and we evaluate changes over time in 
patients with TB on treatment. The strategies described here may improve the diagnosis and 
management of potentially infectious patients with suspected pulmonary TB in a developing 
country setting and address major public health objectives; first, early identification and 
diagnosis of TB cases, with rapid treatment initiation; and second, improved, early, and 
intensive TB education to increase the acceptability of patient-specific infection control 
measures, in order to reduce TB transmission at health care facilities, and in home and work 
settings. These field-adapted strategies can provide long-term sustainability to TB control 
programmes where resources are scarce.   
 
 
SPUTUM INDUCTION FOR DIAGNOSIS OF TUBERCULOSIS: 
A SYSTEMATIC REVIEW AND META-ANALYSIS 
 
Studies have assessed sputum induction for the diagnosis of active TB in patients 
who are unable to produce spontaneous sputum; or who have smear-negative spontaneous 
sputum samples; and in children with paucibacillary TB. These studies have compared 
sputum induction to several different comparator methods. The diagnostic yield of culture 
positive M. tuberculosis that might be expected using sputum induction under programmatic 
















 Key findings 
 The diagnostic yield of sputum induction in individual studies ranged from 35% to
95%.
 M. tuberculosis was isolated through sputum induction in 627 cases of 975 culture-
confirmed patients with TB (64%) in 17 studies.
 Sources of heterogeneity which could be attributed to within-study factors (HIV
prevalence and age group) and between-study factors (comparator method) were 
explored by meta-regression. However, significant heterogeneity in diagnostic yield
was not explained by these variables.  
 The findings of this meta-analysis suggest that higher saline concentrations are not
associated with better diagnostic yield in sputum induction, after adjusting for
confounders.
Conclusion 
Prospective, comparative studies of the diagnostic yield of sputum induction are 
needed, with rigorous definition of the study populations and standardization of technique.
PATIENT-SPECIFIC INFECTION CONTROL MEASURES FOR TUBERCULOSIS IN 
DEVELOPING COUNTRIES
Background 
Previous authors have demonstrated that health education should be a continuous 
process which starts when patients are confirmed to have pulmonary TB and continues until 
patients are cured. The association between knowledge of TB and acceptability of patient-
















The following were major findings of this study: 
 Participants showed poor to moderate levels of knowledge regarding TB
disease and measures to reduce TB transmission, coupled with low levels
of acceptability of certain patient-specific measures, at baseline.
 Core knowledge elements, such as understanding of TB transmission
showed low levels of comprehension. 54% of participants claimed to know
how TB was transmitted, but some misconceptions were found in both
patients suspected with TB and in newly diagnosed patients with TB. 
Some participants believed that TB was a hereditary disease, or that it was
spread by sharing food utensils, kissing patients with TB, and living in
cold areas. 
 Patient-specific infection control measures that could be implemented at
health care facilities and at home, showed higher levels of acceptability
than infection control measures to be conducted in work settings.
 We demonstrated that acceptability of these patient-specific infection
control measures increased in relation to improvements in knowledge
about TB, over the course of treatment in patients with TB.
Conclusion 
Public health authorities should design and implement early intensive TB education 
programmes to increase knowledge and acceptability of patient-specific infection control 
measures. These educational resources should be accessible not only for patients suspected 















Each chapter is divided into two sections. The first part comprises aspects related to 
sputum induction for diagnosis of TB; and the second section refers to patient-specific 
infection control measures for TB in developing countries. 
 INTRODUCTION 
The first chapter explores how, in spite of advances in technology to improve TB diagnostics 
and public health measures to control the disease, TB continues to affect individuals of all
ages from communities throughout the developing world. We describe the burden of TB
disease and we provide the rationale for a systematic review and meta-analysis of the 
diagnostic yield of sputum induction. Second, we describe the rationale for a study to 
determine how knowledge and acceptability of patient-specific infection control measures 
changes over time and how implementation of infection control measures might be
optimized by early, intensive TB education to newly diagnosed patients with TB.
 LITERATURE REVIEW 
In the second chapter, we present a literature review of current methods to control TB and 
we summarise two simple and field-adapted measures that could improve TB control in 
developing country settings. The first strategy is a simple and affordable method (sputum 
induction) to improve respiratory specimen collection and provide early diagnosis of TB, 
including paucibacillary TB among immunocompromised patients and children. The second 
strategy focuses on patient-specific infection control measures to prevent TB transmission in 
















 RESEARCH METHODOLOGY 
The third chapter describes the methods used to conduct a systematic review and meta-
analysis of studies reporting the use of sputum induction for the diagnosis of pulmonary
tuberculosis; second, this chapter describes a questionnaire-based study to determine the
knowledge and acceptability of patient-specific infection control measures among patients
suspected with TB, at the time of investigation, and among patients with TB, at baseline and 
at the end of treatment.
 RESULTS 
In this section we present the results of the systematic review and meta-analysis of sputum
induction for the diagnosis of pulmonary TB; and the results of the study of patient-specific
infection control measures for TB.
 DISCUSSION 
The final chapter presents a summary of the principal results and explores the implications of 
our observations. We highlight the clinical and public health implications of the use of 
sputum induction, as well as technical and epidemiologic factors that might influence the 
diagnostic yield of this procedure. Second, we discuss the relationship between knowledge 
of TB, acceptability of patient-specific infection control measures, and the implications for 
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 1  




            This chapter provides a brief historical background about tuberculosis (TB) and 
describes how this disease continues to present significant problems for many developing 
nations. This chapter also sets out the rationale for putting into practice simple and 
affordable TB diagnostic methods, and improving infection control strategies for patients 
with pulmonary TB in high TB burden settings.  
 
1.1 HISTORICAL BACKGROUND  
Tuberculosis (TB) has been described as one of the most pervasive, debilitating and 
lethal diseases to humankind. TB has been tracked nearly as far back as humanity has been 
recording its history (1). The spread of TB was documented more than 5000 years ago in 
Egypt, and its causative agent, Mycobacterium tuberculosis, has been reported to have killed 
more people than any other microbial pathogen ever since (1).    
 
Several tentative measures were implemented to control and cure the disease. Such 
methods included prolonged bedrest, sanatoria for the care of consumptives, adequate 
nutrition and also the implementation of collapse therapy methods (e.g., artificial 














patients (2, 3). The anti-tuberculosis drugs were widely implemented in the 1950‘s and 
resulted in cures for 90–95% of patients (4).  The Bacille Calmette-Guérin (BCG) vaccine 
and the standardized treatment regimen (known as directly observed treatment, short-
course—DOTS) contributed to the slow drop in TB prevalence that was experienced for 
many years in succession (5). 
Unfortunately, at the end of the 1980‘s and beginning of the 1990‘s TB rates began to
rise globally; this could be explained due to three main factors: firstly, neglected TB control
programmes; secondly, the deprived economic development of some regions and
deterioration of their public health infrastructure; and lastly, the human immunodeficiency
virus (HIV) infection that up to recently has driven the TB epidemic in high TB burden areas 
(5-8). 
1.2 GLOBAL BURDEN AND PULMONARY TUBERCULOSIS CONTROL
The consequences of pulmonary TB on society are immense, in spite of advances in
technology and public health measures to control the disease. Currently one third of the
world‘s population is infected with M. tuberculosis. Indeed, one person is infected with the
bacteria every second. Up to 9,4 million new active TB cases are reported every year (range,
8.9 million- 9.9 million cases), with an estimated 14 million prevalent cases (range, 12
million–16 million), of which 440 000 cases are reported as multi-drug resistant cases
(range, 390 000–510 000) and nearly 5000 patients with TB are estimated to die every day,
mostly in the developing world (9) (See Error! Reference source not found. and Error!
Reference source not found.). TB accounts for 2.5 % of the global burden of disease and it
is the most common cause of death in young women, killing more women than all causes of
















Global burden of tuberculosis [Numbers in thousands] 
 
 
WHO Region Population Mortality Prevalence Incidence HIV in Incident TB Cases (%) 
Africa 824401 430 3900 2800 37 
Americas 929509 20 350 270 8.5 
E. Mediterranean 596509 99 1000 660 1.6 
Europe 891559 62 560 420 5.3 
South-East Asia 1783587 480 4900 3300 5.7 
Western Pacific 1800640 240 2900 1900 1.8 
Global Estimate 6826205 1300 14000 9400 12 
 
Table 1. Estimated Epidemiological Burden of Tuberculosis according to WHO regions 




Figure 1. Epidemiological Distribution of new cases of Tuberculosis cases according to WHO regions 
Source—. Adapted from the global plan to stop TB 2011-2015. Transforming the fight towards elimination of  




Interventions to control pulmonary TB were sought to address three public health 
objectives: (1) to reduce infectiousness, (2) to decrease transmission capacity from 
bacilliferous patients to the rest of the community and (3) to reduce morbidity and mortality 
(12).  These objectives were partially accomplished by increasing BCG vaccination 






























through BCG vaccination and treatment have not been sufficient. The current vaccine, BCG, 
does not provide longlife immunity but provides unreliable protection against pulmonary 
TB, and it is only effective against severe forms of TB in childhood (13, 14). Moreover, TB 
chemotherapy has challenges: availability of drugs, availability of drug susceptibility testing 
(DST) to provide accurate diagnosis and effective treatment to either patients with sensible 
or resistant M. tuberculosis strains, the DOTS regimen is still six months or more and, socio-
economic factors that lead patients to abandon TB treatment (15, 16). 
 
 Poor access to diagnostic services along with the low performance of current tools 
and strategies for the diagnosis of TB contributes to underdiagnosis of millions of infectious 
TB cases (17). TB control programmes in high TB burden settings may not have adequate 
diagnostic tools to early identify TB cases. Bacteriological confirmation of pulmonary TB 
has been achieved through sputum evaluation (18). However, the direct observation of the 
mycobacterium (smear microscopy) is affected under three circumstances: firstly some 
patients provide sputum samples of poor quality or scanty sputum; secondly, there is a 
significant number of paucibacillary cases in whom M. tuberculosis can not be detected. 
Such is the case of paediatric patients and HIV infected persons (18); and thirdly,  low 
quality laboratory infrastructure, especially in resource-constrained settings in the 
developing world, hinders the bacteriological confirmation of TB.  
 
TB control activities are not implemented universally. Under these circumstances, the 
diagnosis of pulmonary TB in low and middle income countries becomes difficult. patients 
with suspected TBare not early diagnosed, or are misdiagnosed because of the lack of 















resistant to TB chemotherapy are unavailable; and the measures to prevent transmission of 
the disease are difficult to implement.  
1.3 TOOLS TO CONTROL TB 
In order to interrupt TB transmission, early diagnosis and prompt treatment are 
considered the most effective TB control strategies (19-21). Yet, both approaches have 
encountered limitations, principally the detection of the bacillus in clinical specimens, which 
has impeded  TB control due to a lack of rapid, accurate and affordable diagnostic methods, 
particularly in low and middle income countries (21). For instance, in high-burden settings, 
mainly in the developing world, sputum smear microscopy is the predominant test to 
diagnose patients suspected with TB (21, 22), and although different methods to increase the 
speed and sensitivity of acid fast bacilli (AFB) smear microscopy have been or are being 
developed (23, 24), these may not be available in low and middle income countries. In the 
case of industrialized countries, where the burden of TB is low, high-tech molecular 
methods and rapid culture systems have been designed to detect cases with many fewer 
organisms in less time (22).  
 
Another paradoxical example of availability of resources to interrupt TB 
transmission in low and middle income countries and high income countries is reflected by 
implementation of infection prevention and TB control plans. For instance, in industrialized 
countries, environmental controls such as high efficiency particulate air (HEPA) filtration or 
sterilization methods with ultraviolet germicidal irradiation (UVGI) are used to control the 
transmission of M. tuberculosis TB in confined areas (25). This is not the case in poor areas 
where infectious patients can be easily missed, and therefore, contribute to the chain of 

















1.3.1 TB diagnostics 
1.3.1.1 The “gold” standard  
TB follows a human-to-human transmission pattern. TB transmission only occurs 
when individuals with pulmonary TB exhale infectious droplets by speaking, laughing and 
sneezing and a susceptible person inhales these infectious droplets. Hence, the importance of 
ensuring early recognition of individuals with suspected pulmonary TB, since they are 
considered sources of infection. For several decades, the examination of spontaneously 
produced sputum samples (routine sputum) from patients suspected with TB has been the 
mainstay for the diagnosis of active TB (26). Smear microscopy is considered the gold 
standard method for the diagnosis of pulmonary TB, particularly in communities of the 
developing world, where 95% of TB cases and 98% of deaths occur (27). However, this 
technique requires approximately 10,000 mycobacteria per millilitre of sputum for a positive 
diagnosis (28). The yield of sputum smear microscopy depends on intrathoracic 
manifestations of TB disease. Hence, for patients with advanced disease, the bacteriologic 
yield tends to be higher, as compared to patients with mild to moderate disease, since the 
mycobacterial load is likely to be lower (29). The use of AFB smear is limited in children 
and HIV positive individuals, because of the paucibacillary nature of their disease.  
 
Figure 2. Distribution of Sputum Smear Microscopy (Acid-Fast Bacilli [AFB] among patients with 
TB/suspects) 





















The STOP TB working group on ―NewDiagnostics for TB‖ reported that more than 
50% of the TB cases are AFB smear negative (See Error! Reference source not found.
above). This represents a clear public health problem. As stated by Behr et al, AFB smear
negative patients are generally not diagnosed, and consequently not treated on time (30). 
Furthermore, it has been shown that TB transmission does occur from smear-negative
patients1 (30, 31). In addition to the poor diagnostic yields (30% - 70%) of AFB smear
microscopy (21), the collection of pulmonary specimens is often problematic. When
collecting sputum samples, it is common to collect low quality specimens, either because
patients provide excessive salivary contamination of sputum samples, or do not produce any
sputum. Error! Reference source not found. summarizes some of the factors that can lead to
a negative AFB smear microscopy result after the collection of a routine sputum sample. 
Limitations of collected sputum samples for smear and culture processing 
Sputum Processing Stages     Cause 
Sputum collection  Inadequate sputum sample (i.e. oropharyngeal sample)
 Inappropriate sputum container
 Sputum stored too long before microscopic examination
Sputum processing  Faulty sampling for smear
 Faulty smear preparation and staining
Smear examination  Inadequate time spent examining smear
 Inadequate attention to smear
Table 2. Factors that can lead to a negative AFB smear microscopy result on regular sputum samples 
Source—.Adapted from Long R. (32) 
Demonstration of acid-fast bacilli in a smear made from a clinical specimen 
provides an initial diagnosis of mycobacterial disease, while the isolation and identification 
of the mycobacterium on culture provides a definite diagnosis of TB. In the case of children 
and HIV positive patients, current guidelines for the management of such cases have 
1 The threshold for detecting bacilli on microscopy is about 5000-10000 bacilli/mL, while the infecting dose is 















established that all samples need to be cultured.   Even though culture requires a greater 
amount of sputum2, only 10 bacilli/mL are needed [in concentrated samples] for a cultured 
specimen to be positive, fact that confers sputum culture a higher sensitivity (70-90%) than 
that of smear. Nevertheless, bacteriological confirmation of TB via culture methods is 
arduously long due to the mycobacterium‘s slow growth rate.  
 
1.3.1.2 Current alternative sample collection methods  
Without effective, rapid and affordable diagnostic tools, the bacteriological 
confirmation of TB will not be established in patients in disease-endemic areas.    
 
In the presence of factors that impede the collection of good quality specimens, 
different methods have been recommended as an lternative to routine sputum. For example, 
because of the difficulty in achieving bacteriologic confirmation in sputum smear-negative 
disease or paucibacillary cases, gastric lavage  and fiber-optic bronchoscopy (FOB) with 
bronchoalveolar lavage (BAL) have been recommended as the reference diagnostic tools to 
collect adequate specimens and thus, improve the sensitivity of AFB smear microscopy and 
culture (33, 34). Both, BAL and gastric lavage have shown good results, nevertheless 
tolerability of the procedures and safety become an issue given that these are invasive 
specimen-collection methods. Moreover, there are notable resource implications for both 
procedures. For instance, in order to obtain gastric specimens, patients may be required to 
stay in hospital while two or three samples are consecutively taken. Lobato et al did 
demonstrate that the yield of gastric aspirates from paediatric outpatients was similar of that 
in hospitalized patients (35). Although the yield from gastric aspirates is relatively low, it 
also has been shown that when gastric lavage is done on three consecutive days, its 
diagnostic yield is better than that of FOB/BAL for the bacteriologic diagnosis of TB. 
                                                          
2 AFB smear processing requires 0,01 mL per slide. Once the sample is extended in 10,000 microscopic fields, in 















Although FOB/BAL has additive value in the rapid diagnosis of TB (36); however, the 
sensitivity of sputum or FOB/BAL microscopy for the detection of AFB is variable, ranging 
from 50 to 80% for three consecutive specimens (37).  Moreover, this technique requires 
highly sophisticated equipment which is unavailable in high TB burden areas or resource-
constrained settings in the developing world. 
 
1.3.1.2.1 A simple and cost-effective method of diagnosis 
Simpler and more accurate diagnostic tools must be implemented in low and middle 
income countries as a key resource in the fight against TB. For several years, sputum 
induction has been used as a method to collect respiratory specimens directly from the lungs 
for the macro and microscopic study of a number of respiratory pathologies.  It has been 
implemented as a diagnostic tool to detect morphologic changes in lung carcinoma; to 
observe patterns of airway inflammation in asthmatics and patients with chronic obstructive 
pulmonary disease (COPD); and to confirm the diagnosis of Pneumocystis jiroveci 
pneumonia in HIV infected individuals. This method has been described as a useful tool in 
the diagnosis of TB, especially in paucibacillary cases. Furthermore, this diagnostic tool is 
suitable for resource-limited areas where bronco-alveolar or gastric lavage are not 
financially feasible.  
 
1.3.2 Controlling TB transmission during diagnostic work-up of patients 
suspected with TB disease 
In 1994, the Centers for Disease Control and Prevention (CDC) published the 
guidelines for preventing the transmission of pulmonary TB in health-care facilities. The 
guidelines were issued in response to 1) a resurgence of pulmonary TB disease that occurred 
in the United States in the mid-1980‘s and early 1990‘s; 2) the documentation of several 















an increase in the prevalence of TB disease and HIV co-infection; 3) lapses in infection-
control practices; 4) delays in the diagnosis and treatment of persons with infectious TB 
disease; and 5) the appearance and transmission of multidrug-resistant (MDR) and 
extensively drug-resistant (XDR)  M. tuberculosis strains. The 1994 guidelines, which 
considered statements issued in 1982 and 1990 about the dramatic increase in global trends 
of TB, presented recommendations for TB infection control based on a risk assessment 
process that classified health care institutions in accordance with different categories of TB 
risk. 
 
1.3.2.1 Adoption of nosocomial / health care associated TB control measures in 
developing countries 
TB transmission occurs in all overcrowded and poorly ventilated spaces, such as 
hospitals, schools, prisons, households and work places. However, the CDC guidelines for 
TB infection control were designed primarily for health care facilities in industrialized 
countries (25).  By contrast, in low and middle income countries, infection control strategies 
as proposed by the CDC remained unachievable due to the high cost of implementation (38).  
 
The WHO acknowledged that TB infection control was largely neglected in low and 
middle income countries, principally due to inappropriate allocation of resources, unclear 
policies, and lack of awareness of TB control (39). Consequently, the WHO designed a 
framework for the implementation of TB infection control measures in health-care facilities, 
congregate settings and households, centering attention in low and middle income countries. 
This framework was designed under the same principles or hierarchical levels established by 
the CDC: administrative, environmental and respiratory protection controls, and outlined 
cost-effective strategies and patient-specific measures to prevent the transmission of M. 















The framework on TB infection control in health-care facilities, congregate settings 
and households highlighted individual and community participation as key elements the 
control of TB. Also, it was specified that in order for communities to help stop transmission 
of the disease, they should firstly understand how TB affects them and their families, and 
also how the disease is transmitted, cured and prevented. However, patients‘ knowledge, 
perceptions and attitudes towards TB depends on socio-cultural and economic factors. 
Several studies have reported how prejudice and stigma can influence health seeking 
behaviour in individuals with suspected TB (41-43). Others have reported the correlation 
between TB knowledge and completion of chemotherapy (44, 45) . Relatively little research 
has been conducted on the acceptability and implementation of measures to prevent the 
transmission of TB in community settings.   
 
1.3.3 Need for improvement of infection control methods 
TB is not exclusively a disease of the poor; however, the disease imposes a social and 
economic burden on individuals of all ages from communities and societies everywhere, 
especially in very poor populations where accurate and simpler diagnostic tools as well as 
infection control measures are lacking or are poorly implemented.  Poverty increases the 
risks of TB infection and the development of TB disease, and adequate and affordable 
diagnostic tools could prevent delays in diagnosis in high TB burden areas, and so the 
implementation of simple and cost-effective infection control measures could reduce the 
transmission of M. tuberculosis in at high-risk individuals and communities (46-48). 
 
Attention has been focused on the need for the development of new and better 
medicines and, high-technology diagnostic systems. Despite global expenditures on TB 
diagnostics, large numbers of TB cases are detected late or are not detected at all. 














might not be viable for resource-constrained settings, but without affordable, rapid and 
simple diagnostics, patients suspected with TB in the developing world would not be 
diagnosed opportunely. A method such as sputum induction which certainly can improve the 
sensitivity of both, smear microscopy and culture, could be of practical use in disease-
endemic settings and contribute to an increase in diagnosis rate, a subsequent reduction of 
M. tuberculosis transmission (due to early administration of TB chemotherapy) and
therefore it will have a positive impact on morbidity and mortality attributed to TB. 
In addition to simple diagnostic methods, adequate implementation of patient-specific
and other low-cost infection control measures could reduce repetitive exposure to M.
tuberculosis, not only in close contacts of patients with TB, but also in health care workers.
Moreover, empowerment of patients with TB through on-going educational programmes to
implement TB infection control measures could be more cost-effective than diagnosing and
treating every new reported TB case. 
In 2007, Loveday et al identified three major ―leakages‖ during patients‘ journey from
diagnosis to treatment completion (See Figure 3) (49). The identified ―leakages‖ highlight
the problems and challenges that TB control programmes face during different stages of
diagnosis and treatment. Initially, patients with active TB were not registered as patients
with TB—total leakage of smear-positive patients with TB from the laboratory to the TB
register was 58%; 31% were counted as having leaked from the system between the hospital
and the clinic, and finally, 39% of all diagnosed patients who started chemotherapy, failed to
complete it (49). Loveday‘s study highlighted the importance of adopting measures that not
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Figure 3. Identified Leakages between Case Detection and Completion of Anti-TB treatment 
Source—. Adapted from the Loveday et al, 2007 
 
 
The need to put into practice simple and affordable diagnostic methods and 
management of infection control for patients with suspected TB in high TB burden settings, 
prompted us to conduct two studies. The first one, to determine the diagnostic yield of 
sputum induction, a rapid and simple method to diagnose TB; and the second, to evaluate 
TB knowledge levels and acceptability of patient-specific infection control measures among 




















 To conduct a systematic review and meta-analysis of studies reporting the use of sputum 
induction for the diagnosis of pulmonary tuberculosis. 
 
 
Infection Control Measures Project: 
 To conduct an observational study to determine TB knowledge and acceptability of 
patient-specific infection control measures among patients suspected with TB and newly 
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In the following chapter, we present a literature review on current methods to 
control TB. The first section describes aspects related to the collection of pulmonary 
specimens for the bacteriological confirmation of TB, and also, it points out characteristics 
of sputum induction, its utility and diagnostic yield in patients with TB, and its advantages 
over other diagnostic procedures. Then, the second section describes fundamental aspects on 
infection control in TB, and lastly, we focus on the implementation of patient-specific 
measures to reduce the transmission of M. tuberculosis.  
 
2.1 SPUTUM INDUCTION AND TUBERCULOSIS 
2.1.1 Background 
Collection of sputum is the simplest non-invasive procedure available to examine 
aetiologic agents in tracheal, bronchial and pulmonary infections as well as to evaluate 
cytologic and inflammatory changes in the tracheobronchial tree. However, some patients 
are unable to produce sputum for examination. In such cases, sputum induction  is a key 
diagnostic procedure.  This diagnostic tool allows collection of adequate samples from the 














paucibacillary TB or sputum-unproductive cases, providing an opportunity for bacteriologic 
diagnosis and also, giving the public health authorities the opportunity to administer 
effective and prompt treatment to the patient.  
The method was first described by Garcia et al in 1952 (1). Initially, bronchial
secretions were obtain by nebulization and inhalation of sterile distilled water (1). The 
method was soon modified and several researchers induced sputum production by inhalation
of heated hypertonic aerosols. Initially, Bickerman et al used various concentrations of
hypertonic solutions ranging from 3 to 15 %, for the cytologic diagnosis of lung cancer (2, 
3). Subsequently, the inhalation of sodium chloride was used to collect pulmonary
specimens from patients under investigation for TB. Hensler et al and other researchers
implemented sputum induction in absence of spontaneous cough, or scant sputum
production (4-7).  
Even though preliminary studies set the scene for the use of sputum induction in the
diagnosis of pulmonary TB, particularly in paucibacillary patients with TB, its clinical use
gradually declined as a result of an increased risk for nosocomial transmission of M.
tuberculosis and the advent of bronchoscopy (8).  
Collection of pulmonary secretions by inhalation of hypertonic solutions remained 
ideal to examine cellular and molecular markers of airway inflammation in patients with 
asthma and chronic obstructive pulmonary disease (COPD) (9). Interest in the technique for 
the diagnosis of pulmonary infections returned following the increasing number of cases 
with unusual infections during the beginning of the HIV epidemic in the 1990‘s (10). 
Initially, sputum induction appeared to have value in the diagnosis of Pneumocystis Jiroveci 















diagnostic utility of sputum induction for confirming the presence of M. tuberculosis in 
immunocompromised individuals or paucibacillary cases (13). 
 
2.1.2 The pulmonary effect of hypertonic solution inhalation  
Hypertonic saline has been shown to have a favourable effect on mucus rheology 
(14). The postulated mechanism whereby inhalation of hypertonic saline improves 
mucociliary clearance is as follows: (a) hypertonic saline breaks the ionic bonds within the 
mucus gel, thereby it reduces the degree of cross-linking and entanglements and lowers the 
viscosity and elasticity of the mucus (15); (b) hypertonic saline also increases the ionic 
concentration of the airway surface fluid, causing water to be drawn into the airway lumen 
along its osmotic gradient, thereby it rehydrates the airway surface fluid and promotes the 
separation of mucus, which facilitates its expectoration; (c)  hypertonic saline stimulates 
cilial activity via the release of prostaglandin E2, which increases mucociliary clearance  and 
stimulates the cough reflex (16, 17). 
 
In order for hypertonic solutions to improve mucociliary clearance, the aerosol must 
be deposited correctly in the tracheobronchial tree. The effectiveness of deposition of an 
aerosol in the tracheobronchial tree is determined by a number of physical and physiologic 
factors (18, 19). Theoretically, maximum aerosol deposition on all segments of the 
respiratory tree would be desirable to facilitate bronchial drainage and later expectoration, 
and even though factors such as density and tonicity of the aerosol, temperature, volume of 
solution nebulized per minute, and the rate and depth of respiration, have been described as 
contributing factors to deposition inefficiency, particle size has been the most important 















Particle size and aerosol density depend on the nebulization device used for 
hypertonic solution inhalation. Different devices, such as ultrasonic nebulizers, conventional 
nebulizers (or air compressors) and oxygen cylinders have been used to deliver hypertonic 
aerosols directly into the respiratory system. Although every device can produce a regular 
―mist‖ for inhalation, only aerosol particles in the therapeutic range of 1-10 μm in diameter 
will be deposited in the airway surface. Even though all of the previously mentioned devices 
can produce particles within that range, their size varies due to the nebulizer output (flow). 
Either very small particles (< 1 μm) or large particles (>10 μm) will not be properly 
deposited. Small particles, due to their instability and high speed, will enter the airway, 
remain suspended in the airstream and afterwards approximately 80 percent will be exhaled, 
whereas bigger particles will be deposited in the upper r spiratory tract.  
 
2.1.3 TB diagnosis in paucibacillary and sputum unproductive patients 
suspected with TB   
In its most recent report on TB control, the World Health Organization (WHO) 
presented the following disaggregated estimates of the global burden of TB: 9.4 million 
incident cases, 14 million prevalent cases, 1.3 million deaths among HIV-negative people, 
and 0.4 million deaths among HIV-positive people. Moreover, 57% of global notifications 
were sputum smear-positive (2.6  million cases) whereas the remaining 43% were reported 
as sputum smear-negative patients (2.0 million cases) (20) . The latter represents a clear 
challenge for the early detection of patients suspected with TB, especially in developing 















The microscopic examination of routine sputum3 for M. tuberculosis is still the 
reference standard test for TB diagnosis (22). However, in sputum smear-negative patients 
(commonly paucibacillary and sputum-unproductive cases4), FOB/BAL and gastric lavage 
have been suggested as the most optimal diagnostic tools (23). However, the use of these 
diagnostic tools faces two major limitations: on the one hand, resource-constrained settings 
in the developing world may not have the health care facilities supplied with materials and 
instruments to collect specimens via FOB/BAL and gastric lavage; and on the other hand, 
the diagnostic yield of such alternative diagnostic tools has been reported to be of equal or 
lower to that of sputum induction. 
The use of sputum induction for establishing a diagnosis in patients with suspected 
smear-negative pulmonary TB has been previously studied. Parry et al for example, 
investigated the yield of this procedure and concluded that sputum induction was a useful 
technique for improving the case detection rate of patients suspected with TB in resource-
limited settings (24). 
 
2.1.3.1 Hypertonic inhaled solutions for the diagnosis of tuberculosis 
The clinical utility of sputum induction provides a real alternative to FOB and BAL 
in the diagnosis of pulmonary TB. Moreover, sputum induction has been reported to be as 
effective as, or superior to, gastric lavage or FOB for diagnosis of TB (23, 25). As a matter 
of fact, this method has been shown to have a better diagnostic yield than spontaneous 
sputum and gastric aspirates (25) and several studies have also demonstrated that the yield of 
one induced sputum—as a primary diagnostic modality for paucibacillary cases––is at least 
equivalent to that of one bronchoscopy with BAL (26, 27). The yield of sputum induction is 
                                                          
3 Routine sputum (also known as spontaneous sputum) is understood as a sputum specimen which is provided by 
an individual in whom TB—or any other respiratory infection is suspected. This specimen is usually provided by 
















further increased when multiple pulmonary specimens are obtained, with reported 
mycobacterium identification rates by smear microscopy of 91% to 98%, and 99% to 100% 
by culture, significantly higher than with bronchoscopy alone (27).  
 
Several authors have evaluated not only the clinical utility of the procedure but also 
its tolerability by patients suspected with TB and safety. Kawada et al found sputum 
induction to be better than gastric aspiration in patients suspected with TB (28, 29).  
Anderson et al reported that the diagnostic yield of sputum induction is as good as FOB for 
diagnosis of smear-negative pulmonary TB (23).  Hatherill et al found the diagnostic yield 
of sputum induction in children to be equivalent to that of gastric lavage (30). Conde et al 
reported that sputum induction was safe, with high diagnostic yield and substantial 
agreement with FOB, in both HIV seronegative and seropositive patients (26). Menzies et al 
championed the role of induced sputum in the diagnosis of pulmonary TB and stated that, as 
compared to bronchoscopy, repeated induced sputum testing offers many advantages in 
terms of safety and cost, with at least comparable, if not greater diagnostic yield (8). 
However, induced sputum testing in the diagnosis of pulmonary TB carries a risk of 
nosocomial TB (8). 
 
2.1.3.2 The use of sputum induction in low resource settings 
Sputum induction is a potential tool for improving specimen quality and positivity 
rates in smear microscopy and culture techniques. Unlike routine sputum, sputum induction 
allows the collection of pulmonary secretions. The inhalation of saline solutions increases 














airway, promoting cough, fostering mobilization of mucus and allowing patients to 
expectorate satisfactory quality specimens (9).  
Studies from high TB burden settings in which sputum induction has been used in
patients suspected with TB who were found to be AFB smear negative have shown that this
procedure is a safe, simple and cost effective method to obtain sputum in smear negative 
patients (10, 13, 31). Unfortunately, one of the limitations with this procedure is that up till
recently, no clear protocols to carry out the procedure have been described. Technical
variations to implement this method (i.e., different saline concentrations; different outputs;
nebulisation times) clearly reflect the variability in the diagnostic yield of sputum induction.
Current literature shows yields that range from 20% to 99%. Many factors could be causing
the wide range in the yield of this procedure. For example, different saline concentration, 
nebulization devices (e.g., ultrasonic or venturi-type face mask nebulizers), flow rate
provided during nebulization, time, patient‘s position during saline administration, and
others that have not been wide explored. Toubes et al compared the performance of two
sputum induction methods and concluded that the collection of sputum samples with an
ultrasonic device was more effective than the use of oxygen cylinders for the same purpose
(32). Reported diagnostic yields are 66% and 46%, respectively. Toubes‘ study has been the 
only report which explores other technical factors that can affect the procedure. Although 
saline solutions increase airway hyperactivity, the use of variable sodium chloride (NaCl)
concentrations has commonly been studied in asthma and COPD, as a mean to determine 
safety of the procedure and in order to recommend the use of bronchodilators for patients
















Although this method has been described as a high-risk procedure on account of 
infectious droplet nuclei that are expelled into the air while patients suspected with TB are 
coughing, it is clear that implementation of appropriate infection control measures should 
reduce the likelihood of transmission of M. tuberculosis to health care workers and other 
patients. In low and middle income countries, where major infrastructural or environmental 
changes are needed to control TB, measures such as the implementation of negative pressure 
isolation rooms or specific TB isolation areas can not be carried out due to their high 
operative costs. In 1997, Kellerman et al determined the costs of infection control measures 
at hospitals with a history of M. tuberculosis outbreaks and concluded that the costs 
associated with implementing control measures similar to those recommended by the CDC 
involved the largest capital outlay in health care facilities (34). Therefore, the 
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2.2 INFECTION CONTROL IN TUBERCULOSIS 
 
2.2.1 Risk of M. tuberculosis transmission 
 
M. tuberculosis can be easily spread by aerosol droplets expelled by people with 
active disease when speaking, coughing, sneezing or singing (1). These infectious aerosol 
droplets contain the mycobacterium, which being only 0.5 to 7 µm in diameter, can easily be 
inhaled and become established in the lung parenchyma of susceptible individuals.  
 
In a study conducted to measure the number of pathogenic organisms that could be 
expelled from the respiratory tract, it was determined that speaking, coughing and sneezing 
produce a significant quantity of mycobacterium-containing aerosols (2). Accordingly to 
Duguid, speaking and coughing could release between 0 to 210 and 0 to 3500 infectious 
particles respectively, whereas by sneezing, a bacilliferous individual could liberate from 
4500 infectious particles to more than one million particles (2). Beggs et al studied the most 
significant factors that influence and/or increase the probability of TB transmission and the 
development of disease (3), and determined that for a susceptible individual to become 
infected with M. tuberculosis and develop disease, it was necessary to consider the following 
factors: quantity of infectious droplets expelled by the infectious source 5; virulence of the 
M. tuberculosis strain; duration of exposure and ventilation rate. 
 
Subsequent studies estimating the infectiousness of M. tuberculosis, determined that 
the infectious dose of M. tuberculosis is very low, and that inhaling fewer than ten bacteria 
may cause TB infection and subsequent TB disease (4-6). Therefore, preventing the 
generation of infectious droplet nuclei by the early identification of patients suspected with 
                                                          
5―Infectious Source‖ refers to an individual in whom TB is highly suspected or a TB patient who is not receiving 















TB and administration of effective chemotherapy can reduce the infectivity of an individual. 
Although the virulence of M. tuberculosis mostly depends on intrinsic properties of the 
mycobacterium, duration of contact and frequency of exposure are important factors in the 
transmission of TB, with the risk of infection increasing with the total time of exposure (3). 
If a susceptible person remains in the presence of a patient with active pulmonary TB for 
long enough, they will inevitably become infected, even when the concentration of 
infectious particles is relatively low (3). It is also probable that brief exposures to a 
bacilliferous source can also increase the risk of transmission if contact between a 
susceptible individual with an active case of TB remains frequent (7).  The ability of an 
infected individual to transmit M. tuberculosis also depends on ventilation. Smear positive 
patients usually contain ≥ 5000 bacilli per millilitre of sputum (8). Under insufficient 
ventilation conditions, M. tuberculosis transmission would result due to dissemination of 
infectious droplet nuclei that remain suspended in air. Although aerosolisation of infectious 
particles depends upon the frequency, force, and region of the cough, simple respiratory 
manoeuvres (speaking; coughing; and sneezing), can produce infectious aerosols containing 
a large amount of bacilli. Therefore, poor ventilation conditions increase the risk of infection 
in households, health care facilities and other congregate settings6 with insufficient 
ventilation (9-11). 
 
In health care facilities, once a TB suspect seeks medical attention, the risk of 
infection for health care workers and other inpatients might be diminished considerably if 
infection control measures (early diagnosis and treatment and specific strategies to reduce 
transmission) are correctly set in place. However, the risk of infection for close contacts is 
not reduced immediately after patients start receiving TB chemotherapy. 
 
                                                          
6The term congregate settings include correctional facilities and military barracks, to homeless shelters, refugee 















2.2.2 Fundamentals of infection control  
 
The CDC guidelines were designed when M. tuberculosis re-emerged as a 
significant nosocomial pathogen (12). Several nosocomial outbreaks of TB involved 
inpatients and health care workers (12, 13)  late 1980s and early 1990s, and as stated by the 
CDC Division of Tuberculosis Elimination, the factors contributing to these outbreaks 
included (1) the delayed recognition of patients with tuberculosis; (2) the convergence in 
health care facilities of bacilliferous cases and immunocompromised patients; (3) the 
delayed diagnosis and initiation of effective anti-tuberculosis chemotherapy; (4) inadequate 
ventilation for TB isolation and (5) inadequate precautions for c ugh-inducing procedures in 
patients suspected with TB. In response to this problem, TB infection control measures 
aimed to ensure prompt detection, airborne precautions, and rapid diagnosis of patients 
suspected with TB and early treatment of patients with confirmed TB disease through the 
implementation of a combination of measures grouped as administrative, environmental 
respiratory protection, and described as follows: 
 
2.2.2.1 Administrative controls 
This first set of administrative measures intended to reduce the risk of exposing 
uninfected individuals to patients suspected with TB by ensuring the development of 
infection control policies and protocols that allow the rapid identification, diagnostic 
evaluation, and treatment of persons likely to have   TB; also by educating and training of 
health care staff on TB, biosafety practices, and health care workers screening for TB 















2.2.2.2 Environmental controls 
The second level of the hierarchy defined by the CDC was the use of environmental
controls to prevent the spread of M. tuberculosis, and reduce the concentration of infectious
droplet nuclei in ambient air. Primary environmental controls consisted of controlling the
source of infection by using local exhaust ventilation (natural and mechanical) and room air
extractors to remove contaminated air to the outside. Secondary environmental controls
consisted of controlling the airflow to prevent contamination of air in areas adjacent to the
source and cleaning the air by using HEPA filtration, or Ultraviolet germicidal irradiation
(UVGI) (12).
2.2.2.3 Respiratory protection controls 
The first two control levels were designed to minimize the number of areas in which 
exposure to M. tuberculosis could occur and, therefore, minimize the number of individuals
that could be exposed. However, these control levels aimed at reducing, but do not
eliminate, the risk for exposure in areas in which exposure could still occur (procedure and
isolation rooms). Since persons entering these areas could be exposed to M. tuberculosis, the
third level of the hierarchy was the implementation of respiratory protective equipment in
situations that posed a high risk for exposure. Therefore, health care staff working in 
isolation wards or who were in frequent contact with patients with TB should use high
efficiency masks for protection against infection with M. tuberculosis. Moreover, with the
implementation of a respiratory-protection program, in which health care workers were
instructed on the correct use of respiratory protection, and in which patients received
education on respiratory hygiene and cough etiquette procedures, the risk of TB exposure for














2.2.3 Implementation of initial infection control measures 
In a descriptive study, Blumberg et al evaluated  the effectiveness of the infection 
control measures proposed by the CDC (13).  Researchers measured the number of TB 
exposure episodes and tuberculin skin test (TST) conversion rates among health care 
workers before and after the implementation of administrative (or managerial), 
environmental, and personal respiratory controls.  Their experience at an institution located 
in a high TB burden area showed that, implementation of these guidelines was effective in 
preventing nosocomial transmission of TB to health care workers (13).  
Basu et al constructed a mathematical model to simulate TB transmission and
investigated the effect of infection control measures on the epidemic trajectory of MDR TB
in the rural community of Tugela Ferry, South Africa (14). They modelled the reduction of
hospitalisation time for patients with TB, the implementation of rapid drug-susceptibility
assays, the involuntary detention of XDR patients with TB who refused to take
chemotherapy or default from treatment, improved natural ventilation by using fans and
opening windows, the use of a mechanical ventilation systems, HEPA filters, UVGI and the 
use of N95 respirators for health care workers and surgical masks for patients with TB, as
infection control measures (14). The model predicted that different combinations of the early
mentioned infection control strategies could prevent almost 50% of XDR TB cases, even in
resource-constrained settings. Also, emphasis was made on the importance of implementing
parallel community-based programmes to reduce TB transmission within communities.
Projections of the model indicated that if infection control measures were not introduced, up
to 1300 cases of XDR TB were predicted to occur (14).
Although Basu et al concluded that correct implementation and combination of 














nuclei, it is evident that environmental and respiratory-protection measures such as the use
of high-tech diagnostic tests, mechanical ventilation systems, HEPA filters, UVGI, and the
use of N95 respirators, are not available for most low and middle income countries. Another
study conducted to determine the limits of protection achievable by improvements in 
environmental controls, demonstrated that in cases where the concentration of infectious
particles is very high (e.g., enclosed spaces, settings with air recirculation), even large
ventilation rates make very little difference on infection rates (15). Nardell‘s study also
highlighted the importance of implementing a combined set of infection control measures 
(15).
Work carried out in several countries has provided evidence on effectiveness of the 
three-level hierarchy of control measures (12, 16, 17). However, the adoption of these 
guidelines faced one major challenge for the control of the epidemic in high burden 
countries (HBCs): A high operational cost. As a solution to this challenge, and due to the
recent outbreaks of MDR-TB and XDR-TB, the WHO adapted the guidelines earlier
established by the CDC and recommended a set of measures that could be implemented in
congregate settings and households from resource-limited areas (18); these
recommendations were based on the same hierarchy of control measures or infection control
policies previously described by the CDC. 
2.2.4 Patient-specific infection control measures 
The WHO described the importance of community participation to reduce the 
transmission of TB and stated that the empowerment of the community—particularly at-risk 
groups—was a crucial element in TB control and urged public health authorities to create 
public awareness campaigns to allow populations to understand TB, its impact on 















cured and prevented. Therefore TB education and a particular set of recommendations to 
control TB infection in health-care facilities, congregate settings and households were 
recognized as a fundamental element of TB control in developing countries. 
 
Recommended patient-specific infection control measures7 included: 
 
 Implementation of cough etiquette and respiratory hygiene protocols, and  
 
 Implementation of environmental practices such as: 
 
1. Improvement of Ventilation - Houses should be adequately ventilated, 
particularly rooms where people with infectious patients with TB spend 
considerable time (natural ventilation may be sufficient to provide adequate 
ventilation), 
 
2. Spending as much time as possible outdoors (while smear positive), 
 
3. Sleeping alone in a separate, adequately ventilated room, if possible (while 
smear positive), 
 
4. Spending as little time as possible in congregate settings or in public transport 
(while smear positive),  
 
5. And, in the case of children below five years of age, they should spend as little 
time as possible in the same living spaces as the smear positive patient. 
 
                                                          
7Recommendations developed by the WHO and published in an evidence-based policy report for the 















In spite of being low-cost strategies to reduce M. tuberculosis transmission, patient-
specific infection control measures have not been well-studied. Researchers have centred 
their attention on documenting the risk of nosocomial transmission of M. tuberculosis as an 
occupational hazard for health care staff, mainly in industrialised countries (12, 13, 19, 20). 
The design and performance of isolation areas, negative pressure isolation rooms (NPIR) 
and respiratory wards have been well documented (17, 21, 22).  The effectiveness and 
efficiency of high efficiency particulate air (HEPA) filtration has been evaluated for several 
years but natural ventilation as a strategy to improve ventilation in resource-limited settings 
has not been well explored.  
 
There is clear evidence of the occupational risk of TB for health care workers in 
facilities or areas with a high prevalence of TB. However, close contacts of patients with TB 
have as much risk of acquiring M. tuberculosis infection and developing TB disease as 
health care workers in these settings do, and a higher risk than do casual contacts (23).  
 
Few studies have given particular attention to TB education and patient-specific 
infection control measures in congregate settings and households. Escombe et al studied 
natural ventilation as a low-cost alternative to reduce transmission of airborne infections, 
especially in resource–limited settings (10, 24). Although this study was carried out in a 
health care facility, it provides basic information on how by implementing a low-cost 
strategy such as opening windows and doors, natural ventilation is maximised, and the risk 
of airborne TB infection (percent of susceptible persons who are infected) decreases. 
Escombe‘s study showed that in order to improve ventilation and reduce the amount of 
infectious droplet nuclei, opening windows and doors can work as well as a negative 
















Although improvements on natural ventilation may be sufficient to provide adequate air 
changes in an area with a high potential risk of TB transmission, no more studies reporting 
the utility and cost-effectiveness and feasibility of natural ventilation have yet been 
published. Moreover, although improvements in natural ventilation and the use of fans in 
households are a highly recommended practice for patients with TB, no studies showing the 
effectiveness and feasibility of these simple measures have been conducted in resource-
constrained areas. 
 
In addition, other strategies that aim at decreasing infectious aerosol particles in closed 
environments and reducing exposure for contacts of patients with TB include the use of face 
masks when available, covering mouth principally when coughing or sneezing, and spend as 
little time as possible with susceptible individuals (e.g., children; HIV infected individuals).  
The use of face masks as a means to prevent health care workers from inhaling infectious 
droplets has been a well-known practice for the prevention of respiratory infections. As for 
TB, due to the characteristic size of the mycobacterium, the use of high efficiency masks 
(i.e. N95 masks) is a common practice when institutions can afford the provision of such 
masks for their staff (25). Face masks have been recommended for patients with TB, patients 
with suspected TB and health care workers. However, in some facilities, high efficiency 
masks can not always be afforded, and as a result, institutions must decide who gets to wear 
them. Nettleman et al conducted a study designed to determine the cost of high-efficiency 
masks required in a health care facility, and the number of TB cases in employees that could 
potentially be prevented; the study concluded that high-efficiency masks are a costly means 
of trying to prevent TB, and that costs could be reduced by reusing masks or by restricting 
the number of health care workers allowed to have contact with potentially infectious 
patients (25). Therefore, the efficient applicability of this measure depends on the effective 














burden of TB. Controlling the sources of infection by either providing patients with high 
efficiency masks or giving them instructions to cover their mouth when coughing, could 
theoretically, reduce the infectious droplets that are released and that remained suspended in 
the air. However, patients might not implement this measure at all times, especially in their 
homes, work places and health care facilities.  Some of the reasons that could be 
contributing to this are described below: 
 Patients do not feel the need for infection control measures in their homes and/or work 
places;
 Patients might not have a clear understanding of the importance of covering mouth with
a face mask, handkerchief, or with their hands; 
 Patients might be afraid of social stigma and prejudice if they are identified as patients
with TB;
Previous reports have indicated that one of the major limitations in TB control
programmes is the deficient educational systems (26). If patients do not understand how TB
is transmitted, how the disease can affect their close contacts, and how they can help prevent
TB transmission, the measures could not be implemented, and transmission will continue.  
Respiratory protection strategies as well as measures to reduce exposure time (e.g., 
patients with TB sleeping in a room by themselves or spending less time with children) if 
applied correctly, could reduce the amount of infectious droplets in congregate settings and 
households. Under unavailability of DST for all patients with TB in resource-constrained 
settings, even if patients are receiving TB chemotherapy, the use of face masks or the 














the exposure to M. tuberculosis to health care providers and close contacts of patients with 
TB. 
2.2.5 Gap in Infection Control 
Little research and limited resources have been expended on TB infection control
during the past 50 years especially the implementation of preventive and cost-effective
measures in different settings other than health care facilities. There has been extensive
guidance written on prevention of pulmonary TB at health care settings (3, 13, 19) but little
on transmission of TB in congregate and household settings. A number of studies have 
addressed the health education requirements of at-risk populations and the need to increase
patient‘s knowledge about TB (27-29). Yet the literature reveals that, overall, the emphasis
in health care has centred on TB treatment, adherence to anti-tuberculosis drugs, but not on
the implementation of patient-specific measures to reduce the possibility of TB transmission
to close contacts. 
In spite of growing evidence that nosocomial transmission of TB is a critical factor
in the epidemic HIV-associated TB and the emergence of MDR-TB and XDR-TB strains,
many argue that the evidence demonstrating that community transmission is not playing an 
equally important role in resource-constrained settings is not available. A top priority, then,
should be to obtain that evidence, so that resources will be allocated toward protecting health
care workers, patients, and other occupants of congregate settings (i.e. HIV/AIDS
facilities, prisons, refugee camps, etc).
In a study conducted by Jaramillo on the impact of health education on TB, it was 















challenges of the current strategy of control (30).  Another study conducted in Rwanda about 
the perception and beliefs of cough revealed that many patients, regardless of the severity of 
their disease, are too afraid to even seek early care (31). TB knowledge therefore, is an 
important contributing factor that interferes with TB control activities; particularly in 
infection control because in spite of the availability of some strategies such as TB 
chemotherapy or the feasibility of implementing patient-specific infection control measures, 
some patients refuse to adopt these measures because of the experienced or believed social 
stigma which seems to outweigh the fear of having TB (31). John et al stated that every 
person must participate in TB control activities and that providing basic information about 
TB and practical elements to control the disease in resource-limited settings must become a 
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CHAPTER 3: RESEARCH METHODOLOGY 
RESEARCH METHODOLOGY  
Chapter Introduction 
The following section presents the methods used to conduct a systematic review and 
meta-analysis of studies reporting the use of sputum induction for the diagnosis of
pulmonary TB; second, it describes the steps conducted on a questionnaire-based study to
determine the knowledge and acceptability of patient-specific infection control measures
among patients suspected with TB, and among patients with TB at baseline and at the end of
treatment.
3.1 METHODS FOR SPUTUM INDUCTION FOR THE DIAGNOSIS OF PULMONARY TB
3.1.1 Study design
We conducted a systematic review, aiming to identify, appraise and synthesize 
studies reporting the yield of sputum induction in the diagnosis of pulmonary TB. Explicit 
methods used in systematic reviews allow researchers to produce more reliable findings that 
can be used in the evidence-based decision making process. In our case, presenting the 
summary of the yield of sputum induction would allow us to reach a conclusion on the 
clinical use of sputum induction as a practical and effective method for improving the 















3.1.2 Search strategy 
We searched the online database of biomedical citations and abstracts, 
MEDLINE/PubMed using a search strategy which combined logical operators from the 
Boolean language (OR, AND, NOT) with a sequence of medical/clinical terms included in 
our PICO framework (See diagram 1). We also conducted a systematic manual search of 
biomedical journals and conference proceedings for relevant studies to ensure that our search 
included inaccurately indexed or unindexed papers, as well as to identify papers other than 
the ones published in high-impact journals. Unavailable electronic copies of Chest Journal 
and American Journal of Respiratory and Critical Care Medicine (past volumes) were 
searched. In addition, researchers who had experience in the use of sputum induction as an 
alternative method for the diagnosis of TB provided us with lists of relevant articles. Also, a 
fully recursive search of reference lists of the original studies was performed to find studies 








Patients with suspected TB and/or patients with 


















Routine expectorated sputum; gastric lavage; 
nasopharyngeal aspiration; or FOB with 
bronchoalveolar lavage. 
 
O [Outcome]:  Microbiological confirmation of pulmonary TB. 
 
 
Diagram 1. Applied PICO framework. 
3.1.3 Inclusion and exclusion criteria 
All prospective diagnostic studies that compared sputum induction using hypertonic 
saline (sodium chloride) solution and compared its yield to any of the following techniques 
were eligible for review: (1) routine expectorated sputum; (2) gastric lavage; (3) 














nebulized solutions other than sodium chloride were excluded from this review; in addition, 
papers reporting the use of specialized induction devices (eg. Lung flute®); and studies 
reporting the use of sputum induction for the diagnosis of pulmonary infections other than 
tuberculosis were also excluded. 
3.1.4 Quality assessment and data extraction 
In order to minimize human error and selection bias, two reviewers examined each 
citation for relevance. Those deemed relevant were retrieved in full and compared each
study against the selection criteria. We designed an Access® data extraction form and once
both reviewers selected the eligible studies, data extraction proceeded (See Table 3); data
gathered from these papers were tabulated in a summary data table. Two reviewers
crosschecked the information and verified the methodological details of the sputum
induction procedure as well as the exact number of cases diagnosed by culture of M.
tuberculosis using sputum induction and the total number of patients diagnosed by culture of
M. tuberculosis using induction of sputum and/or any of the comparator techniques listed
above. In cases in which the data reported by the authors was unavailable or insufficient for
the purposes of this review, we contacted authors aiming to complete our data extraction
form.
Extracted Data 
General Information:  First author
 Year of Publication
 Study Design and study population
Sputum Induction Methodology:  Saline solution concentration
 Solution volume
 Nebulizer output and time
Patients:  Number of cases diagnosed by sputum induction
 Number of cases diagnosed by other procedure
 Total of TB cases confirmed by culture















3.1.5 Statistical analysis 
Pooled diagnostic yield and 95% confidence intervals (CI) were calculated from the 
raw study data.  Diagnostic yield was defined as the number of TB cases diagnosed by 
sputum induction (numerator), divided by the total number of culture-confirmed tuberculosis 
cases by any technique (denominator). 
 
3.1.6 Meta-analysis: A random effect model 
The goal of a meta-analysis will often be to estimate the overall or combined effect 
of all the studies reporting the diagnostic yield of sputum induction.  Although, the 
meticulous search in systematic reviews aims to bring together similar studies which can 
provide a general summary estimate, due to various characteristics of the papers that were 
selected for this study, we decided to compute a meta-analysis under the random effects 
model (1, 2). Included papers were assumed to be a random sample of the relevant 
distribution of effects, and the combined effect estimated the mean effect in this distribution.  
3.1.6.1 Measuring hete ogeneity and estimating its causes: Sub-group and meta-
regression analyses 
Sources of variation in meta-analysis include the following: random variation in 
outcome definition, variation between the patient groups in different studies, variation 
between sputum induction protocols, and variation in the way a given protocol is 
implemented. Selected studies showed a difference of effect across various studies. This 
variability commonly referred to as heterogeneity (3) and which may have been responsible 
for observed discrepancies in the results of included studies was also graphically and 
















We measured heterogeneity with the Cochran test (Q) which was calculated as the 
weighted sum of squared differences between individual study effects and the pooled effect 
across studies. Also, we used the I² statistic to describe the percentage of variation across 
studies that was due to heterogeneity rather than chance. Given the fact that, selected studies 
gave us very different effects, we examined the reasons why effects differed across studies 
by subgroup and meta-regression analyses. These techniques allowed us to work out whether 
particular characteristics of studies were related to the yield of sputum induction. We 
identified four groups defined by: (1) age (adults vs. children); (2) saline concentration (<5 
vs. ≥5); (3) HIV prevalence; and (4) the use of comparator methods of diagnosis (FOB with 
BAL). We also conducted a meta-regression analysis as an extension to the subgroup 
analyses in order to investigate whether particular covariates (‗potential effect modifiers‘) 
explain any of the heterogeneity of our estimated effects between studies. It is not reasonable 
to assume that all of the heterogeneity is explained, and the possibility of ‗residual 
heterogeneity‘ must be acknowledged in the statistical analysis.  
 
3.1.7 Study duration 
This systematic review and meta-analysis of the diagnostic yield of sputum induction was 






















3.2 METHODS FOR PATIENT-SPECIFIC INFECTION CONTROL MEASURES 
3.2.1 Study design 
We conducted a prospective observational study to determine levels of TB 
knowledge among patients with suspected TB and newly TB diagnosed patients. Moreover, 
we determine which infection control measures for prevention of TB transmission are 
acceptable among patients with suspected TB and patients with TB in the Breede Valley 
community.  
3.2.2 Data collection tool 
We designed a questionnaire survey consisting of a series of questions on core 
knowledge about TB and patient-specific infection control measures (See Appendix 1). The 
questionnaire was divided into four main sections: (1) a profile (containing some 
demographic characteristics of the respondents such as age, gender, employment status, 
housing conditions) and also, some baseline questions regarding general knowledge on TB, 
particularly on TB transmission mode; (2) infection control measures at health care 
facilities; (3) infection control measures at home; and (3) infection control measures at work 
settings respectively.  
 
Although the Breede Valley region has an average literacy rate of 73% (4), and most 
participants speak English as their second language, we decided to conduct this 
questionnaire survey in participants‘ home language (Afrikaans and IsiXhosa) and adopted 
face-to-face interviews as a means to establish rapport with participants and increase 
participation and response rates. Both, the questionnaire and consent forms were translated 















3.2.2.1 Data collection tool development 
Questionnaire development and evaluation followed criteria that have been defined
as important in patient satisfaction measurement. The development of the questionnaire was 
based on a review of the literature that included TB knowledge questionnaires and
recommendations of members of infection control committees. After a process of peer-
review, the questionnaire was revised and adjusted. This process was designed to ensure
content validity; that the questionnaire addressed important aspects of TB knowledge and 
patient-specific measures to control TB in sufficient detail. The resulting questionnaire was
then piloted by means of semi-structured interviews with five patients with TB and five
patients with suspected TB. Some of the steps in our questionnaire development are 
summarised in the following graph:
Instrument development [Draft version]
Initial peer-review 






Diagram 2. Questionnaire development phases. 
3.2.2.2 Question types 
The questionnaire was structured using both, open-ended and closed-ended 














nominal-polychotomous questions; in some instances, participants had to answer filter and 
contingency questions, which were determined by their responses to some other question. 
Open-ended questions were numerical (discrete) variables (i.e., How many people do you 
share the room with?; How many people are in the same room with you while you are 
working?) 
3.2.2.3 Validity 
In order to improve and test the adequacy of our research instrument, assess the 
feasibility of this project, and identify logistical problems which might have occurred using
proposed methods, we piloted the questionnaire. The initial assessment allowed us to 
determine if this research tool was valid, in other words, if the questionnaire was measuring
what it intended to measure and how appropriate it was for participants. The questionnaire
was tested to ten respondents whose answers were only used for evaluation purposes. After
the questions were answered, we asked the respondents for any suggestions or any necessary
corrections to ensure further improvement and validity of the instrument. The questionnaire
was revised based on the suggestion of the respondents, and irrelevant questions were
excluded. Also, vague or difficult terminologies were changed into simpler ones in order to
ensure the participants‘ comprehension.
Furthermore, the questionnaire was peer-reviewed by three members of the infection control 
committee from the Brewelskloof Hospital, two registered nurses from local TB clinics in 
the Breede Valley Municipality, and six academic members from the South African 
Tuberculosis Vaccine Initiative (SATVI).  
Pre-testing the questionnaire and peer-revision helped us control 
both, external and internal validity. On the one hand, we addressed external validity by 















and infection control practices so that our results could be generalizable. On the other hand, 
internal validity was improved by contacting experts who provided us with assistance in the 
study's design, questionnaire construction, and decisions concerning what should and should 
not be measured. 
 
3.2.2.4 Reliability 
As considered in questionnaire-based studies, the data collection tool must have 
the ability to produce similar or consistent results if this tool is tested several times. And 
although, reliability is difficult to achieve in practice, we addressed it firstly by creating a 
data collection tool that was simple and understandable for participants. Also, considering 
that reliability is more likely to be ensured when participants devote a consistent degree 
of concentration and interest throughout the interview process, we decided to train our 
research staff in how to interact with participants and how to be consistent when asking 
the questions. 
 
3.2.3 Sample size estimation  
Given that no previous research was conducted to determine TB knowledge and 
acceptability of patient-specific infection control measures, we drew a minimum sample size 
anticipating that 50% of participants had core knowledge about TB and knew some of the 
measures for TB control. We estimated an acceptable margin of error of 10%, if the true 
population proportion was 50%. We estimated a minimal sample size of 96 individuals using 
the formula shown below (5). However, we increased our sample to one hundred and ten 
individuals. The first ten participants were recruited in order to pilot our data collection 
instrument. The rest of the participants were divided into two groups, patients with TB and 
















𝒁𝟐 𝑷(𝑷 − 𝟏)
𝒅𝟐
 
Formula: Sample Size Estimation 
Note—. Characters refer to: n: Sample size; Z: Z Statistic for a level of confidence; P: Expected prevalence or 
proportion; d: Precision 
 
 
3.2.4 Selection of participants 
Participants were selected mainly from Worcester, De Doorns, and Rawsonville 
municipalities in the Breede River Valley. This region is located i  the Western Cape 
province of South Africa, and has a population of about 134,271 people and an estimated TB 
prevalence of 1188 / 100 000 population (4). The South African Tuberculosis Vaccine 
Initiative (SATVI) developed a trial site to conduct clinical and epidemiological studies at 
the Brewelskloof Hospital. The present study was nested upon 2 SATVI studies that were 
enrolling adult participants with suspected and confirmed TB in the Breede Valley region 
[An International Multicentre Controlled Clinical Trial to Evaluate High Dose Rifapentine 
and A Quinolone in the Treatment of Pulmonary Tuberculosis—RIFAQUIN (REC REF 
077/2007), and Diagnostic Yield Of Induced Sputum for Rapid Diagnosis of Pulmonary 
Tuberculosis (REC REF 263/2006)]. Participants were selected according to their TB status: 
Patients with TB were defined as individuals who were recently diagnosed and were 
participating in the RIFAQUIN trial; Patients with suspected TB were defined as individuals 
being screened (or under investigation) for TB and who were participating in the Sputum 
Induction Trial. 
 
By the time this study was conducted, patients with suspected TB were in recent 
contact with the TB clinics from the area, and had not received TB education, contrary to 
patients with TB, who initially received TB education from health care workers at the local 















who were also providing participants with information about TB.  The purpose of this 
classification into patients suspected with TB and patients with TB was to determine 
whether on-going contact influences levels of knowledge, with a subsequent increase in 
acceptability of patient-specific measures to control TB.  
3.2.4.1 Inclusion criteria:  
  Male and female adults (> 18 years old)  
 Suspected or confirmed TB  
 Ability to give informed consent  
 Ability to understand and complete the questionnaire  
3.2.4.2 Exclusion criteria:  
 Previous TB  
 Failure to obtain informed consent  
 Participation in another research protocol which precludes taking part in another 
study.  
3.2.4.3 Withdrawal:  
Participants could decide to withdraw at any time, before or during the interview, without 
affecting their routine health care or participation in other SATVI studies.  
 
3.2.5 Ethical considerations 
Permission to carry out the two previously mentioned SATVI trials (REC REF 
077/2007and REC REF 263/2006) was obtained from respective public health authorities 
from the Breede Valley Municipality following all ethical and clinical requirements 
established to conduct research in human subjects. The current study was undertaken after 















the University of Cape Town Research Ethics Committee (UCTREC) and later approved 
(See Appendixes 3 and 4). Translated versions of the consent form and questionnaire were 
also submitted for UCTREC approval (See official translation certificate in Appendix 5). As 
part of the SATVI academic team, researches had the prerogative to conduct this project at 
the clinical research site at Brewelskloof Hospital. 
 
As this study required the participation of human respondents, participants‘ interests 
were safeguarded according to the South African and International standards of Good 
Clinical Practice (GCP) guidelines, applicable government regulations, and institutional 
research policies and procedures.  
 
The consideration of these ethical issues was necessary for the purpose of ensuring 
the privacy as well as the safety of the participants. In order to secure the consent of the 
selected participants, we communicated all important details of the study, including its aim 
and purpose. By explaining these important details, the respondents were able to understand 
the importance of their role in the completion of this study. The respondents were also 
advised that they could withdraw from the study even during the process. With this, the 
participants were not forced to participate in the research. The confidentiality of the 
participants was also ensured by not disclosing their names or personal information in the 
research. Only relevant details that helped in answering the research questions were 
included.  
 
All participants in the study were  provided with a consent form describing adequate 
information concerning the study, providing adequate opportunity for the subject to consider 
all options, responding to the subject's questions, ensuring that the subject has 














and, continuing to provide information as the subject or situation requires.this study and 
providing sufficient information for them to make an informed decision about participation. 
The formal consent of a participant, using the approved consent form, was obtained before 
he or she proceeded to be interviewed. The consent form was signed by the participant or a 
legally acceptable surrogate and by the research staff member obtaining the consent.  
3.2.6 Study time-points 
3.2.6.1 Consenting Process 
Participants being recruited for the RIFAQUIN and the Sputum Induction SATVI
trials were given information about this questionnaire survey on TB knowledge and the
implementation of infection control measures. Then, they proceeded to give us their consent
to take part in this study. Written informed consent for participation was taken either at the
participant‘s home, at the local TB clinics, or at the SATVI research site (See Appendix 2).
3.2.6.2 Interviews 
After informed consent was obtained, participants proceeded to be interviewed. Both
groups were interv ewed at baseline so that we could determine the initial levels of
knowledge about TB and the acceptability of patient-specific measures. Ultimately, only
patients with TB continued to be interviewed for a second time—at the end of their TB
treatment—in order to determine TB knowledge and acceptability of patient-specific
measures over time.
3.2.7 Data analysis 
For each question, differences between proportions were compared at different time-















screening) and patients with TB (at the start of TB treatment). Moreover, differences 
between patients with TB at the start of TB treatment and patients with TB at the end of 
treatment were also calculated through a before and after analysis. 
 
In order to compare the differences between groups (patients with suspected 
TBversus patients with TB; Patients with TB at the start of treatment versus patients with TB 
at the end of treatment) and quantify the association between knowledge and acceptability of 
patient-specific measures for TB control, we computed the Chi-square test—or the Fisher‘s 
exact when applicable, to compare different proportions, and the association between 
knowledge and acceptability of patient-specific measures with different demographic 
variables (patients with suspected TB versus Patients with TB; patients with TB at baseline 
versus patients with TB at the end of treatment). Spearman‘s correlation analysis was 
applied to determine bivariate relationships between knowledge and acceptability scores. 
The level of statistical significance was set at 5%. The statistical package Stata® 11 was used 
for data analysis. 
 
3.2.7.1 Rating scales: Knowledge and acceptability of patient-specific infection control 
measures 
Additionally, in order to measure if there was an association between TB knowledge 
and acceptability of infection control measures, we constructed two analogue psychometric8 
scales, knowledge score and acceptability score, respectively.  
 
Core TB knowledge was determined by a score based on answers given to seven questions 
(TB cause; TB transmission; transmission mode; chemoprophylaxis in children; and, TB 
                                                          















treatment). These questions were based on the ―core TB education elements‖ which are 
described in the South African National TB control programme (6), and which should be 
provided on a regular basis to individuals attending TB clinics (6).  As observed in the 
following schematic table (See Table 4), one point is given for each affirmative answer (e.g., 
Do you know how a person gets TB?; Answer: ―yes‖), and each correct answer would also 
be assigned with a point (e.g., ―TB is transmitted by being in close contact with people who 
have TB‖).  
 






TB cause 7 1 1 
TB transmission 4 1 1 
Transmission mode 8 1 5 
Chemoprophylaxis for children 4 1 1 
TB treatment 4 1 1 
Infection control measures 9 1 9 
Importance of Inf. Control measures 3 1 3 
Total points: 7 21 
 
Table 4. Schematic representation of core TB knowledge score 
 
 
Answers were categorised as poor knowledge and acceptable knowledge depending on the 
total of points obtained by each participant. A perfect score for knowledge would be 28 
points. Poor knowledge was defined by scores ≤ 12 points; acceptable knowledge was 
delimited as a score > 12 points. 
 
The acceptability score was created on the same basis as the knowledge score. The sections 
about infection control measures at health care facilities, home and workplaces comprised a 
total of 14 questions, which along with their ―attributes‖ gave us a total of 18 points for a 
perfect score. Low acceptability of patient-specific measures was then delimited by a score ≤ 














3.2.8 Study Duration 
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            This chapter comprises two sections which cover (1) the results of the systematic 
review and meta-analysis of sputum induction for TB diagnosis; and (2) results from the 
prospective observational study of TB infection control measures in the Breede Valley 
community.  
4.1 SPUTUM INDUCTION: A COST-EFFECTIVE METHOD TO IMPROVE TB 
DIAGNOSIS 
 
4.1.1 Study selection 
A total of 90 publications were identified by a combined search in an electronic 
database and also by examining relevant reference lists and consultation with experts. Forty-
one papers were selected and reviewed (See detailed study selection flow gram in Figure 4). 
After revision, only 17 studies were included in the review. Selected studies comprised a 
total sample of 3,988 participants and study sample sizes ranged from 28 to 1,869 
individuals (median n=129, IQR 94 - 189). The number of participants diagnosed with 
culture-positive TB ranged from 7 to 138 individuals (median n=20, IQR 15 – 48). 29% of 
studies were conducted in children and 47% were either conducted in high HIV prevalence 
areas, or researchers reported a HIV sero-prevalence greater than 10% among participants. 















induction was performed using saline concentrations ranging from 3% to 20% (median 3%, 
IQR 3 - 10), using a variety of ultrasonic nebulizers, conventional air compressors or by 
providing hypertonic saline nebulisation via O2 cylinders.  
 
Study Selection Process 
 
Figure 4.  Flow chart of the study selection process 
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PubMed search 
n=78 
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4.1.2 Publication bias 
We explored the potential for publication bias using a funnel plot. The funnel plot 
was plotted using proportions versus standard error (See Figure 5). The graphical analysis 
showed no evidence of publication bias. We complemented the funnel plots by using the 
Eggers test as a bias indicator (Egger bias test = -1.75 [95% CI = -4.8 - 1.3]  p = 0.24) 
Figure 5. Symmetrical funnel plot in the absence of Publication Bias
4.1.3 Sputum induction and comparison procedures
Among the selected studies, 35% of the articles compared sputum induction to 
gastric lavage, 24% compared sputum induction to FOB, 6% compared sputum induction 
to spontaneous expectorated sputum, 17% compared sputum induction to other invasive 
procedures (including the string test, lymph node biopsy, and nasopharyngeal aspiration), 
and finally 18% of the studies compared three diagnostic procedures (sputum induction, 
spontaneous sputum, and FOB in one publication; and sputum induction, gastric lavage, 
and FOB in the other) (See Table 5).   
Publication Bias Assessment 
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Hensler  [1961] Adults SNEG/SUNPROD 28 0 10 GL 3 3 19 14 20 
Beck  [1962] Adults SNEG/SUNPROD 62 0 10 SS NS† NS† 8 3 10 
Yue  [1967] Adults SNEG/SUNPROD 189 0 10 GL NS† NS† 138 84 153 
Anderson  [1995] Adults SNEG/SUNPROD 92 0 3 FOB 1 1 20 19 26 
Zar  [2000] Children SALL 142 100 5 GL 1 2 15 9 16 
Conde  [2000] Adults SNEG/SUNPROD 251 10 3 FOB 1 1 94 103 143 
McWilliams [2002] Adults SNEG/SUNPROD 129 0 3 FOB 3 1 13 1 27 
Zar  [2005] Children SALL 250 38 5 GL 3 3 51 38 62 
Vargaz  [2005] Adults SNEG/SUNPROD 212 76 20 ST 1 1 9 15 15 
Iriso  [2005] Children SALL 126 49 3 PLNB 1 1 30 6 36 
Brown  [2007] Adults SNEG/SUNPROD 140 0 3 GL / FOB 3 3/1 42 37 54 
Schoch  [2007] Adults SALL 101 0 3 FOB / SS 2 1/2 27 28 33 
Owens  [2007] Children SALL 94 47 3 NPA NS† NS† 19 21 24 
Ganguly  [2008] Adults SNEG/SUNPROD 52 0 3 FOB NS† NS† 7 5 20 
Morse  [2008] Adults SALL 140 81 20 GL NS† NS† 48 13 57 
Hatherill  [2009] Children SALL 1869 2 5 GL 2 2 108 127 191 
Bell  [2009] Adults SNEG/SUNPROD 111 68 3 FOB /GL/ SS NS† NS† 13 26 18 
Table 5. Description of Studies included in the Meta-Analysis 
Note.—“Category of TB Suspect‖ differentiates studies that included all patients with suspected TB(SALL ) from those that pre-screened only smear negative (SNEG) and/or sputum unproductive (SUNPROD) 
participants.  “NS†‖ Refers to included studies in which the total of samples per procedure was not clearly specified. 














4.1.4 Sputum induction diagnostic yield 
M. tuberculosis was isolated in 975 (24%) of the 3,988 participants. Microbiological
diagnosis of TB was established through sputum induction in 627 cases (64% of all culture-
confirmed TB diagnoses). Figure 6 shows the Forest plot of diagnostic yield with 95% CI 
for each study. . Diagnostic yields for sputum induction ranged from 35% to 95% (median 
79%), with pooled diagnostic yield of 74% (95% CI 65 to 81%).  
Sputum Induction Diagnostic Yield 
Figure 6. Overall Sputum Induction Diagnostic Yield
Diagnostic Yield of Sputum Induction among all the studies: Heterogeneity tests: Cochran Q = 115.29 (df = 16) 
P < 0.0001 Moment-based estimate of between studies variance = 0.12 I² (inconsistency) = 86% (95% CI = 79% 
to 90%).  Pooled proportion = 74 (95% CI = 65 - 81). 
Inspection of the above forest plot showed that the sputum induction diagnostic yield was 
inconsistent across the outcomes reported by each study; Statistical tests to determine 
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variability showed was substantial heterogeneity in study results: X2 (df=16) = 115, P < 
0.0001, I² 86% (95% CI 79% to 90%). Further analyses were conducted to explore the 
possible sources of this variability via sub-group and meta-regression analyses. 
 
4.1.5 Exploring sources of heterogeneity 
4.1.5.1 Sub-Group Analyses 
Sub-group analyses of diagnostic yield by age category, concentration of nebulized 
saline, HIV prevalence, and use of FOB as the comparator method, were displayed in 
separate Forest plots (See Figures 7a, 7b ,8a, 8b, 9a, 9b, 10a, and 10b). Summary estimates 
are shown in Table 6. 
 
Category Pooled Estimate (%) 
Confidence 
Interval 
Overall Yield 74 (65-81) 
Adults vs. Children 
Adults 71 (60 -81) 
Children 79 (62-92) 
Saline Concentration 
Saline Concentration <5 73 (63-82) 
Saline Concentration ≥5 75 (59-89) 
HIV Prevalence 
High HIV Prevalence 78 (69-86) 
Low HIV Prevalence 69 (54-83) 
Use of Fiber-Optic Bronchoscopy (FOB) 
No use of FOB 81 (70-90) 
Use of FOB 58 (38-77) 
 
Table 6.  Diagnostic Yield of Sputum Induction by sub-groups. 
 
The pooled diagnostic yields for adults and children were not significantly different: 
71% (95% CI 60% to 81%) and 79% (95% CI 62% to 92%) respectively.  However, the 
confidence intervals were wide and significant heterogeneity was observed [adults:  














0.0001, I² = 89% (95% CI 77% to 94%)].  Age category was not significantly associated 
with diagnostic yield in univariate analysis (p = 0.354).  
Sputum Induction Diagnostic Yield: Adults vs. Children. 
Diagnostic Yield of Sputum Induction by Subgroup Analysis according age groups:   Adults (a): Heterogeneity 
tests: Cochran Q = 73.36 (df = 11) P < 0.0001 Moment-based estimate of between studies variance = 0.13 I² 
(inconsistency) = 85% (95% CI = 75% to 90%) Pooled proportion = 71 (95% CI = 60 - 80). 
Figure 7a. Sputum Induction in Adults 
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Diagnostic Yield of Sputum Induction by Subgroup Analysis according age groups: Children (b):
Heterogeneity tests: Cochran Q = 37.6 (df = 4) P < 0.0001 Moment-based estimate of between studies variance
= 0.17 I² (inconsistency) = 89% (95% CI = 77% to 94%) Pooled proportion = 79 (95% CI = 61 - 92).
Studies using saline concentrations < 5% demonstrated pooled diagnostic yield of
72% (95% CI 63% to 82%), compared to 75% (95% CI 59% to 89%) for studies that used
concentrations ≥ 5%. Significant heterogeneity was also found in each subgroup [saline 
concentration <5%: X²(df=9) = 56, P < 0.0001, I² = 84% (95% CI 71% to 90%); and saline
concentration ≥ 5%: X²(df=6) = 47, P < 0.0001, I² = 88% (95% CI 76% to 92%)]. %)].  
Saline concentration was positively associated with diagnostic yield in univariate analysis,
although results were not statistically significant (p = 0.517). 
Figure 7b. Sputum Induction in Children 
0.0 0.2 0.4 0.6 0.8
Combined 
0.79 (0.62, 0.92)
Hatherill [2009] 0.56 (0.48, 0.63) 
Owens [2007] 0.79 (0.58, 0.93) 
Iriso [2005] 0.83 (0.67, 0.94) 
Zar [2005] 0.88 (0.77, 0.95) 
Zar [2000] 0.94 (0.70, 1.00) 




















Diagnostic Yield of Sputum Induction by Subgroup Analysis according to Salinity:  Saline Concentration <5% 
(a): Heterogeneity tests: Cochran Q = 56.55 (df = 9)  P < 0.0001 Moment-based estimate of between studies 
variance = 0.09 I² (inconsistency) = 84% (95% CI = 71% to 90%) Pooled proportion = 73 (95% CI = 63 - 82). 
(b): Cochran Q = 47.94  (df = 6)  P < 0.0001 Moment-based estimate of between studies variance = 0.19 I² 
(inconsistency) = 88% (95% CI = 76% to 92%)  Pooled proportion = 75 (95% CI = 59 - 89). 
 
Figure 8b. Sputum Induction with Saline Concentrations ≥ 5% 
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Figure 8a. Sputum Induction with Saline Concentrations < 5% 
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Pooled diagnostic yield did not differ in studies conducted in high HIV prevalence 
populations compared to low HIV prevalence study populations: 75% (95% CI 65% to 84%) 
versus 71% (95% CI  55% to 85%), respectively. There is considerable between-study 
variability in each subgroup [high HIV prevalence: X²(df=8) = 47, P < 0.0001, I² = 83% 
(95% CI 67% to 89%); and low prevalence: X²(df=7)  = 60,  P < 0.0001, I² = 88% (95% CI 
79% to 92%)].  HIV prevalence was not significantly associated with diagnostic yield in the 
univariate analysis (p = 0.358).  
 




Diagnostic Yield of Sputum Induction by Subgroup Analysis according to HIV Prevalence:  High HIV 
prevalence (a): Heterogeneity Tests: Cochran Q = 21.97 (df = 7) P < 0.0026 Moment-based estimate of between 
studies variance = 0.05 I² (inconsistency) = 68% (95% CI = 12% to 83%).  Pooled proportion = 78 (95% CI = 






0.0 0.2 0.4 0.6 0.8 1.0 
Combined 0.78 (0.69, 0.86) 
Bell [2009] 0.72 (0.47, 0.90) 
Morse [2008] 0.84 (0.72, 0.93) 
Owens [2007] 0.79 (0.58, 0.93) 
Iriso [2005] 0.83 (0.67, 0.94) 
Vargaz [2005] 0.53 (0.27, 0.79) 
Zar [2005] 0.88 (0.77, 0.95) 
Conde [2000] 0.66 (0.58, 0.74) 
Zar [2000] 0.94 (0.70, 1.00) 
Diagnostic Yield (95% confidence interval) 














Diagnostic Yield of Sputum Induction by Subgroup Analysis according to HIV Prevalence: Low HIV
prevalence (b): Heterogeneity Tests: Cochran Q = 89.93 (df = 8) P < 0.0001 Moment-based estimate of between
studies variance = 0.20 I² (inconsistency) = 91% (95% CI = 86% to 94%) Pooled proportion = 69 (95% CI = 54
- 82).
The diagnostic yield of sputum induction in studies that did not use FOB as the 
comparator method was higher than those which included this procedure: 81% (95% CI 69 –
90%) versus 58% (95% CI 37 – 77%) respectively. 
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Sputum Induction Diagnostic Yield: Use of Fiber-optic Bronchoscopy (FOB) as the comparator 
method. 
Diagnostic Yield of Sputum Induction by Subgroup Analysis according to the use of Fiberoptic Bronchoscopy.  
Studies reporting no use of FOB (a): Heterogeneity Tests: 78.03 (df = 9) P < 0.0001; Moment-based estimate of 
between studies variance = 0.15; I² (inconsistency) = 89% (95% CI = 81% to 92.1%).  Pooled proportion = 81 
(95% CI = 69 - 90). Studies reporting the use of FOB (b): Heterogeneity Tests: Cochran Q = 93.51 (df = 6) P < 
0.0001; Moment-based estimate of between studies variance = 0.28; I² (inconsistency) = 93.6% (95% CI = 90% 
to 96%)  Pooled proportion = 58% (95% CI = 37 - 77). 
Figure 10b. Sputum Induction Studies in comparison to FOB
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Figure 10a. Sputum Induction Studies without FOB 
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Figure 11. The Effects of Saline Concentration and FOB Use on Diagnostic Yield. 
4.1.5.2 Univariate and Meta-Regression Analysis 
Univariate regression analysis demonstrated no significant associations between 
diagnostic yield and HIV prevalence (p=0.37), or age category (p=0.35). Use of FOB as the
comparator method was associated on average with 22% reduction in the diagnostic yield of
sputum induction (95% CI 2 – 42%), p=0.036, compared to studies that did not use FOB, in
the univariate analysis. However, interpretation of this association was confounded by use of
3% saline in all studies using FOB as the comparator method. A meta-regression analysis
including the covariates ―Saline concentration‖, ―Study Population‖, ―Use of FOB‖ and
―Study HIV Prevalence‖ was conducted in order to examine all possible confounders that
might conceal the effect these covariates on the yield of sputum induction. HIV prevalence
and age category had no effect on the model and were excluded. The meta-regression model
confirmed that FOB usage (p=0.21) and s line concentration (p=0.31) were not
















4.2 TB KNOWLEDGE, TB INFECTION CONTROL AND ACCEPTABILITY OF 
PATIENT-SPECIFIC MEASURE TO REDUCE TB TRANSMISSION 
 
4.2.1 Participants Demographic Profile 
 
We recruited one hundred and ten adults with suspected and confirmed TB, who 
were participants in on-going community studies. Ten participants were interviewed to pilot 
and validate the questionnaire (See appendix 1). The remaining 100 participants, 50 patients 
with TB and 50 patients with suspected TB, were interviewed. Demographic data are 
presented as follows:  
 
 
Variable and Attribute (s) Patients with suspected TB (%) 
Patients with TB 
(%) Total P-Value 
Language: IsiXhosa 10 (20) 12 (24) 22 
0.629 
  Afrikaans 40 (80) 38 (76) 78 
Gender: Females 28 (56) 19 (38) 47 
0.071 
  Males 22 (44) 31 (62) 53 
Age (median)   33 years (18-54) 33 years (19 - 54) ─ 0.526 
Housing Conditions           
Total people in home:   ≥ 5 people 20 (40) 24 (48) 44 
0.42 
  < 5 people 30 (60) 26 (52) 56 
Total people/room (median) 2 people (2-9) 2 people (2-7) ─ 1.000 
Sleep alone   11 (22) 7 (14) 18 0.298 
Working Status:  Currently working 29 (58) 27 (54) 56 0.687 
  Working indoors 14 (48) 7 (26) 21 
0.084 
  Working outdoors 15 (52) 20 (74) 35 
 
Table 7. Demographic Data 
  
 
Table 7 summarizes descriptive information from the 100 participants enrolled in 
this study. All participants were living in the Breede Valley River community when the 
interviews were conducted. Seventy-eight percent (78%) of the recruited participants were 
Afrikaans speakers while the remaining 22% were IsiXhosa speakers. There was a similar 
gender distribution among participants, 53% males and 43% females. No differences were 















Although no statistical differences were found between patients with suspected TB and 
patients with TB, housing or living conditions reflected overcrowding conditions9 among 
both groups. 44% of all participants responded that they were living with more than 5 
individuals in their homes. A significant proportion of participants (82%) confirmed that 
there were more than 2 individuals per room, whereas only 18% of the participants slept 
alone; 29% of the participants responded that they were sharing their room only with 
children; 24% responded that they were sleeping in the same room as both adults and 
children; and 29% were sharing a room only with other adults (See Figure 12). 
 
 
Figure 12. Sleeping Conditions 
 
 
Only 56% of the participants were working. Taking into account that the risk of 
transmitting TB is higher when the proximity of contact increases, we asked the participants 
whether they were working indoors or outdoors. 21% of the participants were working 
                                                          
9Overcrowding is defined as households which don‘t have at a minimum number of rooms equal to: one room for 
the household; one room per couple in the household; one room for each single person aged 18 or more; one 
room per pair of single people of the same gender between 12 and 17 years of age; one room for each single 
person between 12 and 17 years of age and not included in the previous category; and one room per pair of 
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indoors and the remaining 35% out of all participants worked outdoors. Patients with TB 
who were working indoors (7%) were in contact with median 15 co-workers, whereas the 
median number of co-workers in the case of patients with suspected TB was 8 (Patients 
suspected with TB, range 1 - 84 co-workers; patients with TB, range 6 - 50 co-workers). 
 
We also gathered information regarding ―cough status‖. Eighty-seven percent (87%) 
of the participants were coughing before seeking medical attention. In total, 18% of the 
participants stated to have been coughing for less than 2 weeks. More patients with 
suspected TB had been coughing for 2 weeks compared to patients with TB. There were no 
significant differences in relation to cough duration of two weeks or more before seeking 
medical attention. However, patients with TB were more likely to report that they were 
coughing for more than 4 weeks when they sought medical care (See Figure 13). 
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4.2.2 Baseline knowledge among participants 
Patients‘ responses to questions regarding core knowledge elements about 
transmission of TB such as: what is TB?, what causes it?, how is TB transmitted?, who is 
more susceptible to developing TB disease?, what measures can be taken to limit TB 
transmission?, and the implementation of chemoprophylaxis for children, showed no major 
differences between patients with TB versus patients with suspected TB at baseline (See 
Table 8). 
Only 57% of all respondents reported that they knew the cause of TB. When these
participants were asked to specify their answer, 32% of respondents attributed causes other
than “Germs”. Participants reported that TB was caused by: drinking alcohol (5%),
uncleanliness (5%), smoking (12%), the use of drugs (4%), and that it was passed down
through generations (6%). Only 25% of the participants agreed that TB was caused by a
micro-organism. Surprisingly, more patients with suspected TB knew that TB was a
microbial disease as compared to patients with TB (p –value 0.003) (See Table 8). 
Ninety-five percent of the participants reported that TB could be transmitted to other
people. A small difference was found between patients with suspected TB (45%) and
patients with TB (50%) when asked about TB transmission: Patients with TB were more
aware that TB follows a human-to-human transmission pattern (p-value 0.022). However, 
only 54% of the participants confirmed that they knew how the disease was transmitted.
Participants reported that TB could be transmitted through sharing food utensils; by kissing;
and even by living in low-temperature areas. Only 20% and 26% of patients with TB and
patients with suspected TB, respectively, reported that TB was transmitted by being in close














When participants were asked whether children would require chemoprophylaxis 
(isoniazid preventive therapy [IPT]) if they were exposed to TB, most participants (93%) 
agreed. However, knowledge of which particular group of children require IPT was low 
among patients with TB and patients with suspected TB. For instance, 75% of participants 
believed that all children would require IPT after exposure to M. tuberculosis (See Table 8). 
Less than half of the participants reported that TB transmission could be stopped or
reduced once an effective treatment regimen is started. Neither groups reported a clear













General Information on Tuberculosis 
Patients with suspected TB (%) 
 n = 50 
Patients with TB (%) 
n = 50 
Total 
n = 100 
P-Value
Do you know the cause of TB? 32(32) 25(25) 57 0.157 
Alcohol 2(2) 3(3) 5 1.000 
Generations 2(2) 4(4) 6 0.678 
Germs 19(19) 6(6) 25 0.003* 
Uncleanliness 2(2) 3(3) 5 1.000 
Smoking 5(5) 7(7) 12 0.538 
Toxic Substances 2(2) 2(2) 4 1.000 
Do you think TB can be passed on to other people? 45(45) 50(50) 95 0.022* 
Adults 5(5) 9(9) 14 0.249 
Young children 11(11) 10(10) 21 0.806 
Elderly people 3(3) 6(6) 9 0.487 
Co-Workers 4(4) 5(5) 9 1.000 
HIV/AIDS Patients 4(4) 5(5) 9 1.000 
All above mentioned 26(26) 30(30) 56 0.420 
Not sure 7(7) 9(9) 16 0.585 
How a person does get TB? 29(29) 25(25) 54 0.422 
Sharing food utensils 3(3) 6(6) 9 0.487 
Kissing people 6(6) 4(4) 10 0.505 
Living or being in close contact with people 26(26) 20(20) 46 0.229 
Living in or moving to cold areas 9(9) 6(6) 15 0.401 
Do young children need chemoprophylaxis therapy once exposed to MTB? 44(44) 49(49) 93 0.112 
Children < 5 years 4(4) 10(10) 14 0.084 
Children > 5 years 1(1) 2(4) 3 0.558 
All HIV(+) children 1(1) 0(0) 1 1.000 
All children 38(38) 37(37) 75 0.817 
Table 8. Difference in core TB knowledge between patients with suspected TB and patients with TB from the Breede Valley Community, Worcester, 2011. 













General Information on Tuberculosis 
Patients with suspected TB (%) 
n = 50 
Patients with TB (%) 
n = 50 
Total 
n = 100 
P-Value
Do you know when a TB patient usually stops transmitting the disease? 18(18) 23(23) 41 0.309 
First day of treatment 1(1) 3(3) 4 0.617 
> 2 weeks 3(3) 6(26 9 0.487 
2nd month 2(2) 2(2) 4 1.000 
Complete a course of anti-TB treatment 12(12) 12(12) 24 1.000 
Do you know some measures to control tuberculosis? 30(30) 19(19) 49 0.028* 
Use facemask during transportation to a hospital or clinic 14(14) 14(14) 28 1.000 
Use facemask in a hospital or clinic 17(17) 17(17) 34 1.000 
Cover his/her mouth when coughing and/or sneezing in a hospital or clinic 24(24) 16(16) 40 0.102 
Cover his/her mouth when coughing and/or sneezing at home or at work 24(24) 15(15) 39 0.065 
Be separated from other patients and requested to wait in a separated area 11(11) 11(11) 22 1.000 
Sleep in a room alone, or avoid sleeping in a room with small children 17(17) 12(12) 29 0.271 
Open house windows to the outside air 20(20) 12(12) 32 0.086 
Use fans for moving air to the outside 13(13) 8(8) 21 0.220 
Complete their course of anti—TB treatment 27(27) 14(14) 41 0.008* 
Do you know why measures to control tuberculosis are important? 30(30) 23(23) 53 0.161 
Prevention for HCW 17(17) 15(15) 32 0.668 
Prevention at home/close contacts 26(26) 20(20) 46 0.229 
Prevention at work 17(17) 15(15) 32 0.668 
Cont. Table 8. Difference in Core TB knowledge between patients with suspected TB and patients with TB from the Breede Valley Community, Worcester, 2011.














Only 49% of the participants reported they knew of measures to control TB. A
higher proportion of patients with suspected TB claimed to know of patient-specific
measures to help reduce TB transmission (30%), compared to patients with TB (19%).
However, answers regarding implementation of patient-specific measures such as: (1) use
of facemasks during transportation to a hospital or clinic; (2) use of facemasks in a 
hospital or clinic; (3) covering the mouth at a health care facility; (4) covering the mouth 
at home or at work; (5) separation from other patients, (6) sleeping alone, or avoiding
sleeping in a room with small children; (7) opening house windows to the outside air; and
(8) the use of fans for moving air to the outside, showed no significant difference between 
patients with suspected TB and patients with TB (See Figure 14). On the other hand,
when participants were asked about treatment as an infection control measure, more 
patients with suspected TB (27%) acknowledged that TB chemotherapy was a means to
reduce transmission of the disease, compared to patients with TB (14%).
Figure 14. Difference in baseline knowledge about infection control measures among patients with suspected 











Isolation Sleep alone Open windows Fans' use
Anti—TB 
treatment 
TB Patients 14 17 16 15 11 12 12 8 14

















Knowledge of individual infection control measures at baseline among TB
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When participants were asked if they knew of any methods to reduce the
transmission of M. tuberculosis, more patients with suspected TB than patients with TB
reported that they knew of such infection control measures (patients with TB60% patients
with suspected TB compared to 38% Patients with TB). However, when participants were
questioned about which measures could reduce TB transmission, a greater proportion of
patients with suspected TB believed that by completing a course of anti-TB treatment, TB
transmission could be prevented, compared to patients with TB (p-value 0.008). Also,
23% and 30%of patients with TB and patients with suspected TB, respectively, reported
that they knew why these TB infection control measures were important. Most
participants reported that the prevention measures were aimed at preventing transmission
of TB at home. 52% of patients with suspected TB r ported that these measures were
essential to prevent family members from developing infection, compared to 40% of
patients with TB (See Figure 15). 

















































Participants reported that they had received information about TB from different 
sources: Health care facilities, other patients with TB, family, friends, at work, on the 
radio and also on T.V. (See Figure 16). Although most participants said that they 
received information from health care workers, no significant differences were found 
when between patients with suspected TB and patients with TB, except that more patients 
with suspected TB received information at their work place as compared to patients with 
TB. 
Figure 16. Difference on baseline knowledge about infection control measures among patients with 
suspected TB and patients with TB from the Breede Valley Community, Worcester, 2011. 
*HCW Health care worker.
4.2.2.1 Acceptability of infection control measures at a health care facility 
When participants were asked about infection control measures at health care 
facilities, there seemed to be a high level of acceptability for these precautions. Eighty-
nine percent (89%) of the participants were willing to use facemasks in health care 
facilities. Similar levels of acceptability of such measures were found among patients 
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disagreed with the use of facemasks highlighted that they did not understand the
importance of this measure. No differences were found between patients with suspected
TB and patients with TB when participants were asked whether they were prepared to
cover their mouth with a handkerchief or tissue while at health care facilities. The only
measure at health care facilities that many participants were reluctant to participate in was
isolation and/or separation from other patients (48%). Patients with suspected TB and
patients with TB who did not agree with the implementation of this measure reported that
they would not like to be separated from other patients, and the fear of rejection or TB













Infection Control Measures at Health Care Facilities 
Patients with suspected TB (%) 
n = 50 
Patients with TB (%) 
n = 50 
Total 
n = 100 
P-Value
Use facemask in health care settings? Y/N 41 (41) 48 (48) 89 0.025* 
If no, why? Uncomfortable 3 (3) 1 (1) 4 0.617 
Not important 5 (5) 0 (0) 5 0.056 
TB stigma 1 (1) 1 (1) 2 1.000 
Cover mouth when coughing and/or  sneezing in a health care setting?  Y/N 48 (48) 50 (50) 98 0.495 
If no, why? No handkerchief or tissue 2 (2) 0 (0) 2 0.495 
Complete a course of anti—TB treatment?  Y/N 50 (50) 50 (50) 100 - 
Be separated from other patients? Y/N 32 (32) 36 (36) 68 0.391 
If no, why? Do not like being separated from others 9 (9) 6 (6) 15 0.401 
TB stigma 7 (7) 5 (5) 12 0.538 
HIV stigma 3 (3) 5 (5) 8 0.715 
Table 9. Infection control measures at health care facilities among patients with suspected TB and patients with TB














4.2.2.2 Acceptability of infection control measures at home 
Certain measures to control the transmission of TB in the home were acceptable
to most participants. Precautions such as covering the mouth with a handkerchief and/or
tissue, opening house windows to the outside, and being isolated at home, were accepted
by most participants. No significant differences were found between groups (See Table
10). Even though more than 50% of the participants considered that these patient-specific
measures were feasible, the use of facemasks at home, the use of fans to increase
ventilation, as well as sleeping in a room by themselves or avoiding sleeping in a room
with small children were less acceptable. Patients with TB were more accepting of the use
of facemasks compared to patients with suspected TB. Sixty-five percent (65%) of the
participants who were willing to use isolation at home as a method to reduce the
transmission of M. tuberculosis to their families, reported that this was feasible in their
homes, whereas 20% reported that even though they were willing to be isolated, isolation
was not feasible at their homes. Only 15% of all participants reported that they were not













Infection Control Measures at Home 
Patients with suspected TB (%) 
n = 50 
Patients with TB (%) 
n = 50 
Total 
n = 100 
P-Value
Cover mouth with a handkerchief/tissue when coughing and/or 
sneezing? 50 (50) 49 (49) 99 1.000 
If no, why? HIV stigma 1 (1) 0 (0) 1 1.000 
Cover mouth with facial mask when coughing and/or sneezing? 21 (21) 33 (33) 54 0.016* 
If no, why? Forget 8 (8) 2 (6) 10 0.046* 
Not interested 9 (9) 0 (0) 9 0.003* 
No facial mask with me all the time 17 (17) 12 (12) 29 0.271 
Secret 1 (1) 0 (0) 1 1.000 
TB stigma 5 (5) 0 (0) 5 0.056 
HIV stigma 5 (5) 3 (3) 8 0.715 
Sleep in a room by oneself or avoid sleeping in a room with small 
children? 33 (33) 35 (35) 68 0.668 
If no, why? Not necessary 4 (4) 7 (7) 11 0.338 
Not enough rooms 10 (10) 9 (9) 19 0.799 
Secret 1 (1) 0 (0) 1 1.000 
Family rejection 3 (3) 1 (1) 4 0.617 
Open house windows to the outside? 43 (43) 46 (46) 89 0.338 
If no, why? Not necessary 1 (1) 1 (1) 2 1.000 
No windows 1 (1) 0 (0) 1 1.000 
Cold 3 (3) 3 (3) 6 1.000 
Security 2 (5) 0  (0) 2 0.495 
Table 10. Infection control measures at home among patients with suspected TB and patients with TB 













Infection Control Measures at Home 
Patients with suspected TB (%) 
n = 50 
Patients with TB (%) 
n = 50 
Total 
n = 100 
P-Value
Use fans if possible for moving air to the outside? 30 (30) 29 (29) 59 0.839 
If no, why? Not important 8 (8) 8 (8) 16 1.000 
No fans 10 (10) 13 (13) 23 0.476 
Cannot afford it 3 (3) 1 (1) 4 0.617 
Isolation at home? 42 (42) 43 (43) 85 0.779 
Isolation is feasible 31 (31) 34 (34) 65 0.529 
Willing to do it, but not feasible 11 (11) 9 (9) 20 0.617 
If not willing, why? 8 (8) 7 (7) 15 0.779 
Physically impossible to be isolated 6 (6) 6 (6) 12 1.000 
It won't work 1 (1) 0 (0) 1 1.000 
Family won't allow 1 (1) 1 (1) 2 1.000 














4.2.2.3 Acceptability of infection control measures at work 
Infection control measures at work had a relatively high level of acceptability
among participants at baseline. Sixty-five percent (65%) of all participants would be
willing to stop working until they have completed 2 weeks of treatment, or until smear
microscopy is negative. The majority of patients who did not agree with this measure
stated that they would not receive any income. TB and HIV stigma were not contributing
factors to participants‘ decision. 98% of the participants stated that they would be more 
willing to cover their mouth with a handkerchief or tissue at work, compared to 58% who













Infection Control Measures at Work 
Patients with suspected TB (%) 
n = 50 
Patients with TB (%) 
n = 50 
Total 
n = 100 
P-Value
Stop working until you have completed 2 weeks of treatment, or longer? 32 (32) 33 (33) 65 0.834 
If no, why? Not so sick 7 (7) 9 (9) 16 0.585 
No compensation 10 (10) 8 (8) 18 0.795 
TB stigma 1 (1) 1 (1) 2 1.000 
HIV stigma 2 (2) 2 (2) 4 1.000 
Cover mouth with a handkerchief/tissue when coughing and/or sneezing? 48 (48) 50 (50) 98 0.495 
If no, why? TB stigma 2 (2) 0 (0) 2 0.495 
Cover mouth with facial mask when coughing and/or sneezing?  Y/N 25 (25) 33 (33) 58 0.105 
If no, why? Forget 6 (6) 0 (0) 6 0.027* 
Not interested 7 (7) 1 (1) 8 0.059 
No facial mask all the time 12 (12) 9 (9) 21 0.461 
Secret 3 (3) 2 (2) 5 1.000 
TB stigma 3 (3) 0 (0) 3 0.242 
HIV stigma 3 (3) 3 (9) 6 1.000 
Table 11. Infection control measures at work among patients with suspected TB and patients with TB














4.2.2.4 Relationship between baseline knowledge and acceptability of 
infection control measures 
No major differences were found between patients with suspected TBand patients
with TB neither in knowledge nor in acceptability of field-adapted measures to prevent
TB transmission. At baseline, only 33% of the participants (15% patients with TB; 18%
patients suspected with TB) had an adequate understanding of core TB knowledge (i.e. 
what TB is, how TB is transmitted, the causative agent, and essential infection control
measures—covering mouth, improve ventilation, complete TB treatment). Eighty percent
(80%) of all participants agreed to implement some TB prevention measures. However, 
more than half of the individuals in each group disagreed with the implementation of
patient-specific measures.
Core knowledge and acceptability of TB infection control measures at 
baseline
Figure 17. Relationship between baseline TB knowledge and acceptability of infection control measures 
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Neither differences in level of knowledge (p-value 0.523) nor differences in 
acceptability of patient-specific infection control measures (p-value 0.134) were found 
between patients with suspected TB and patients with TB. When we quantified the 
relationship between core TB knowledge and the acceptability of these measures at 
baseline (See Figure 17), we did not find any significant correlation (Spearman 
correlation-coefficient 0.003 p = 0.9980). 
4.2.3 Knowledge of patients with TB at the end of treatment
Patients with TB were interviewed for a second time. Nine percent (9%) of all
participants who were recruited at baseline could not attend the second interviews and
therefore 82 paired-interviews were analyzed.
Knowledge about TB and infection control measures increased significantly over
time, between start and end of treatment, under research conditions. There was a 32%
increase in the proportion of participants who stated that they knew what the cause of TB
was, and a 41% increase in participants who agreed that TB was caused by a micro-
organism. 44% of respondents, who, at baseline, stated that they did not to know how TB
is transmitted, reported that they knew how a person can get TB, at the second interview.
When participants were asked to specify how TB was transmitted, an increase of 54% of
participants reported that only by being in close contact with an infectious source, other
individuals could get TB. Most participants believed that children require IPT once
exposed to M. tuberculosis, but there was no change over time. After receiving education
under research conditions, most participants reported that they knew when a TB patient
usually stops transmitting the disease (32% increase in response rate). Measures such as














the outside air and completing anti—TB treatment were more often recognized as 
measures to reduce the transmission of TB at the end of participant‘s follow-up, 
compared to baseline. An increase of 41% in a positive response over time was found 
when participants were asked whether they knew the importance of these measures. A 
higher proportion of participants responded that these preventive methods helped to 
reduce TB transmission for health care workers (56%), home contacts (66%) and co-













Knowledge & Perceptions about Tuberculosis 
Baseline (%) 
n = 41 
End 
Treatment (%) 






Do you know the cause of Tuberculosis (TB)? 23 (28) 36 (44) 32 13.21 - 36.46 0.001* 
Germs /Other causes 6 (7) 25 (30) 41 5.38 - 56.82 <0.001* 
How a person gets TB? Y/N 19 (23) 37 (45) 44 24.51 - 48.66 <0.001* 
Sharing food utensils 5 (6) 6 (7) 2 ─10.79 - 13.69 1.000 
Kissing people 3 (4) 9 (11) 15 ─1.03 - 19.39 0.07 
Living or being in close contact with people 14 (17) 36 (44) 54 33.81 - 58.41 <0.001* 
Living in or moving to cold areas 6 (7) 10 (12) 9 ─5.89 - 18.27 0.289 
Do you think tuberculosis can be passed on to other people? 41 (50) 41 (50) ─ ─ N/A 
Adults 8 (10) 4 (5) 10 ─5.89 - 18.27 0.289 
Young children 8 (10) 5 (6) 7 ─8.81 - 18.66 0.508 
Elderly people 5 (6) 4 (5) 2 ─8.62 - 10.91 1.000 
Co-Workers 5 (6) 3 (4) 5 ─8.11 - 13.37 0.688 
HIV/AIDS Patients 4 (5) 4 (5) 0 ─13.38 - 13.38 1.000 
All above mentioned 24 (29) 29 (35) 12 ─8.50 - 27.93 0.302 
Not sure 8 (10) 6 (7) 5 ─11.59 - 18.46 0.754 
Do young children need treatment? 40 (49) 41 (50) 2 ─2.32 - 2.44 1.000 
Who? Children <5 and HIV /All children 7 (9) 4 (5) 8 ─7.34 - 16.22 0.4531 
Do you know when a TB patient usually stops transmitting the
disease? 21 (26) 34 (41) 32 11.24 - 40.25 0.002* 
Table 12. Difference in core TB knowledge among patients with TB at the beginning and at the end of treatment 













Knowledge & Perceptions about Tuberculosis 
Baseline (%) 
 n = 41 
End 
Treatment (%) 






Do you know some measures to control tuberculosis? Y/N 16 (20) 33 (40) 41 18.41 - 52.98 <0.001* 
Use facemask during transportation to a hospital or clinic 11 (13) 26 (32) 36 13.99 - 48.10 0.002* 
Use facemask in a hospital or clinic 14 (17) 24 (29) 25 0.87 - 40.33 0.041* 
Cover his/her mouth when coughing and/or sneezing in a hospital or clinic 13 (16) 23 (28) 24 0.87 - 40.34 0.041* 
Cover his/her mouth when coughing and/or sneezing at home or at work 12 (15) 19 (23) 17 ─6.07 - 34.69 0.167 
Be separated from other patients and requested to wait in a separated area 8 (10) 13 (16) 12 ─7.25 - 25.94 0.267 
Sleep in a room by him/herself or avoid sleeping in a room with small children 9 (11) 15 (18) 15 ─5.53 - 28.42 0.18 
Open house windows to the outside air 9 (11) 19 (23) 24 2.07 - 38.27 0.031* 
Use fans if possible for moving air to the outside 6 (7) 14 (17) 19 ─1.86 - 33.35 0.077 
Complete their course of anti—TB treatment 11 (13) 30 (37) 46 22.90 - 57.87 <0.001* 
Do you know why measures to control tuberculosis are important? Y/N 16 (20) 33 (40) 41 20.10 - 50.02 <0.001* 
Prevention for HCW 10 (12) 23 (28) 32 8.29 - 45.65 0.007 * 
Prevention at home/close contacts 13 (16) 27 (33) 34 10.43 - 48.09 0.004* 
Prevention at work 10 (12) 22 (27) 30 9.09 - 37.81 0.004* 
Cont. Table 12. Difference in core TB knowledge among patients with TB at the beginning and at the end of treatment














4.2.3.1 Acceptability of infection control measures at a health care facility at 
baseline and end of treatment 
The majority of all participants accepted infection control measures at health care 
facilities. No significant differences were observed when we compared to the baseline, 
due to the high levels of acceptability of infection control measures in health care 













Infection Control Measures at Health Care Facilities 
Baseline 
(%) n = 41 
End 
Treatment (%) 






Use facemask HC settings?  Y/N 39 (48) 41 (50) 5 ─3.34 - 4.88 0.5 
If no, why? Uncomfortable 1 (1) 0 (0) 2 ─2.32 - 2.44 1.000 
TB stigma 1 (1) 0 (0) 2 ─2.32 - 2.45 1.000 
Cover mouth when coughing and/or sneezing in a health care setting?  Y/N 41 (50) 41 (50) - - N/A 
Complete a course of anti—TB treatment? Y/N 41 (50) 41 (50) - - N/A 
Be separated from other patients? Y/N 28 (34) 26 (32) 5 ─15.71 - 23.61 0.804 
If no, why? Do not like being separated from others 5 (6) 6 (7) 2 ─12.64 - 15.94 1.000 
TB stigma 5 (6) 6 (7) 2 ─12.64 - 15.95 1.000 
HIV stigma 5 (6) 5 (6) 0 ─12.64 - 15.96 1.000 














4.2.3.2 Acceptability of Infection Control Measures at Home at baseline and 
end of treatment 
There were no major changes between start and end of treatment in the
acceptability of measures such as covering the mouth, and being isolated at home. Both
measures had a high level of acceptability before and after exposure to TB education.
However, measures such as using facemasks at home (p = 0.023), opening windows to
the outside (p = 0.023) and, use of fans to improve ventilation (p = 0.023), were more
likely to be acceptable by participants at the end of treatment. On the other hand, although
there was a small increase in the number of participants who were willing to be isolated,














Infection Control Measures at Home 
Baseline (%) 
n = 41 
End 
Treatment (%) 






Cover mouth with a handkerchief/tissue when coughing and/or sneezing? 41 (50) 40 (49) 2 ─2.32 - 2.44 1.000 
If no, why? HIV stigma 0 (0) 1 (1) 3 ─2.32 - 2.45 1.000 
Cover mouth with facial mask when coughing and/or sneezing? 26 (32) 35 (43) 22  2.89 - 30.49 0.023* 
If no, why? Forget 2 (2) 1 (1) 2 ─5.94 - 7.19 1.000 
No facial mask with me all the time 10 (12) 2 (2) 22  2.68 - 24.27 0.022* 
TB stigma 0 (0) 1 (1) 2 ─2.32 - 2.44 1.000 
HIV stigma 3 (4) 3 (4) 0 ─8.44 - 8.44 1.000 
Sleep in a room by oneself or avoid sleeping in a room with small children? 28 (34) 33 (40) 12 ─4.39 - 20.72 0.18 
If no, why? Not necessary 5 (6) 2 (2) 7 ─5.28 - 12.07 0.375 
Not enough rooms 7 (9) 4 (5) 7 ─7.16 - 15.82 0.453 
Family rejection 1 (1) 2 (2) 2 ─2.32 - 2.44 1.000 
Open house windows to the outside? 37 (45) 40 (49) 22  2.07 - 38.27 0.031* 
If no, why? Not necessary 1 (1) 0 (0) 2 ─2.32 - 2.44 1.000 
Cold 3 (4) 1 (1) 5 ─5.97 - 9.63 0.625 
Use fans if possible for moving air to the outside? 23 (28) 32 (39) 22  4.68 - 26.71 0.012* 
If no, why? Not important 8 (10) 3 (4) 12 ─0.53 - 12.20 0.063 
No fans 9 (11) 5 (6) 10 ─7.44 - 21.13 0.344 
Cannot afford it 1 (1) 1 (1) 0 ─4.76 - 4.76 1.000 
Isolation at home? 37 (45) 39 (48) 5 ─5.97 - 9.63 0.625 
Isolation isn't a problem 28 (34) 30 (37) 5 ─11.59 - 18.46 0.754 
Willing to be isolated at home 9 (11) 9 (11) 0 ─15.26 - 15.26 1.000 
If not willing, why? Physically impossible to be isolated 4 (5) 2 (2) 5 ─5.97 - 9.63 0.625 
Table 14. Infection control measures at home among patients with TB at the beginning and at the end of treatment 














4.2.3.3 Acceptability of infection control measures at work at baseline and 
end of treatment 
Few participants reported changes in acceptability of implementation of infection
control measures at work at the end of treatment. Small absolute differences were found
when patients were asked about the implementation of measures, such as stop working
for at least 2 weeks, or until smear results were negative, or even the use of facemasks at
work. All participants reported that they were willing to cover their mouths with a













Infection Control Measures at Work 
Baseline (%) 
n = 41 
End 
Treatment (%) 






Stop working until you have completed 2 weeks of treatment, or longer? 26 (32) 31 (38) 12 ─4.39 - 20.72 0.18 
If no, why? Not so sick 8 (10) 5 (6) 7 ─8.81 - 18.66 0.508 
No compensation 8 (10) 5 (6) 7 ─8.81 - 18.66 0.508 
TB stigma 1 (1) 2 (2) 2 ─2.32 - 2.44 1.000 
HIV stigma 1 (1) 0 (0) 2 ─2.32 - 2.44 1.000 
Cover mouth with a handkerchief/tissue when coughing and/or sneezing? 41 (50) 41 (50) - - N/A 
Cover mouth with facial mask when coughing and/or  sneezing? 27 (33) 33 (40) 15 ─1.03 - 19.39 0.070 
If no, why? Not interested 1 (1) 0 (0) 2 ─2.32 - 2.44 1.000 
No facial mask all the time 7 (9) 1 (1) 15 ─1.03 - 19.39 0.07 
Secret 1 (1) 2 (2) 2 ─5.94 - 7.19 1.000 
TB stigma 0 (0) 4 (5) 10 ─2.00 - 9.76 0.125 
HIV stigma 3 (4) 5 (6) 5 ─3.34 - 4.88 0.5 














4.2.3.4 Relationship between knowledge and acceptability of infection control 
measures at the end of treatment 
The proportion of participants with an acceptable level of knowledge increased by 
42% between the start and end of treatment (p = 0.0005). Moreover, acceptability of these 
patient-specific measures increased from 54% to 76% (p = 0.0225). The increase in 
knowledge was associated with a significant increase in acceptability of TB infection control 
measures (Spearman correlation-coefficient 0.5288 p = 0.0033) (See Figure 18). 
Core knowledge and acceptability of TB infection control measures at the end of
treatment
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CHAPTER 5: DISCUSSION 
DISCUSSION  
Chapter Introduction 
This research provides an insight into two simple and cost-effective strategies for
TB control in developing countries. Below we discuss how both strategies—sputum
induction, a simple method to identify potentially TB infectious patients and on-going TB
education—can be implemented in low income countries. Moreover, we emphasize the
implications of these strategies for TB control in resource-constrained areas. 
5.1 EVALUATION OF THE DIAGNOSTIC YIELD OF SPUTUM INDUCTION
In response to the critical need for new and accurate TB diagnostic tools, researchers have 
made remarkable progress in development of new and better TB diagnostics. However, in an
era of increasing multi-drug resistance, it remains important to obtain good quality sputum
specimens from patients with suspected TB for mycobacterial culture and drug sensitivity
testing (1). Cost effective sample collection methods such as sputum induction may be 
implemented in high TB burden and resource-constrained areas.
We conducted the first systematic review and meta-analysis of the diagnostic yield of 
sputum induction. The strengths of the study include the comprehensive search strategy; 














use of meta-regression analysis. It is particularly important that potential sources of 
heterogeneity are examined in a meta-analysis showing high levels of inconsistency in yield.  
Sources of variability that could be attributed to within-study factors (eg. participant 
selection) and between-study factors (study design and conduct) are explored by meta-
regression.  
This evaluation of studies reporting the utility of sputum induction as a simple method to
identify potentially TB infectious patients showed that, sputum induction is likely to detect
between 65 to 81% of culture-confirmed TB cases under study conditions, regardless of age 
group or HIV prevalence in the study population. We might have expected the comparative
diagnostic yield of sputum induction to be greater among studies reporting paucibacillary
disease, such as paediatric studies and those with high HIV prevalence in the study
population, but no such effect was observed. We found that use of bronchoscopic lavage as a
comparison method was associated with, on average, 22% lower diagnostic yield from
sputum induction, compared to studies that did not employ FOB; second, we observed that
use of 3% saline nebulisation for sputum induction was a significant confounder in studies
using FOB. However, we have demonstrated by meta-regression analysis that neither saline
concentration nor FOB usage were independently associated with diagnostic yield from
sputum induction.  
5.1.1 Saline Concentration 
The optimal saline concentration for sputum induction is not known. It has been suggested 
that higher nebulised saline concentrations might have a greater osmotic effect on airway 
secretions (2, 3), increasing the volume of the induced sputum sample, and thereby 














and tolerable, with minimal physiologic changes, when used for sputum induction among 
adults investigated for PTB in an ambulatory setting (4). However, others have suggested
that higher nebulised saline concentrations might be associated with greater risk of airway
reactivity and higher rates of adverse events during the procedure (5). The findings of this
meta-analysis suggest that higher saline concentrations are not associated with better
diagnostic yield in sputum induction after adjusting for confounders. We suggest that the
safety and diagnostic yield of low nebulised saline concentrations, perhaps even 0.9% saline,
should be studied prospectively in an effort to minimize adverse events.
5.1.2 Comparative Procedures 
We have shown that the observed reduction in sputum induction diagnostic yield in those 
studies using FOB as the comparator method is confounded by use of lower saline
concentration (3%) in this group. Studies using invasive diagnostic techniques might be 
more likely to include smear-negative or sputum-unproductive individuals, leading to
selection bias towards lower yield. It is also possible that, if FOB were better at detecting
paucibacillary culture-positive TB cases than sputum induction, the observed yield of this
procedure relative to the total number of culture-confirmed cases would be lower in studies
reporting FOB data. However, some studies have shown that the yield of sputum induction
is equal to, or even better than that of FOB, which is consistent with our finding that FOB
usage was not independently associated with lower diagnostic yield (6-8). 
5.1.3 Standardization of Sputum Induction 
Observed variability might also be explained by unreported differences in the sputum 
induction technique and lack of standardization. Technical factors that affect density of the 














saline solution in the tracheobronchial tree and diagnostic yield of the procedure. The
selected studies used a broad range of nebulisation devices and oxygen cylinders with
different flow outputs, which would have directly affected nebulised particle size and airway
deposition. However, there were limited data on the number of IS samples required, the 
optimum volume of the sample for mycobacterial culture, devices, the timing of specimen
collection, and other technical factors. Therefore reporting of these important data was
inconsistent, incomplete, and did not allow meaningful analysis. Other potential sources of
heterogeneity include severity of pre-existing lung disease, inclusion bias towards 
paucibacillary TB disease, and other patient-specific characteristics that might explain the
presence of outliers in this analysis.  
5.1.4 Limitations 
Several limitations of this meta-analysis must be considered. The literature search was
restricted to three sources, including one electronic database; additional references
recommended by experts in the field; and published reference lists and reviews. One
reviewer conducted the primary search to screen for citations, which might have introduced
study selection bias, although two reviewers conducted the secondary search and quality
assessment of papers identified by the primary screening. Another limitation that affects this
meta-analysis is the lack of a gold standard diagnostic comparator group in the reported
studies. Although some diagnostic methods, such as FOB, are believed to provide better
diagnostic accuracy than others, it is clear that none of the reported comparator methods are
sufficiently sensitive to define the population with true TB disease with 100% accuracy. It
follows that surrogate measures must be used to infer sensitivity, as others have done using
percentage diagnostic yield, which utilizes all culture-confirmed TB cases as the 














sputum induction procedure and reporting of this important information was often 
inconsistent.   
5.1.5 Conclusion 
Sputum induction has been widely used for the diagnosis of pulmonary TB and it has shown
to have a superior diagnostic yield to other invasive methods such as gastric lavage and 
FOB. Our study has demonstrated that M. tuberculosis can be isolated in nearly three-
quarters of suspected cases using sputum induction for sample collection. In resource-poor
countries, sputum induction would be an ideal diagnostic tool for TB diagnosis, as it is a
low-cost technique and more feasible than invasive procedures, since it does not require
hospitalization. However, despite the advantages—such as the lower risk of occupational
exposure compared to bronchoscopy (11), excellent acceptability by patients (12), cost (7), 
and safety—that other authors have shown, and due to the variability found in this meta-
analysis, we recommend further prospective, comparative studies of the diagnostic yield of
sputum induction. These studies should standardize the sputum induction methodology for
the initial investigation of suspected TB cases.
In the following section, we will discuss the implications of our findings about knowledge of 
TB and infection control measures, and acceptability and willingness to implement patient-
specific infection control measures, in patients with suspected TB a nd patients with TB who 
at the beginning of treatment; second, we discuss the potential for early intensive TB 
education to replicate the gains in knowledge and acceptability that we have shown by the 














5.2 IMPLEMENTATION OF INFECTION CONTROL MEASURES 
In developing countries, the force of TB transmission increases due to overcrowding, 
social deprivation, poverty and other factors that contribute to immunosuppression, such as 
HIV infection (13-15). It is clear that better field-adapted and cost-effective infection control
measures are urgently needed in highly endemic settings (16). The DOTS strategy promoted 
by the WHO endorses education for patients with TB, household members and other close
contacts as a simple community-based approach to help reduce the proportion of previously
uninfected individuals who are newly infected each year and are at risk of developing TB
disease (16). 
The effect of health education for patients with TB has primarily been studied to
determine how TB education influences adherence to TB treatment (17-19). Several authors
have stated that well-informed patients are more likely to adhere to a treatment protocol and 
to undertake appropriate preventive measures for their families (18, 20). We report the first
study of knowledge and attitudes to TB in relation to the acceptability and implementation
of patient-specific infection control measures, including environmental and respiratory
protection measures. One of the activities carried out by TB control programmes is to 
provide TB information when patients start treatment. Although education to patients with
TB and their family members should be provided at baseline and reinforced continuously
throughout treatment, implementation may not be optimal under field conditions. After
interviewing patients with suspected TB and newly diagnosed patients with TB, our study
revealed limited knowledge about TB and a low degree of acceptability of patient-specific
measures for TB control, immediately after individuals have had initial contact with health
care providers. Gender and the role of cultural characteristics (e.g., Xhosa-speaking versus














patient-specific infection control measures. In our study, patients on TB treatment, who had 
received some limited TB education at diagnosis, did not show greater core knowledge 
about TB and preventive measures, compared to patients with suspected TB, who had not 
received any information or education. However, we have shown that with on-going 
education and experience of diagnostic procedures and a course of TB treatment, patients 
with TB showed increased knowledge of TB and infection control measures over time. 
Furthermore, the increase in knowledge was associated with a significant increase in the 
acceptability of patient-specific measures. 
5.2.1 Core TB knowledge 
No major differences were found at baseline between patients with suspected TB
and patients with TB, except for a slightly higher proportion of patients with suspected TB
who reported that TB was caused by a micro-organism and highlighted anti-TB treatment as
the most important infection control measure. In general, TB knowledge among participants
was found to be poor to moderate. Only 57% of the participants reported that they knew the
cause of TB and only 25% knew that TB was caused by a micro-organism. Although most
participants (95%) reported awareness about who was more likely to get TB, there was no
clarity about the risk that TB poses for young children and HIV-positive patients. This is of
particular importance from a public health perspective, since the risk of disease progression 
is mainly determined by the age (21) and immune-compromise —the risk of developing TB
is between 20 and 37 times greater in HIV infected individuals (22). Therefore, the lack of
recognition that other susceptible individuals might develop TB once exposed to an
infectious patient at home or in work settings, hinders the acceptance and implementation of
specific measures that might reduce transmission in overcrowded spaces occupied by small














Fifty-four percent of the participants claimed to know how TB was transmitted, 
although some misconceptions were found in both groups. Some participants believed that
TB was a hereditary disease, or that it spread by sharing food utensils, kissing patients with
TB, and living in cold areas. As has been highlighted by many authors, lack of knowledge of
the modes of TB transmission leads to misconceptions about preventive measures and
encourages people to consider alternatives for their TB care (23-25). Yadav et al evaluated
knowledge levels and attitudes of sand-stone quarry workers in Jodhpur towards tuberculosis
and reported that only 1.6% knew that tuberculosis was caused by germs and 45.2%
respondents had the misconception that TB was a hereditary disease (26).
These initial findings were surprising. One might expect that core TB knowledge
among patients with TB would be at least moderate, since they had received some
information regarding TB at the time of diagnosis and initiation of TB treatment. Other
studies evaluating knowledge levels among patients with suspected TB and newly diagnosed
patients with TB have also shown low overall knowledge among participants (27-29).
5.2.2 Acceptability of patient-specific infection control measures 
The patient-specific infection control measures considered in this study were 
adapted from the infection control hierarchy endorsed by the CDC and the WHO (16, 30). 
Covering the patient‘s mouth with a facemask, handkerchief, and tissues; completing a 
course of anti-TB treatment; cohorting and isolation; opening windows to the outside and the 
use of fans to improve ventilation, are ―field-adapted‖ measures intended to reduce the risk 
of exposing uninfected individuals to M. tuberculosis. Initially, nearly half of the 
participants reported that they knew of some TB infection control measures. The most well-














covering the mouth with a handkerchief or tissue at a hospital or clinic; and completing TB 
treatment. Other potential measures, such as wearing facemasks during transportation to a 
hospital or clinic; covering the mouth when coughing/sneezing at work; being separated 
from other patients; sleeping alone; and other environmental [field-adapted] measures were 
less well-known to participants. Field-adapted environmental and respiratory protection 
measures presented moderate levels of acceptability among patients with suspected TB and 
patients with TB. 
5.2.3 Patient-specific environmental control Measures
5.2.3.1 Completing TB treatment 
Initially, when participants were asked if they considered TB treatment a measure to
control TB, a significant difference was found between each group. patients with suspected
TB were more likely to recognize completion of chemotherapy as an infection control
measure, compared to patients with TB. However, when participants were asked if they
would complete a course of anti-TB treatment, so that they could be cured, all participants
agreed they would do so. It is not clear why more patients with suspected TB, who have
never received anti-TB treatment, believed that TB transmission can be reduced by adhering
to chemotherapy, compared to patients with TB. Health care systems should explore the
reasons why patients default treatment (e.g, patients begin to feel better; lack of knowledge
on the benefits of completing treatment; adverse effects of TB drugs; duration of treatment)
and emphasize the family and community benefits of TB treatment completion.
5.2.3.2 Cohorting 
In general, patient-specific measures that could be implemented at health care 














infection control measures in work settings. However, it should be noted that measures
related to cohorting or isolation, whether at health care facilities, at home, or at work,
showed lower acceptability rates than other patient-specific measures that did not involve
separation from others. We assume that one of the reasons why patients are reluctant to
apply these measures might be related to rejection. The fear of the stigma of isolation and
other psychosocial factors might have had an impact on the willingness of patients to accept
such measures. Kelly et al stated that stigma of isolation is related to two other themes, 
separation from family and avoidance by the community (31). It was not surprising
therefore, that patients chose to avoid infection control practices that might reveal their TB
disease status, but also have significant psychosocial implications for them and their
families. Patients might decide to keep their TB status a secret for fear of being shunned 
(either as a TB patient, HIV patient or both). It appears that increased education and
incentives would be needed for patients to accept cohorting and isolation, regardless of the
setting. The alternative, given the increasing incidence of drug resistant TB, is that
compulsory or statutory cohorting and isolation measures might need to be considered, if
interventions to improve acceptability fail. 
5.2.3.3 Leave of absence from the work place 
Sixty-five percent (65%) of all participants reported that they would be willing to 
stop working until their AFB smear status became negative, although only 56% of 
participants were working at the time the interviews were conducted. Only 36% of 
participants who were currently working affirmed that they would stop working if they were 
asked to do so. Lack of compensation and loss of wages were two major factors influencing 
participants not to accept this measure. However, providing employees the right to stop 
working, until smear negativity is confirmed, is not a current health policy in South Africa. 














permission to be absent from work, might be given to patients attending health care facilities 
at the time of diagnosis. 
5.2.3.4 Improving ventilation 
Eighty-nine percent (89%) of participants in this study reported that they were
willing to open house windows to the outside, so that natural ventilation could help remove
infectious particles. A small proportion of our patients were not willing to implement this
measure, mainly due to the prevailing climatic conditions. Forty-one percent (41%) of
participants were not willing to use fans, either because they did not have access to a fan, or
because they did not understood the importance of this measure. 
5.2.3.5 Patient-specific respiratory protection
5.2.3.5.1 The use of facemasks, handkerchiefs or tissues
A reduction in the burden of airborne droplet nuclei containing M. tuberculosis may
be achieved by controlling the number of particles released by the sources of infection –
usually undiagnosed, untreated, or partially treated patients with TB. At baseline, most of
our participants were willing to cover their mouths to reduce the risk of TB transmission to
others. Wearing facemasks at health care facilities showed a high acceptance rate (89%).
However, the acceptability of facemask usage decreased by 35% at home and by 31% in
work settings. Use of facemasks might not be affordable for use at all healthcare facilities in
developing countries. Therefore, participants were asked about covering their mouth with














The majority of subjects considered covering the mouth with a handkerchief or 
tissues as an acceptable option for implementation. A small proportion of participants 
reported that using facemasks was not feasible, since they did not understand the importance 
of this measure. This situation was observed in both groups and reflects that, even though 
educational material is provided when patients are investigated, diagnosed, and treated in 
programmatic circumstances, the educational process around TB infection control measures 
needs to be strengthened.  
5.2.4 Acceptability of patient-specific infection control measures at the end of
TB treatment 
Mohamed et al states that health education is a continuous process, which starts
when patients are being investigated for TB, continues after their diagnosis has been
confirmed, and ends once patients are cured and complete treatment. Similar to the findings
of other authors, who investigated levels of knowledge and practices among newly TB
diagnosed patients (19, 32-34), our study showed low baseline levels of knowledge 
regarding TB disease and measures to reduce transmission, coupled with low levels of
acceptability of certain patient-specific measures. However, after on-going contact with 
treating staff, personal experience, observation, and education, over the course of TB
treatment, we could demonstrate that acceptability of these patient-specific measures
increased in parallel with improvements in knowledge about TB at the end of treatment.
Some infection control measures were considered acceptable by a high proportion of 
patients, even at baseline; For instance, the use of face masks at health care facilities; Cover 














with a handkerchief or tissue at home; and, open windows to the outside were practices that
most patient were willing to implement. The most acceptable infection control measures
were those to be implemented at health care facilities, with the exception of isolation.
Patients did not feel comfortable being separated from others while waiting in health care
facilities, neither at the start nor at the end of treatment. However, a high proportion of
participants (85%) were willing to be isolated at home, both at baseline and at the end of
treatment. Acceptability of other patient-specific measures to be implemented at home 
increased at the end of treatment. The use of face masks, isolation, and the use of fans at
home particularly showed a higher suitability among participants. 
5.2.5 Factors that could affect TB knowledge and acceptability of infection
control measures 
5.2.5.1 Participants’ educational level, TB knowledge, and acceptability of infection 
control measures 
We recognize that educational level may be a determining factor for an increased
understanding and acceptability of any measures to control the disease (25, 34). Previous
studies have shown that people with higher educational levels tend to accept and implement
more preventive measures, compared to individuals with a lower educational background. At
the end of treatment, participants considered isolation at home, the use of facemasks, and 
other practices to improve ventilation at home (opening house windows; and the use of fans)
as feasible infection control measures. We can infer that on-going education provided by
clinic staff and research workers over time had a positive effect on TB knowledge, and on
















We know that TB is a highly stigmatized disease (35-38). However, contrary to 
what we were expecting, stigma or fear to rejection did not contribute significantly to
participants‘ decision whether or not to accept infection control measures. The Breede
Valley area has one of the highest incidence rates of TB in South Africa (518 per 100 000)
(39). The high prevalence in this community may be the reason why stigma seemed not to 
play a significant role in our participants‘ decisions to practice these patient-specific 
measures. Communities with lower prevalence of TB might be more concerned by potential
stigma, which might result in lower rates of acceptability of measures that clearly identify a
TB patient to other members of the community 
5.2.5.3 Social desirability bias 
We understand that when interviewing participants, we must take into account the
possibility of a tendency of respondents to reply in a manner that we would consider
―favourable‖ (40). We acknowledge that some of our participants might have overreported 
―good behaviour‖ or underreported ―bad behaviour‖, in relation to the acceptability of
patient-specific infection control measures. We tried to mitigate the effects of social
desirability bias, firstly by training our clinical research workers in the conduct of in-depth
interviews and secondly, by ensuring confidentiality according to ethical research standards,
and by creating a stable relationship with our research staff.
5.2.6 Limitations of this research 
There were some potential limitations of our study. First, a major limitation of this research 
was the low-power statistics because of the small number of participants enrolled to this 














estimation was drawn on the basis of participants‘ availability and recruitment rates of the 
nest trials.  
One of the challenges in health education is that the quality and amount of
information provided to patients depends on the knowledge, perceptions and attitudes of 
providers. In this case, information was provided by health care staff from public health 
facilities and by clinical research workers under study conditions. In both cases, these
providers have been trained to educate patients. However, public health institutions in
developing countries face overcrowded conditions and in many cases, the quality and
duration of interaction between health care providers may be insufficient for a complete and
satisfactory educational dialogue. As revealed in our evaluation of knowledge and
acceptability of infection control measures at baseline, both groups, patients with suspected
TBa nd patients with TB had similar levels of knowledge, even though patients with
suspected TB had not received any TB education from health care facilities prior to
diagnosis. We were not able to evaluate the quality of information that health care staff from
public health facilities might be providing to patients in the interim, between baseline and
end of treatment. Therefore, our findings (increased acceptability of some patient-specific
measures as knowledge increased) might not be replicable in settings in which health care
staff or other patients with TB might be providing inaccurate information, or demonstrating
inadequate infection control practices. For example, a study reporting knowledge, attitudes
and practices among health care workers in Iraq established that, although TB knowledge
among health care workers might be high, by contrast, their infection control practices were 
suboptimal (41). Further, Hashim et al showed that only 38.2% of health care workers from
primary care centres in Iraq handled suspected TB cases correctly (41). 
Moreover, when waiting at a health care facility, patients are surrounded by other 














instance, patients with TB in this study were in frequent contact with research staff, but also 
with other patients with TB with their own opinions about TB, transmission and prevention. 
Therefore, it is clear that under programmatic conditions, levels of knowledge and 
acceptability of these infection control measures might vary according to the specific clinic 
setting and patient population. The findings of our study, in which on-going TB education 
was provided under research conditions, may represent an ideal situation that may not be 
achievable under programmatic conditions in many low-resourced health care settings. 
5.2.7 Implications for policy 
This research presents an opportunity for TB control programmes to strengthen measures to
decrease TB transmission. TB still ranks as one of the leading causes of death in low and
middle-income countries and many of these deaths might have been prevented by more 
effective infection control measures. The dynamics of TB transmission vary according to the
socio-economic status of families, and communities. Poorer communities face social
conditions that predispose them to develop TB disease once exposed to M. tuberculosis, 
whereas wealthier communities, with well-established health policies and financial
resources, are able to contain transmission. New policies have advocated the use of isolation, 
or even short term incarceration, as well as other ―environmental‖ practices to reduce TB
transmission (42). However, in resource-constrained areas, public health authorities face (a)
a lack of accurate, accessible diagnostic tools, which delays confirmation of infectious cases;
(b) overcrowded health care facilities, in which patients with TB mix with other patients,
increasing the risk of nosocomial TB transmission to other patients and health care staff; and 
(c) lack of personnel in health care facilities, which hampers the quality of information and














tuberculosis, and increase the possibility of developing TB disease, particularly for close 
contacts of patients with TB and health care workers. 
The ―National Infection Prevention and Control Policy for TB, MDR-TB and XDR-TB‖, 
published by the South African Department of Health, suggests that patients who are
identified as TB suspects on screening must be given advice on respiratory hygiene
and cough etiquette; provided with a facemask or tissues to cover their mouths and
noses; and separated from other patients and requested to wait in a separate area. Our
findings showed that patients are reluctant to be isolated in health care facilities, although 
they are more willing to be isolated at home. Increased emphasis on home-based care could
help reduce nosocomial transmission of TB, by removing the infectious source case from the
enclosed hospital environment. Clearly, the implementation of effective isolation at home 
must be followed by implementation of other measures to protect household members from
incident TB: first, adequate TB treatment must be provided and health care institutions must
promote adherence to TB chemotherapy; second, education about optimal infection control
measures must also be provided to family members and community members, to create a
strong support network for patients with TB. The risk of transmitting the disease to close
contacts might also be reduced if patients are equipped with high efficiency (N95) masks to 
use at home, especially during the first weeks after treatment has been initiated. 
The mission of public health is to fulfil society's interests and to foster practices and 
behaviours that assure populations stay healthy. Governmental bodies would need to interact 
and work synergistically in order to create appropriate policies to protect the rights of 
patients with TB, while ensuring that communities are not at risk of developing TB infection 















Baseline knowledge about TB pathogenesis and TB infection control measures was
poor to moderate among patients with suspected TB and patients with TB, although the latter
had received TB education and information after their diagnosis was confirmed. 
Acceptability of patient-specific infection control measures increased over time, in parallel
with increased knowledge of TB pathogenesis. Public health authorities should design and
implement early intensive TB education programmes to increase knowledge and
acceptability of patient-specific infection control measures. These educational resources
should be accessible not only for patients with suspected TBa nd patients with TB, but for
entire communities in which TB poses a challenge. Information given to patients with TB 
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Administrative controls: Defined as managerial or administrative measures that guide work 
practices to reduce significantly the risk of TB transmission by preventing the generation of 
droplet nuclei. These include early diagnosis, prompt isolation or separation of infectious 
patients with TB, prompt initiation of appropriate anti-tuberculosis treatment. 
 
Droplet nuclei: Microscopic particles that are estimated at 1-5 microns in diameter and are 
produced when a person coughs, sneezes, shouts or sighs. Such particles may remain 
suspended in the air for hours. 
 
Environmental control measures: Measures th t can be used in high-risk areas to reduce 
the concentration of droplet nuclei in the air (e.g., maximizing natural ventilation or 
controlling the direction of airflow).  
 
Health care associated infection (nosocomial or hospital-associated infection): An 
infection acquired in a health care facility by a patient, health care worker, or a visitor to a 
health care facility, who was in the facility for a reason other than that infection.  
 
High Efficiency facemasks (N95): Mask prevents the spread of microorganisms by 
providing a high filtration capacity, and at least can filter 95% of airborne particles. 
 
Infection prevention and control: Specific measures and work practices that reduce the 















Mucociliary Clearance: Refers to the mechanical elimination of fluid, bacteria, and 
particulates from the respiratory tract, relying on the close coordination of ciliary function, 
airway surface fluid secretion, and mucin secretion. 
 
Natural ventilation: Defined as natural air movement to achieve dilution and air exchange 
in an area with free-flow of ambient air (e.g. through the open windows). 
 
Personal protective equipment: This refers to items specifically used to protect the health 
care worker from exposure to body substances or from droplet or airborne organisms. 
Personal protective equipment includes gloves, aprons, gowns, caps, masks and protective 
eye wear. 
 
Respirators: A special type of closely fitted mask with the capacity to filter particles 1 
micron in size to protect from inhaling infectious droplet nuclei. 
 
Ultraviolet germicidal irradiation (UVGI): An environmental control measure to kill or 
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APPENDIX 
Appendix 1: Questionnaire 
[English Version] 









 TB Suspect           TB Patient 
If TB patient, please specify: 
 1
st
 Month  6
th
 Month
1. Do you know the cause of Tuberculosis (TB)?
a. Yes
b. No
If yes, please specify what the most important cause of TB is: 
a. Tuberculosis is a disease that is passed through generations
b. Tuberculosis is a disease that is caused by drinking alcohol
c. Tuberculosis is a disease that is caused by smoking
d. Tuberculosis is a disease that is caused by lack of cleanliness
e. Tuberculosis is a disease that is caused by witchcraft
f. Tuberculosis is a disease that is caused by germs
g. Tuberculosis is a disease that is caused by inhaling toxic substances
h. Other:  _______________________________________________________________________________________________
2. Do you know how a person gets TB?
a. Yes
b. No
If yes, please specify: 
Please, select all that apply: 
a. TB is transmitted by sharing food utensils with people who are ill from tuberculosis
b. TB is transmitted by kissing people who are ill from tuberculosis
c. TB is transmitted by living or being in close contact with people who have tuberculosis (by one person to another) 
d. TB is transmitted by living in or moving to cold areas
3. Do you think that tuberculosis can be passed on to other people?
a. Yes
b. No
If yes, please specify who are more likely to get tuberculosis? 
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h. Not sure
4. Do young children need treatment to stop getting TB once they have been exposed to the disease in their house?
a. Yes
b. No
If yes, please specify what children must receive treatment to prevent them to get TB?  
Please, select all that apply: 
a. Children under the age of 5
b. Children over 5 years of age
c. All HIV positive children
d. All children
5. Do you know when a TB patient usually stops transmitting the disease?
a. Yes
b. No
If no, please go to question number8. 
If yes, please specify: 
Please, mark an X on the appropriate answer: 
a. On the first day after they start receiving treatment
b. After 2 weeks on treatment
c. After 2 months of treatment
d. Once treatment is completely over
6. For how long were you coughing before you sought medical attention for this illness?
a. Not at all 
b. Less than two weeks
c. More than two weeks
d. More than four weeks
e. Monte than six weeks
 General Measures / Instructions to Control Tuberculosis 
7. Do you know some measures to control tuberculosis?
a. Yes
b. No
If yes, please specify which ones you know:
Please, select all that apply:
a. A Person with TB must use facemask during transportation to a hospital or clinic
b. A Person with TB must use facemask in a hospital or clinic
c. A Person with TB must cover his/her mouth when coughing and/or sneezing in a hospital or clinic
d. A Person with TB must cover his/her mouth when coughing and/or sneezing at home or at work
e. A Person with TB must be separated from other patients and requested to wait in a separated area
f. A Person with TB must sleep in a room by him/herself or avoid sleeping in a room with small children
g. A Person with TB must open house windows to the outside air
h. A Person with TB must use fans if possible for moving air to the outside
i. A Person with TB must complete their course of anti—TB treatment
j. Other(s): _________________________________________________________________________________
8. Do you know why measures to control tuberculosis are important?
a. Yes
b. No
If yes, please specify: 
Please, select all that apply: 
a. These measures are important to prevent persons with TB from spreading germs  so that health care workers  are not
infected 
b. These measures are important to prevent persons with TB spreading germs  so that close contacts (family and/or people 
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9. From where did you get your information about TB and TB control measures? 
 
Please, select all that apply: 
a. Health Care Workers (Hospital, TB Clinics, etc) 
b. Other patients (e.g., in waiting areas) 







10. Which of the following measures/instructions do you consider acceptable for health care settings (hospital or clinic)? 
 





If not acceptable, why so? Please select all that apply: 
a. Because the mask itself is uncomfortable 
b. Because you are  not sure why it’s important to use a facemask all the time  
c. Because people are going to think that you have tuberculosis and they might avoid you 
d. Because people are going to think that you are HIV positive and they might avoid you 
 
 






If not acceptable, why so? Please select all that apply: 
a. Because you forget to do it 
b. Because you are not be interested in covering your mouth 
c. Because you might not have a handkerchief or tissue to cover all the time 
d. Because people in the hospital are going to think that you have tuberculosis and they might avoid you 
e. Because people in the hospital are going to think that you are HIV positive and they might avoid you 
 
 




If not acceptable, why so? Please select all that apply: 
a. Because the health care centre is too far away from home and you can not afford transport to go there  
b. Because you have been told that TB treatment is very long  
c. Because you have to go to work 
d. Because you do not like taking pills 
e. Because the pills make you sick 
 





If not acceptable, why so? Please select all that apply: 
a. Because you do not like the idea of being separate from others 
b. Because people are going to think that you have tuberculosis and they might avoid you 
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If not acceptable, why so?  Please select all that apply: 
 
Please, select all that apply: 
a. Because you forget to do it 
b. Because you might not be interested in covering your mouth 
c. Because you might not have a handkerchief or tissue to cover all the time 
d. Because you do not want your family to find out that you might be sick 
e. Because people are going to think that you have tuberculosis and they might avoid you 
f. Because people are going to think that you are HIV positive and they might avoid you 
 





If not acceptable, why so? Please select all that apply: 
 
Please, select all that apply: 
a. Because you forget to do it 
b. Because you might not be interested using a mask 
c. Because you might not bring the facial mask with me all the time 
d. Because you do not want your family to find out that you might be sick 
e. Because people are going to think that you have tuberculosis and they might  
f. avoid you 
g. Because people are going to think that you are HIV positive and they might avoid you 
 
 





If not acceptable, why so? Please select all that apply: 
 
Please, select all that apply: 
a. Because you think this is not necessary  
b. Because there are not enough rooms and we have to share  
c. Because you do not want your family to find out that you might be sick 
d. Because your family is going to think that you have an  infectious disease and they may get sick 
because of you 
 
 






If not acceptable, why so? Please select all that apply: 
 
Please, select all that apply: 
a. Because you think this is not necessary 
b. Because there are not windows in your house 
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Please, select all that apply: 
a. Because you do not know why that is important
b. Because there are no fans at home
c. Because you can not afford a fan
12. What instructions do you consider acceptable to follow at work?
12.1 Stop working until you have completed 2 weeks of treatment, or longer if your sputum is still positive for TB 
a. Yes
b. No
If not acceptable, why so? Please select all that apply: 
Please, select all that apply: 
a. Because you are not  so sick that  you cannot work 
b. Because if you do not go to work, you  will not be compensated 
c. Because if you do not go to work, your colleagues and co-workers will think that you have TB and they are going to
d. avoid you 
e. Because if you do not go to work, your colleagues and co-workers will think that you are HIV positive and they are 
f. going to avoid you
12.2 Cover mouth with a handkerchief/tissue when coughing and/or sneezing?
a. Yes
b. No
If not acceptable, why so? Please select all that apply: 
Please, select all that apply: 
a. Because  you  forget to do it
b. Because your colleagues/co-workers are going to think that you have tuberculosis and they    might avoid you 
c. Because your colleagues/co-workers are going to think that you are HIV positive and they might avoid you
12.3 Cover mouth with facial mask when coughing and/or sneezing?
a. Yes
b. No
If not acceptable, why so? Please select all that apply: 
Please, select all that apply: 
a. Because you forget to do it
b. Because you might not be interested using a mask
c. Because you might not bring the facial mask with you all the time
d. Because you do not want your colleagues/co-workers to find out that you might be sick
e. Because people are going to think that you have tuberculosis and they might avoid you
f. Because people are going to think that you are HIV positive and they might avoid you
13. Is it acceptable that health care workers use facemasks during the consultation?
a. Yes
b. No
If acceptable, why so?  Please select all that apply: 
a. Because you understand that they must protect themselves
b. Because you understand that they are protecting you from passing you a disease, if they are sick
c. All the above mention
If not acceptable, why so?  Please select all that apply: 
a. You feel that there is a communication barrier between you and the health care worker (i.e. Sister and/or doctors) because 
they are using facemasks
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c. You think that other people might assume that health care workers are protecting themselves from you because you are 







Tuberculosis Control at Home / Work 
 
14. Tuberculosis Control at home / work 
 
 14.1 Number of people in your house? 
a. 5 or more people at home 
b. Less than 5 people at home 
 
 14.2 Number of people per room in your house? 
a. More than 2 people per room 
b. Less than 2 people per room 
 




14.4 How many people do you share the room with? ______________________________________________________________ 
 
If answer to question 14.3 is yes, please specify who do you share the room with?  Select all that apply: 
: 
a. Children younger than 5 years 
b. Children age  5 years and older 
c. Young adults 
d. Elderly people 
 
 
15. How would you feel about isolation at home (i.eg. sleeping in a room by yourself) until you can no longer spread the 
disease to others?  ? 
a. You have no problem with this 
b. This will not be easy for you but you are willing to try it out 
c. You are definitely not willing to do this 
 
If  you are definitely not willing (c), please specify why: 
a. It’s not physically possible to do this in your home (e.g., too few rooms) 
b. You do not believe that this will help 












And if indoors, please specify: 
 
 
a. How many people are in the same room with you while you are working?  ________________________________ 
 
 
b. How do you get to work most of the time? 
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 TB Vermoed    TB-pasiënt 




Maand    6
de
 Maand 
1. Weet u wat Tuberkulose (TB) veroorsaak?
c. Ja
d. Nee
Indien ja, spesifiseer asseblief wat die belangrikste oorsaak van TB is: 
i. Tuberkulose is ŉ siekte wat oorgeërf word 
j. Tuberkulose is ŉ siekte wat deur die gebruik van alkohol veroorsaak word 
k. Tuberkulose is ŉ siekte wat deur rokery veroorsaak word 
l. Tuberkulose is ŉ siekte wat deur ŉ gebrek aan higiëne veroorsaak word
m. Tuberkulose is ŉ siekte wat deur toordery veroorsaak word
n. Tuberkulose is ŉ siekte wat deur kieme veroorsaak word
o. Tuberkulose is ŉ siekte wat deur die inaseming van giftige stowwe veroorsaak word
p. Ander:
_________________________________________________________________________________________
2. Weet u hoe ŉ persoon TB kry? 
c. Ja
d. Nee
Indien ja, spesifiseer asseblief:
Kies asseblief almal wat van toepassing is:
e. TB word oorgedra deur eetgerei te deel met mense wat met tuberkulose siek is
f. TB word oorgedra deur mense wat met tuberkulose siek is, te soen
g. TB word oorgedra deur saam met mense te woon wat met tuberkulose siek is, of in noue kontak te wees met mense wat
met tuberkulose siek is (van een persoon na ŉ ander) 
h. TB word oorgedra deur in koue areas te woon of na sulke areas toe te verhuis 
3. Dink u dat tuberkulose aan ander mense oorgedra kan word?
c. Ja
d. Nee
Indien ja, spesifiseer asseblief watter mense meer waarskynlik is om tuberkulose op te doen? 
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4. Het jong kinders behandeling nodig om te keer dat hulle TB opdoen nadat hulle by hul tuiste aan die  siekte blootgestel 




Indien ja, spesifiseer asseblief watter kinders behandeling moet ontvang om te keer dat hulle TB kry?  
 
Kies asseblief almal wat van toepassing is: 
e. Kinders onder die ouderdom van 5 jaar 
f. Kinders oor die ouderdom van 5 jaar 
g. Alle MIV-positiewe kinders 
h. Alle kinders 
 
 




Indien nee, gaan asseblief oor na Vraagnommer 8. 
 
Indien ja, spesifiseer asseblief: 
 
Merk asseblief die gepaste antwoord met ŉ X: 
e. Op die eerste dag nadat hulle begin het om behandeling te ontvang 
f. Na 2 weke van behandeling 
g. Na 2 maande van behandeling 
h. Wanneer die behandeling heeltemal klaar is  
 
6.    Vir hoe lank het u gehoes totdat u mediese aandag vir hierdie siekte gaan soek het?  
a.    Glad nie 
b.    Minder as twee weke 
c.    Meer as twee weke 
d.    Meer as vier weke 







Algemene Maatreëls / Instruksies vir die Beheer van Tuberkulose 
 
 




Indien ja, spesifiseer asseblief watter maatreëls u ken. 
 
Kies asseblief almal wat van toepassing is: 
j. ŉ Persoon met TB moet ŉ gesigmasker gedurende vervoer na ŉ hospitaal of kliniek gebruik 
k. ŉ Persoon met TB moet ŉ gesigmasker in ŉ hospitaal of kliniek gebruik 
l. ŉ Persoon met TB moet sy/haar mond bedek wanneer hy/sy in ŉ hospitaal of kliniek hoes en/of nies  
m. ŉ Persoon met TB moet sy/haar mond bedek wanneer hy/sy by die huis of by die werk hoes en/of nies  
n. ŉ Persoon met TB moet van ander pasiënte afgesonder word en versoek om ŉ in aparte area te wag 
o. ŉ Persoon met TB moet alleen in ŉ kamer of slaap, of slaap in ŉ kamer met klein kinders vermy 
p. ŉ Persoon met TB moet oop huisvensters na buitekant toe hê 
q. ŉ Persoon met TB moet waaiers gebruik indien moontlik, om die lug buitentoe te waai 
r. ŉ Persoon met TB moet sy/haar kursus van anti-TB-behandeling klaarmaak 
a. Ander: _________________________________________________________________________________ 
                    
















TB Infection Control Project: Questionnaire, Version No. 3 (2009.06.27). English                                                   Bladsy  3 van 6 
(Afrikaans translation by Wima Maartens)  





Indien ja, spesifiseer asseblief: 
 
Kies asseblief almal wat van toepassing is: 
d. Hierdie maatreëls is belangrik om te keer dat persone met TB die kieme versprei, sodat gesondheid-sorgwerkers nie die 
infeksie kry nie 
e. Hierdie maatreëls is belangrik om te keer dat persone met TB die kieme versprei sodat mense naby hulle (familie en/of 
mense met wie hulle saamwoon) nie die infeksie kry nie 
 
 
f. Hierdie maatreëls is belangrik om te keer dat persone met TB die kieme versprei sodat mense met wie hulle saamwerk nie 
die infeksie kry nie 
 
9.     Waar het u u inligting oor TB en die beheermaatreëls gekry? 
 
Kies asseblief almal wat van toepassing is: 
h. Gesondheidsorgwerkers (Hospitaal, TB-klinieke, ens.) 







10.    Watter van die volgende maatreëls/instruksies beskou u as aanvaarbaar vir gesondheidsorginstellings 
         (hospitaal of kliniek)? 
 




Indien nie aanvaarbaar nie, waarom nie?  Kies asseblief almal wat van toepassing is: 
e. Omdat die masker self ongemaklik is 
f. Omdat u nie seker is waarom dit belangrik is om te alle tye ŉ gesigmasker te dra nie  
g. Omdat mense gaan dink dat u tuberkulose het en u dalk sal vermy 
h. Omdat mense gaan dink dat u MIV-positief  is en u dalk sal vermy 
 
10. 2  Bedek mond wanneer mens hoes en/of nies in ŉ hospitaalopset? 
c. Ja 
d. Nee  
 
Indien nie aanvaarbaar nie, waarom nie?  Kies asseblief almal wat van toepassing is: 
f. Omdat mens vergeet om dit te doen 
g. Omdat u nie daarin belangstel om u mond te bedek nie 
h. Omdat mens dalk nie altyd ŉ sakdoek of snesie byderhand het om mens se mond te bedek nie 
i. Omdat mense in die hospitaal gaan dink dat u tuberkulose het en u dalk sal vermy 
j. Omdat mense in die hospitaal gaan dink dat u MIV-positief is en u dalk sal vermy 
 




Indien nie aanvaarbaar nie, waarom nie?  Kies asseblief almal wat van toepassing is: 
f. Omdat die gesondheidsorgsentrum te ver is van u huis af is en u nie kan bekostig vervoer daarheen te neem nie 
g. Omdat u vertel is dat TB-behandeling baie lank vat  
h. Omdat u moet gaan werk 
i. Omdat u nie daarvan hou om pille te drink nie 
j. Omdat die pille mens siek laat voel 
 




Indien nie aanvaarbaar nie, waarom nie?  Kies asseblief almal wat van toepassing is: 
d. Omdat u nie hou van die idee om van ander mense afgesonder te wees nie 
e. Omdat mense gaan dink dat u tuberkulose het en hulle u dalk sal vermy 
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11. Watter van die volgende maatreëls/instruksies beskou u as aanvaarbaar en doenbaar in ŉ
huishoudelike opset (by die huis)?
11.1 Bedek die mond met ŉ sakdoek/snesie wanneer mens hoes en/of nies? 
c. Ja
d. Nee
Indien nie aanvaarbaar nie, waarom nie?  Kies asseblief almal wat van toepassing is: 
Kies asseblief almal wat van toepassing is: 
g. Omdat mens vergeet om dit te doen
h. Omdat u dalk nie daarin belangstel om u mond te bedek nie
i. Omdat mens dalk nie altyd ŉ sakdoek of snesie byderhand het om mens se mond te bedek nie
j. Omdat u nie sou wou hê u familie moet uitvind dat u dalk siek is nie
k. Omdat mense dalk gaan dink dat u tuberkulose het en u dalk sal vermy
l. Omdat mense dalk gaan dink dat u MIV-positief is omdat u u mond bedek en u dalk sal vermy
11.2 Bedek die mond met ŉ gesigsmasker wanneer mens hoes en/of nies? 
c. Ja
d. Nee
Indien nie aanvaarbaar nie, waarom nie?  Kies asseblief almal wat van toepassing is: 
Kies asseblief almal wat van toepassing is: 
h. Omdat mens vergeet om dit te doen
i. Omdat u dalk nie daarin belangstel om ŉ gesigsmasker te gebruik nie
j. Omdat mens dalk nie altyd ŉ gesigsmasker met jou saamdra nie
k. Omdat u nie sou wou hê u familie moet uitvind dat u dalk siek is nie
l. Omdat mense dalk gaan dink dat u tuberkulose het en u dalk sal vermy
m. Omdat mense dalk gaan dink dat u MIV-positief is omdat u u mond bedek en u dalk sal vermy
11.3  Alleen in ŉ kamer slaap, of slaap in ŉ kamer met jong kinders vermy?
c. Ja
d. Nee
Indien nie aanvaarbaar nie, waarom nie? Kies asseblief almal wat van toepassing is:
Kies asseblief almal wat van toepassing is:
e. Omdat u meen dat dit nie nodig is nie
f. Omdat daar nie genoeg kamers in u huis is nie en almal moet deel
g. Omdat u nie sou wou hê u familie moet uitvind dat u dalk siek is nie
h. Omdat u familie gaan dink dat u ŉ aansteeklike siekte het en dat hulle as gevolg van jou mag siek word
11.4 Oop huisvensters na buite toe?
c. Ja
d. Nee
Indien nie aanvaarbaar nie, waarom nie?  Kies asseblief almal wat van toepassing is: 
Kies asseblief almal wat van toepassing is: 
d. Omdat u meen dat dit nie nodig is nie
e. Omdat daar geen vensters in u huis is nie
f. Omdat dit koud is
g. Weens sekuriteitsredes (bv. rowers kan in jou huis kom)
11.5 Gebruik waaiers indien moontlik om die lug buitentoe te waai 
c. Ja
d. Nee
Indien nie aanvaarbaar nie, waarom nie?  Kies asseblief almal wat van toepassing is: 
Kies asseblief almal wat van toepassing is: 
d. Omdat u nie weet waarom dit belangrik is nie
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12.   Watter instruksies beskou u as aanvaarbaar by die werk? 
 






Indien nie aanvaarbaar nie, waarom nie?  Kies asseblief almal wat van toepassing is: 
 
g. Omdat u nie so siek is dat u nie werk toe kan gaan nie 
h. Omdat u nie betaal sal word as u nie werk toe gaan nie 
i. Omdat, as u van die werk af wegbly, u kollegas en medewerkers gaan dink dat u TB het en u gaan vermy 
j. Omdat, as u van die werk af wegbly, u kollegas en medewerkers gaan dink dat u MIV-positief is en u gaan vermy 
 
12.2 Bedek die mond met ŉ sakdoek/snesie wanneer mens hoes en/of nies?  
c. Ja 
d. Nee  
 
Indien nie aanvaarbaar nie, waarom nie?  Kies asseblief almal wat van toepassing is: 
 
d. Omdat u sal vergeet om dit te doen 
e. Omdat u kollegas/medewerkers gaan dink dat u tuberkulose het u dalk sal vermy 
f. Omdat u kollegas/medewerkers gaan dink dat u MIV-positief is en u dalk sal vermy 
 




Indien nie aanvaarbaar nie, waarom nie?  Kies asseblief almal wat van toepassing is: 
 
g. Omdat u sal vergeet om dit te doen 
h. Omdat u dalk nie daarin belangstel om ŉ gesigsmasker te gebruik nie 
i. Omdat u dalk nie altyd die gesigsmasker met u saamdra nie 
j. Omdat u nie wil hê dat u kollegas/medewerkers moet uitvind dat u dalk siek is nie 
k. Omdat mense gaan dink dat u tuberkulose het en u dalk sal vermy  
l. Omdat mense gaan dink dat u MIV-positief is en u dalk sal vermy 
 
13.  Is dit aanvaarbaar vir gesondheidsorgwerkers om gesigsmaskers gedurende konsultasies te dra? 
a. Ja 
b. Nee  
 
Indien dit aanvaarbaar is, waarom? Kies asseblief almal wat van toepassing is: 
d. Omdat u verstaan dat hulle hulself moet beskerm  
e. Omdat u verstaan dat hulle u beskerm teen ŉ siekte wat hulle kan oordra as hulle siek is 
f. Beide van bogenoemde 
 
Indien dit nie aanvaarbaar is nie, waarom nie? Kies asseblief almal wat van toepassing is 
a.    U voel dat daar ŉ kommunikasieblok tussen u en die gesondheidsorgwerker is (d.w.s. Susters en/of   
       dokters) omdat hulle gesigmaskers dra 
b.   U voel dat hulle bekommerd is en u vermy omdat hulle ŉ siekte by u kan aansteek as hulle nie toemaak 
      nie 
c.   U dink dat ander mense mag aanvaar dat gesondheidsorgwerkers hulself teen u beskerm omdat u TB of 
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Tuberkulose-beheer by die Huis / Werk 
14. Tuberkulose-beheer by die Huis / Werk
14.1 Aantal mens in u huis? 
c. 5 of meer mense by die huis
d. Minder as 5 mense by die huis
14.2 Aantal kamers in u huis? 
c. Meer as 2 mense per kamer
d. Minder as 2 mense per kamer
14.3 Slaap u alleen in ŉ kamer? 
c. Ja
d. Nee
14.4 Met hoeveel mense deel u ŉ kamer?  
_______________________________________ 
Indien u antwoord op 14.4 ja is, spesifiseer asseblief met wie u die kamer deel? Kies almal wat van toepassing is:
e. Kinders onder 5 jaar oud
f. Kinders van 5 jaar en ouer
g. Jong mense
h. Bejaardes
15.  Hoe sou u voel oor isolasie by die huis (d.w.s. alleen in ŉ kamer slaap) totdat u nie meer die siekte aan
ander mense kan versprei nie?
d. U het geen probleem hiermee nie
e. Dit sal nie vir u maklik wees nie, maar u is gewillig om dit te probeer
f. U is beslis nie gewillig om dit te doen nie
Indien u beslis nie gewillig is nie (c), spesifiseer asseblief waarom nie:
d. Dit is nie fisies moontlik om dit by my huis te doen nie (bv. te min kamers)
e. U glo nie dat dit sal help nie
f. U familie sal dit nie toelaat nie
16. Is u werksaam? 
c. Ja
d. Nee
Indien ja, spesifiseer asseblief: 
c. Binnenshuis
d. In die buitelug
a. Hoeveel mense is in dieselfde kamer saam met u terwyl u werk?
________________________________ 
b. Hoe kom u meestal by die werk?
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 TB Suspect                TB Patient 
 












Ukuba ewe, nceda uchaze ukuba ngowuphi oyena nobangela ubalulekileyo we-TB:  
q. Isifo sephepha sisifo esifunyanwa ngofuzo kwizizukulwana ngezizukulwana  
r. Isifo sephepha sisifo esibangelwa kukusela utywala  
s. Isifo sephepha sisifo esibangelwa kukutshaya 
t. Isifo sephepha sisifo esibangelwa kukungacoceki  
u. Isifo sephepha sisifo esibangelwa kukuthakathwa 
v. Isifo sephepha sisifo esibangelwa ziintsholongwane  
w. Isifo sephepha sisifo esibangelwa kukubizela izinto eziyityhefu 




2. Uyayazi ukuba umntu usifumana njani isifo sephepha, i TB? 
e. Ewe  
f. Hayi 
 
Ukuba ewe, nceda uchaze: 
 
Nceda, khetha konke okufanelekileyo: 
i. I-TB igqithiselwa komnye umntu ngokwabelana ngamacephe nezinye izinto zokutya nabantu abagula sisifo sephepha 
j. I-TB igqithiselwa komnye umntu ngokuphuza abantu abagula sisifo sephepha 
k. I-TB igqithiselwa komnye umntu ngokuhlala okanye ukuba kufutshane kakhulu nabantu abanesifo sephepha (omnye ukuya 
komnye) 
l. I-TB igqithiselwa komnye umntu ngokuhlala okanye ukuthuthela kwiindawo ezibandayo  
 





Ukuba ewe, nceda uchaze ukuba ngoobani abangabanesifo sephepha lula?  
 
Nceda, khetha konke okufanelekileyo: 
q. Abantu abadala 
r. abantwana abancinci 
s. Abantu abagugileyo 
t. Abantu osebenza nabo 
u. Abaguli abane-HIV/AIDS 
v. Bonke abakhankanywe ngasentla  
w. Akho bantu  
x. Andiqinisekanga 
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Ukuba ewe, nceda uchaze ukuba ngabaphi abantwana abafanele ukufumana unyango ukubathintela ukufumana i TB? 
Nceda, khetha konke okufanelekileyo: 
i. Abantwana abangaphantsi kweminyaka e-5 ubudala
j. Abantwana abangaphezulu kweminyaka e-5 ubudala
k. Bonke abantwana abane-HIV
l. Bonke abantwana
5. Uyayazi ukuba umguli one-TB uyeka nini ukosulela ngesi sifo?
e. Ewe 
f. Hayi
Ukuba hayi, nceda uye kumbuzo 8. 
Ukuba ewe,nceda uchaze: 
Nceda, uphawule ngo-X kwimpendulo efanelekileyo: 
i. Kusuku lokuqala emva kokuba beqala ukufumana unyango
j. Emva kweeveki ezi-2 kunyango
k. Emva kweenyanga ezi-2 kunyango
l. Xa sele lugqityiwe unyango
6. Ubukhohlela ixesha elingakanani phambi kokuba ufune unyango lwesi sigulo?
f. Bendingakhohleli
g. Ngaphantsi kweeveki ezimbini
h. Ngaphezu kweeveki ezimbini
i. Ngaphezu kweeveki ezine
j. Ngaphezu kweeveki ezintandathu
Amanyathelo jikelele / Imiyalelo yolawulo lwesifo sephepha
7. Uyawazi amanye amanyathelo olawulo lwesifo sephepha?
e. Ewe 
f. Hayi
Ukuba ewe,nceda uchaze ngawaphi owaziyo:
Nceda, khetha konke okufanelekileyo: 
s. Umntu one-TB kufanele asebenzise imaski yokugquma ubuso xa esisiwa esibhedlele okanye ekliniki
t. Umntu one-TB kufanele asebenzise imaski yokugquma ubuso xa esesibhedlele okanye ekliniki 
u. Umntu one-TB kufanele agqume umlomo wakhe xa ekhohlela naxa/okanye xa ethimla esibhedlele okanye ekliniki 
v. Umntu one-TB kufanele agqume umlomo wakhe xa ekhohlela naxa/okanye xa ethimla ekhaya okanye emsebenzini
w. Umntu one-TB kufanele ohlulwe kwabanye abaguli acelwe ukuba alinde kwindawo eyodwa yokulinda
x. Umntu one-TB kufanele alale kwigumbi yedwa okanye akuphephe ukulala kwigumbi elinabantwana abancinane 
y. Umntu one-TB kufanele avule iifestile zendlu ezivulela ngaphandle 
z. Umntu one-TB kufanele asebenzise iifeni xa enako ukukhuphela ngaphandle umoya
aa. Umntu one-TB kufanele alugqibe unyango lwakhe lwe-TB 
b. Okunye: _________________________________________________________________________________
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Ukuba ewe, nceda uchaze: 
Nceda, khetha konke okufanelekileyo: 
g. La manyathelo abalulekile ukuthintela abantu abane-TB banganwenisi iintsholongwane ukuze abasebenzi kwezempilo
bangosuleleki 
h. La manyathelo abalulekile ukuthintela abantu abane-TB banganwenisi iintsholongwane ukuze abantu abakufutshane nawe
(usapho kunye/okanye abantu ohlala nabo) bangosuleleki 
i. La manyathelo abalulekile ukuthintela abantu abane-TB banganwenisi iintsholongwane ukuze abantu abasebenza nawe
bangosuleleki 
9. Ulufumene phi ulwazi onalo malunga ne-TB namanyathelo olawulo lwe-TB?
Nceda, khetha konke okufanelekileyo: 
o. Kubasebenzi kwezempilo (Esibhedlele, kwiikliniki ze-TB, njl-njl)






10. Ngawaphi kula manyathelo/kule miyalelo oyithatha njengeyamkelekileyo kwiindawo zokongiwa kwempilo (esibhedlele
okanye ekliniki)?
 10.1 Sebenzisa imaski yokugquma ubuso xa umntu esisiwa naxa ehlala kwindawo yempilo? 
e. Ewe 
f. Hayi
Ukuba akwamkelekanga, njani njalo? Nceda, khetha konke okufanelekileyo: 
i. Kuba yona imaski ayenzi umntu azive ekhululekile
j. Kuba awuqinisekanga ukuba kutheni kubalulekile ukusebenzisa imaski egquma ubuso lonke ixesha
k. Kuba abantu baza kucinga ukuba unesifo sephepha yaye bangahambela kude kunawe
l. Kuba abantu baza kucinga ukuba une-HIV yaye bangahambela kude kunawe
10.2 Gquma umlomo xa kukhohlelwa naxa/okanye kuthimlwa kwindawo yokongiwa kwempilo? 
e. Ewe 
f. Hayi
Ukuba akwamkelekanga, njani njalo? Nceda, khetha konke okufanelekileyo: 
k. Kuba uyalibala ukukwenza oku
l. Kuba ungathi ungabi namdla wokugquma umlomo
m. Kuba kungenzeka ungabinayo itshefu okanye ithishu yokugquma maxa onke
n. Kuba abantu esibhedlele baza kucinga ukuba unesifo sephepha yaye bangahambela kude kunawe
o. Kuba abantu esibhedlele baza kucinga ukuba une-HIV yaye bangahambela kude kunawe
 10.3 Gqiba unyango olulwa iTB? 
e. Ewe 
f. Hayi
Ukuba akwamkelekanga, njani njalo? Nceda, khetha konke okufanelekileyo: 
k. Kuba iziko lempilo likude kakhulu kunekhaya lakho yaye awunayo imali yokubhatalela ukuhamba usiya khona
l. Kuba uxelelwe ukuba unyango lwe-TB lude kakhulu
m. Kuba kufuneka uye emsebenzini
n. Kuba awuthandi ukusela iipilisi
o. Kuba iipilisi zikwenza ugule
 10.4 Ukohlulwa kwabanye abaguli ucelwe ukuba ulinde kwindawo eyodwa yokulinda? 
e. Ewe 
f. Hayi
Ukuba akwamkelekanga, njani njalo? Nceda, khetha konke okufanelekileyo: 
g. Kuba awuyithandi le nto yokwahlulwa kwabanye
h. Kuba abantu baza kucinga ukuba unesifo sephepha yaye bangahambela kude kunawe
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Ukuba akwamkelekanga, njani njalo? Nceda, khetha konke okufanelekileyo: 
 
Nceda, khetha konke okufanelekileyo: 
m. Kuba uyalibala ukukwenza oku 
n. Kuba ungathi ungabi namdla wokugquma umlomo 
o. Kuba kungenzeka ungabinayo itshefu okanye ithishu yokugquma maxa onke 
p. Kuba awufuni usapho lucinge ukuba ungaba uyagula 
q. Kuba abantu baza kucinga ukuba unesifo sephepha yaye bangahambela kude kunawe 
r. Kuba abantu baza kucinga ukuba une-HIV yaye bangahambela kude kunawe 
 





Ukuba akwamkelekanga, njani njalo? Nceda, khetha konke okufanelekileyo: 
 
Nceda, khetha konke okufanelekileyo: 
n. Kuba uyalibala ukukwenza oku 
o. Kuba ungathi ungabi namdla wokusebenzisa imaski 
p. Kuba ungangazi nemaski yokugquma ubuso lonke ixesha 
q. Kuba awufuni usapho lufumanise ukuba ungaba uyagula 
r. Kuba abantu baza kucinga ukuba unesifo sephepha yaye bangahambela kude kunawe  
s. Kuba abantu baza kucinga ukuba une-HIV yaye bangahambela kude kunawe  
 
 





Ukuba akwamkelekanga, njani njalo? Nceda, khetha konke okufanelekileyo: 
 
Nceda, khetha konke okufanelekileyo: 
i. Kuba ucinga oku akuyomfuneko  
j. Kuba akuko magumbi aneleyo yaye kufanele sabelane ngegumbi  
k. Kuba awufuni usapho lwakho lufumanise ukuba ungaba uyagula 
Kuba usapho lwako luza kucinga ukuba unesifo esosulelayo  yaye bangagula ngenxa yakho  
 
 






Ukuba akwamkelekanga, njani njalo? Nceda, khetha konke okufanelekileyo: 
 
Nceda, khetha konke okufanelekileyo: 
h. Kuba ucinga oku akuyomfuneko 
i. Kuba akukho zifestile endlwini yakho  






















  TB Infection Control Project: Questionnaire, Version No. 3 (2009.06.27). English                                                             Page 5 of 6 
 (Xhosa translation by Yolanda Giyose)                                                                                   
 
Ukuba akwamkelekanga, njani njalo? Nceda, khetha konke okufanelekileyo: 
 
Nceda, khetha konke okufanelekileyo: 
g. Kuba awuyazi ukuba kutheni kubalulekile oku  
h. Kuba akukho zifeni ekhaya 
i. Kuba awunako ukuzithengela ifeni 
 
 
14. Yeyiphi imiyalelo oyithatha ngathi yamkelekile ukuba uyilandele emsebenzini? 






Ukuba akwamkelekanga, njani njalo? Nceda, khetha konke okufanelekileyo: 
 
Nceda, khetha konke okufanelekileyo: 
k. Kuba awuguli kangako ukuba ude ungasebenzi  
l. Kuba ukuba awuyi emsebenzini awusayi kuhlawulwa  
m. Kuba ukuba awuyi emsebenzini, osebenza nabo baya kucinga ukuba une-TB yaye baya kuhambela kude nawe  
n. Kuba ukuba awuyi emsebenzini, osebenza nabo baya kucinga ukuba une-HIV yaye baya kuhambela kude nawe  
 
 






Ukuba akwamkelekanga, njani njalo? Nceda, khetha konke okufanelekileyo: 
 
Nceda, khetha konke okufanelekileyo: 
g. Kuba uyalibala ukukwenza oku 
h. Kuba abantu osebenza nabo baya kucinga ukuba unesifo sephepha yaye bangahambela kude nawe  
i. Kuba abantu osebenza nabo baya kucinga ukuba une-HIV yaye bangahambela kude nawe  
 





Ukuba akwamkelekanga, njani njalo? Nceda, khetha konke okufanelekileyo: 
 
Nceda, khetha konke okufanelekileyo: 
m. Kuba uyalibala ukukwenza oku 
n. Kuba ungangabi namdla wokusebenzisa imaski 
o. Kuba ungangazi nemaski yokugquma ubuso nawe lonke ixesha 
p. Kuba awufuni osebenza nabo bafumanise ukuba ungaba uyagula 
q. Kuba abantu baza kucinga unesifo sephepha yaye bangahambela kude nawe  
r. Kuba abantu baza kucinga une-HIV yaye bangahambela kude nawe 
 




Ukuba kwamkelekile, njani njalo?  Nceda, khetha konke okufanelekileyo: 
d. Kuba uyaqonda ukuba bafanele bazikhusele 
e. Kuba uyaqonda ukuba bakhusela wena ukuba bangakosuleli ngesi sifo, ukuba bayagula 
f. Konke okungasentla, chaza 
g.  
Ukuba akwamkelekanga, njani njalo?  Nceda, khetha konke okufanelekileyo: 
g. Uva ngathi kukho umqobo owenza ningavani ekuthetheni wena nomsebenzi kwezokongiwa kwezempilo (o.k.k.t Usista 
kunye/okanye oogqirha) kuba basebenzisa iimaski zokugquma ubuso  
h. Uva ngathi bakhathazekile yaye bayakuphepha kuba bangafumana into kuwe (bafumane isifo) ukuba abazigqumi  
i. Ucinga ukuba abanye abantu bangacingela kubo ukuba abasebenzi kwezokongiwa kwezempilo bayazikhusela kuwe kuba 
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Ulawulo lwesifo sepepa ekhaya / emsebenzini 
17. Ulawulo lwesifo sepepha ekaya/emsebenzini
14.1 Inani labantu endlwini yakho? 
e. Ba-5 okanye ngaphezulu abantu ekhaya
f. Bangapantsi kwe-5 abantu ekhaya
14.2 Inani lamagumbi endlwini yakho? 
e. Bangapezulu kwe-2 abantu kwigumbi ngalinye
f. Bangaphantsi kwe-2 abantu kwigumbi ngalinye
14.3 Ulala wedwa egumbini? 
e. Ewe 
f. Hayi
14.4 Wabelana ngegumbi nabantu abangaphi? ______________________________________________________________ 
Ukuba impendulo yombuzo 14.3 ngu ewe, nceda ucaze ukuba wabelana nabani ngegumbi? Khetha konke okufanelekileyo: 
: 
i. Abantwana abangaphantsi kweminyaka e-5 ubudala
j. Abantwana aba-5 ngangaphezulu
k. Abantu abadala abasebatsha
l. Abantu abagugileyo
18. Ungaziva njani ngokuhlaliswa wedwa ekhaya (umz. Ukulaliswa egumbini wedwa) de ube awusenako ukubosulela abanye
abantu ngesifo?
g. Awunangxaki noku
h. Oku akusayi kuba lula kuwe, kodwa uyafuna ukuzama
i. Awufuni kwaphela ukwenza oku
Akuba awufuni ngokuqinisekileyo (c), nceda uchaze ngoba: 
g. Akukwazeki ukwena oku ekayeni lam (umz., amagumbi ambalwa kakhulu)
h. Awukholelwa ukuba oku kuya kunceda




Ukuba ewe, nceda uchaze: 
e. Ngaphakati
f. Ngaphandle
Yaye ukuba phakathi, nceda uchaze: 
a. Bangaphi abantu abakwigumbi elinye nawe xa usebenza?  ________________________________
b. Uya ngantoni emsebenzini uninzi lwexesha?
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Participant No. ______________ 
PARTICIPANT INFORMATION AND CONSENT FORM 
Protocol Title:  “Knowledge and acceptability of measures for control of tuberculosis 
transmission in the Breede Valley community” 
The following information will tell you about the study and your part in it.  Please read 
carefully and feel free to ask any questions. 
This is a research study being done by the South African TB Vaccine Initiative (SATVI), 
Institute of Infectious Disease and Molecular Medicine, University of Cape Town Medical 
School, Anzio Rd, Observatory, Cape. The team members in charge of the study are Mark 
Hatherill, Senior investigator and Yulieth Gonzalez-Angulo, MPH student within SATVI. 
Background 
Tuberculosis (TB) is a common infectious disease caused by a bacteria (Mycobacterium 
tuberculosis), which most commonly affects the lungs (pulmonary TB) but it can also 
affect any organ in our body. Tuberculosis has been a serious threat to public health for 
many years and practices have been implemented to prevent the spread of TB infection. 
These infection control measures have an important place in TB control and we
would like to know what is known about TB and infection control measures in the Breede
Valley community. We would also like to know how people who are being, or who have
been tested for TB, feel about these infection control measures. We would like to know
whether or not they would be acceptable to people and whether people would agree to
co-operate with infection control measures.
Participant’s contribution 
One hundred and ten (110) people will take part in this study, of whom half (55) will 
have been diagnosed with TB already and half will be having tests for TB for the first
time. You have been invited to participate in this study because either you are being, or 
have been tested for TB, as part of another SATVI study. This does not necessarily mean
that you do have TB, but you will have had some clinical tests for TB and you may be
waiting for the results. You may have taken part in some infection control measures
already.
You may choose not to take part in this study and you must know that it would not make 
any difference to the health care that you would normally receive, or to your participation 
in other research studies. You can leave the study at any time. You will not pay any 
penalty or lose any benefits you have earned if you say no.  
Participant’s Responsibilities 
In this study, no diagnostic tests will be done, but your time and willingness to answer 
some questions during an interview are needed. Your involvement in this study is limited 
to 1 session where you will be interviewed for about 30 minutes or less about infection 
control measures for TB. Participants who are being tested for TB for the first time will 
have one interview.  Participants who have already been diagnosed with TB at the time 
of the first interview will undergo a second concise interview about TB infection control 
measures once their treatment is completed. 
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Participant’s Benefits 
Your participation in the study is completely voluntary and you will not receive any direct 
benefits for your participation in this study. However your contribution by sharing this 
information with us would help our understanding of people’s knowledge about the 
measures for control of TB.   
Participant’s Compensation 
No compensation or incentive would be given to you for your participation in this study, 
nor would you have to pay for your participation in this project.  
Participant’s Risks 
As this study is an interview, there are no medical or health risks, or potential adverse 
effects. While the topics raised during the questionnaire are quite generic and general, 
you are free to leave if at any point should you become uncomfortable.  
Participant’s Privacy 
Your answers will be kept confidential among the study staff. Your information will be
kept in an electronic database using a coded number that will not be directly traceable to
you. All participants will remain anonymous in the final reporting of the findings.
Contact Information for Questions or Concerns
You will receive a copy of this consent form if you agree to take part. The study has been
approved by the Research Ethics Committee, Faculty of Health Sciences, University of
Cape Town. If you have any concerns about your rights as a research participant, you
should contact the secretary of the research ethics committee at the Faculty of Health
Sciences on (021) 406-6492.  
If at any time, you have questions or concerns about this study or are injured as a result
of participation in this study you should contact:
Researchers: 
Dr. Mark Hatherill, Principal Investigator, and Ms. Yulieth González-Angulo, MPH student.
South African TB Vaccine Initiative (SATVI), Institute of Infectious Disease and Molecular 
Medicine, University of Cape Town School of Public Health and Family Medicine, Health
Sciences Faculty Anzio Rd, Observatory, Cape Town, South Africa. Telephone (27) 21
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Consent to take part in this Study 
I have read and understood this consent form, the contents of which have 
been explained to me.  My questions have been answered and I voluntarily 
agree to take part in the research described in this consent form. 
 Date 
_______________________________________________________________________________ 




Name of study personnel taking consent (please print)
_______________________________________________________________________
Signature: study personnel Date
 Interpreter used (tick only if applicable)
 Witness used (tick only if applicable; tick one below to describe witness)
Study personnel  
Independent/impartial person 
_______________________________________________________________________ 
Name of witness (please print) 
_______________________________________________________________________ 














  Weergawenr.: 1.0 
  27 April 2009 
Bladsy 1 van 3
(Afrikaans translation by Wima Maartens) 
Deelnemernommer: ______________ 
INSTEMMINGSVORM 
Protokoltitel:  “Kennis en aanvaarbaarheid van maatreëls vir die beheer van oordrag 
van tuberkulose in die Breede Vallei-gemeenskap” 
Die volgende inligting gaan u vertel van die studie en u rol daarin.  Lees dit asseblief 
noukeurig deur en vrae gerus enige vrae. 
Hierdie is ŉ navorsingstudie wat deur die Suid-Afrikaanse TB-vaksien-inisiatief (SATVI), 
die Instituut van Infektiewe Siektes en Molekulêre Medisyne, Universiteit van Kaapstad se 
Mediese Skool, Anzio-weg Obervatory, Kaapstad uitgevoer word. Die spanlede in beheer 
van die studie is dr. Mark Hatherill, Senior Ondersoeker, en Yulieth Gonzalez-Angulo, 
MPH-student by SATVI. 
Agtergrond 
Tuberkulose (TB) is ŉ algemene aansteeklike siekte wat deur bakterieë (Mycobacterium
tuberculosis) veroorsaak word en wat meestal die longe (pulmonêre TB) aantas, maar
ook enige ander orgaan in die liggaam kan affekteer. Tuberkulose is al vir baie jare ŉ
ernstige bedreiging vir openbare gesondheid, en praktyke is in plek gestel om die
verspreiding van TB-infeksie te voorkom.
Hierdie infeksiebeheermaatreëls speel ŉ belangrike rol by die beheer van TB, en ons 
wil graag vasstel wat mense in die Breede Vallei-gemeenskap weet van TB en die
infeksiebeheermaatreëls. Ons wil graag weet hoe mense wat vir TB getoets word, of
reeds vir TB getoets is, oor hierdie infeksiebeheermaatreëls voel. Ons wil ook graag
uitvind of dit vir mense aanvaarbaar is, al dan nie, en of mense sou ooreenkom om met
die infeksiebeheermaatreëls saam te werk.
Deelnemer se bydrae
Een honderd en tien (110) mense gaan aan hierdie studie deelneem, waarvan die helfte
(55) reeds met TB gediagnoseer en die ander helfte TB-toetse vir die eerste keer sal
ondergaan. U word genooi om aan hierdie studie deel te neem omdat u nou vir TB 
getoets word, of al in die verlede reeds as deel van ŉ ander SATVI-studie vir TB getoets
is. Dit beteken nie noodwendig dat u TB het nie, maar u het dalk sekere kliniese toetse
vir TB gehad en mag tans die resultate afwag. U mag alreeds aan sekere
infeksiebeheermaatreëls deelgeneem het.
U kan kies om nie aan hierdie studie deel te neem nie, en u moet besef dat dit geen 
verskil sal maak aan die gesondheidsorg wat u normaalweg sou ontvang nie, of aan u 
deelname aan ander navorsingstudies nie. U kan te enige tyd die studie verlaat. As u 
“nee” sê, sal dit geen benadeling vir u inhou nie, of verlies van enige voordele wat u 
verdien nie.  
Deelnemer se verantwoordelikhede 
Geen diagnostiese toetse gaan in hierdie studie uitgevoer word nie, maar u tyd en 
gewilligheid om enkele vra gedurende ŉ onderhoud te beantwoord, word benodig. U 
betrokkenheid by hierdie studie is beperk tot 1 sessie, waartydens ŉ onderhoud vir 
omtrent 30 minute of minder oor infeksiebeheermaatreëls vir TB met u gevoer sal word. 
Deelnemers wat vir die eerste keer vir TB getoets word, sal een onderhoud hê.  
Deelnemers wat ten tye van die onderhoud reeds met TB gediagnoseer is, sal ŉ tweede 
kort onderhoud oor TB-infeksiebeheermaatreëls hê wanneer hulle behandeling voltooi is. 
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Deelnemer se voordele 
U deelname aan hierdie studie is heeltemal vrywillig en u sal geen regstreekse voordele 
weens u deelname aan hierdie studie geniet nie. U bydrae, deur hierdie inligting met ons 
te deel, sal ons egter help om mense se kennis van die maatreëls vir die beheer van TB 
beter te verstaan. 
Vergoeding aan deelnemer 
Geen vergoeding of aansporing sal vir u deelname aan hierdie studie voorsien word nie, 
maar u sal ook nie vir u deelname aan hierdie projek hoef te betaal nie. 
Risiko’s vir deelnemer 
Aangesien hierdie studie ŉ onderhoud behels, is daar geen mediese of gesondheids-
risiko’s of potensiële nadelige effekte nie. Hoewel die onderwerpe wat gedurende die 
vraelys geopper word generies en van ŉ algemene aard is, staan dit u vry om te enige 
tyd die onderhoud te staak indien u ongemaklik begin voel.  
Deelnemer se privaatheid 
U antwoorde sal deur die studiepersoneel vertroulik gehou word. U inligting sal in ŉ
elektroniese databasis bewaar word, met gebruik van ŉ gekodeerde nommer wat nie
regstreeks na u terugherlei kan word nie. Alle deelnemers sal in die finale verslagdoening 
van die bevindings naamloos bly,
Kontak-inligting vir vrae of kwellinge 
U sal ŉ afskrif van hierdie instemmingsvorm ontvang indien u tot deelname instem. Die
studie is deur die Etiese Navorsingskomitee, Fakulteit Geneeskunde, Universiteit van
Kaapstad goedgekeur. As u enige kwellinge het oor u regte as ŉ navorsingsdeelnemer, 
kan u in aanraking kom met die sekretaris van die Etiese Navorsingskomitee, Fakulteit
Geneeskunde, by (021) 406-6492.
As u te enige tyd enige vrae of kwellinge oor hierdie studie het, of as u as gevolg van
deelname aan hierdie studie ŉ besering opdoen, moet u in aanraking kom met:
Navorsers: 
Dr. Mark Hatherill, Hoofondersoeker, en me. Yulieth González-Angulo, MPH-student by 
die Suid-Afrikaanse TB-vaksien-inisiatief (SATVI), Instituut van Infektiewe Siektes en
Molekulêre Medisyne, Universiteit van Kaapstad se Skool van Openbare Gesondheid en
Familiemedisyne, Fakulteit Geneeskunde, Anzio-weg Obervatory, Kaapstad, Suid-Afrika.
Telefoon (27) 21 404 7622
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Instemming tot Deelname aan hierdie Studie 
Ek het hierdie instemmingsvorm, die inhoud waarvan vir my verduidelik is, 
deurgelees en verstaan.  My vrae is beantwoord en ek kom vrywillig ooreen 









Naam van studiepersoneellid wat instemming verkry (drukskrif asseblief)
_______________________________________________________________________
Handtekening van studiepersoneellid wat instemming verkry
 Tolk gebruik (merk slegs indien van toepassing)
 Getuie gebruik (merk slegs indien van toepassing; merk een hieronder 




Naam van getuie (drukskrif asseblief) 
_______________________________________________________________________ 
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Inombolo yomthathi nxaxheba ______________ 
ULWAZI LOMTHATHI NXAXHEBA NEFOMU YOKUNIKA IMVUME. 
Isihloko seNkqubo yoPhando: “Ulwazi nokuvumeleka kwamanyathelo olawulo 
lokosulela ngesifo sephepha kuluntu lwase-Breede Valley” 
Olu lwazi lulandelayo luya kukuxelela malunga nophando nenxaxheba oya kuyithatha 
kulo. Nceda ufunde ngononophelo yaye uzive ukhululekile ukuba ubuze nayiphi imibuzo. 
Olu luphando lwezemfuna-lwazi olwenziwa yi-South African TB Vaccine Initiative (SATVI), 
Institute of Infectious Disease and Molecular Medicine, University of Cape Town Medical 
School, Anzio Rd, Observatory, Cape. Amalungu eqela elongamele olu phando ngu Gqr. 
Mark Hatherill, Umphandi oyintloko no-Yulieth Gonzalez-Angulo, umfundi we-MPH kwi-
SATVI. 
Intsusa 
Isifo sephepha (iTB) sisifo esixhaphakileyo esosulelayo esibangelwa yintsholongwane eyi-
bacteria (i-Mycobacterium tuberculosis), edla ngokuchaphazela kakhulu imiphunga (i-Tb
yemiphunga) kodwa ingakwachaphazela naliphi na elinye ilungu lomzimba wethu. Isifo
sephepha ibe lugrogriso olukhulu kwezempilo kawonke-wonke iminyaka eliqela ngoku
yaye iinkqubo zokuthintela ukunwenwa komosuleleko w -TB zibekiwe. 
La manyathelo olawulo lomosuleleko anendawo ebalulekileyo kulawulo lwe-TB yaye
singathanda ukwazi ukuba kwaziwa ntoni malunga ne-TB namanyathelo olawulo 
lomosuleleko wayo luluntu lwase-Breede Valley. Singathanda nokwazi indlela abantu
abavavanyelwa nasele bevavanyelwe iTB abaziva ngayo malunga nala manyathelo 
olawulo lomosuleleko. Singathanda ukwazi ukuba angavunyelwa ngabantu kusini na
nokuba bangavuma kusini na abantu ukusebenzisana namanyathelo olawulo 
lomosuleleko.
Igalelo lomthathi nxaxheba
Ngabantu abalikhulu elineshumi (110) abaya kuthatha inxaxheba kolu phando, 
isiqingatha sabo (55) esiya kuba sele sichongwe ngokuba ne-TB nesinye isiqingatha esiya
kwenziwa uvavanyo lwe-TB okokuqala. Umenyiwe ukuba uthathe inxaxheba kolu phando 
kuba uvavanyelwa okanye ukhe wavavanyelwa iTB, njengenxalenye yolunye uphando
lwe-SATVI. Oku akuthethi ukuba unayo iTB, kodwa umele ukuba ukhe wenziwa uvavanyo 
luthile lwe-TB ekliniki, yaye ungaba usalinde iziphumo. Ungaba kanti sele wakhe
wathatha inxaxheba kumanyathelo olawulo lomosuleleko.
Ungakhetha ukungathathi nxaxheba kolu phando yaye kufanele wazi ukuba akusayi 
kwenza mahluko kukongiwa kwempilo yakho obuya kukufumana kakade, okanye 
ekuthatheni kwakho inxaxheba kolunye uphando lwezemfuna-lwazi. Ungalushiya 
uphando nanini na. Awusayi kuhlawula nasiphi na isohlwayo okanye ulahlekelwe nazo 
naziphi iinzuzo obungaba uzifumene kakade ukuba uthi hayi.  
Uxanduva lomthathi nxaxheba 
Kolu phando, akusayi kwenziwa luvavanyo lokuchonga isigulo, kodwa kufunwa ixesha 
lakho nokufuna kwakho ukuphendula imibuzo ethile ngexesha lodliwano-ndlebe. 
Ukubandakanyeka kwakho kolu phando luphelele kwiseshoni e-1 apho kuya kudliwana-
indlebe nawe ixesha elingangemizuzu engama-30 okanye ngaphantsi malunga 
namanyathelo olawulo lomosuleleko we-TB. Abathathi nxaxheba abavavanyelwa iTB 
okokuqala baya kuba nodliwano-ndlebe olunye. Abathathi nxaxheba abasele bechongiwe 
njengabanayo iTB ngexesha lodliwano-ndlebe lokuqala baya kuba nodliwano-ndlebe 
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lesibini olufutshane malunga namanyathelo olawulo lomosuleleko we-TB about xa 
unyango lwabo lugqityiwe.  
Iinzuzo zomthathi nxaxheba 
Ukuthatha kwakho inxaxheba kolu phando kukuzithandela ngokupheleleyo yaye awusayi 
kufumana zinzuzo ngqo ngokuthatha inxaxheba kolu phando. Kodwa ke, igalelo lakho 
ngokwabelana ngolu lwazi nathi lingasinceda ukuqonda kwethu malunga Nolwazi 
lwabantu ngamanyathelo olawulo lwe-TB.   
Imbuyekezo yabathathi nxaxheba 
Akusayi kuba khona mbuyekezo okanye nkuthazo ngezinto oya kuyifumana ngenxa 
yokuthatha inxaxheba kolu phando, yaye awusayi kuhlawu;e;a ukuthatha inxaxheba kulo 
msebenzi.  
Ubungozi kumthathi nxaxheba 
Nanjengoko olu phando luludliwano-ndlebe, akukho bungozi bonayngo okanye bempilo,
okanye iziphumo ezisecaleni ezingathi zibe khona. Naxa izihloko eziphakanyiswayo 
ngexesha loluhlu lwemibuzo iyimibuzo ngento zonke ejikelele, ukhululekile ukuba uhambe
ukuba nanini na uziva ungakhululekanga. 
Imfihlelo yomthathi nxaxheba 
Iimpendulo zakho ziya kugcinwa ziyimfihlelo kubasebenzi bophando. Ulwazi lwakho luya
kugcinwa kuvimba wolwazi ekhomputheni kusetyenziswa inombolo enekhodi engasayi 
kubuyela ikuchonge. Bonke abathathi nxaxheba baya kuhlala bengaziwa kwingxelo 
yokugqibela yokufunyanisiweyo. 
Ulwazi loqhagamshelwano lwemiBuzo okanye ezikuKhathazayo
Uya kufumana ikopi yale fomu yokunika imvume ukuba uyavuma ukuthatha inxaxheba.
Olu phando luvunyelwe yiKomiti yezeeNqobo kuPhando (iResearch Ethics Committee),
kwi-Faculty of Health Sciences, e-University of Cape Town. Ukuba ukhathazekile
ngamalungelo akho njengomthathi nxaxheba kuphanmdo, kufanele uqhagamshelane
nonobhala wekomiti yeenqobo kuphando kwi-Faculty of Health Sciences kwinombolo 
(021) 406-6492.
Ukuba nanini na, unemibuzo okanye kukho okukukhathazayo malunga nolu phando
okanye wonzakele ngenxa yokuthatha inxaxheba kolu phando, kufanele
uqhagamshelane:
Nabaphandi: 
Gqr. Mark Hatherill, Umphandi oyiNtloko no Ms. Yulieth González-Angulo, umfundi we-
MPH kwi-South African TB Vaccine Initiative (SATVI), Institute of Infectious Disease and 
Molecular Medicine, University of Cape Town School of Public Health and Family 
Medicine, Health Sciences Faculty Anzio Rd, Observatory, Cape Town, South Africa. 
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IMVUME YOKU THATA INXAXHEBA KOLU PHANDO 
Ndiyifundile ndaza ndayiqonda le fomu yokunika imvume, eziqulatho 
ndizicaciselweyo. Imibuzo yam iphenduliwe yaye ndiyavuma ngokuzithandela 








Igama lomsebenzi kuphando othatha imvume (nceda uprinte)
_______________________________________________________________________
Isandla somsebenzi kuphando othatha imvume
 Kusetye ziswe itoliki (korekisha kuphela ukuba kunjalo) 
 Kusetyenziswe ingqina (korekisha kuphela ukuba kunjalo; korekisha le 




Igama lengqina (nceda uprinte) 
_______________________________________________________________________ 
Isandla sengqina 
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Background: Sputum induction (SI) has been proposed as the optimal sample collection 
method for patients with paucibacillary tuberculosis (TB). 
 
Methods: Studies reporting culture of Mycobacterium tuberculosis from SI were 
reviewed. A random-effects meta-analysis of diagnostic yield (numerator M. tuberculosis 
SI culture-positive cases; denominator all culture-positive cases) was conducted.  
Diagnostic yields (95% confidence intervals, CI) were displayed as Forest plots. 
Heterogeneity was evaluated using Chi-squared and I-squared tests and meta-regression 
analysis. 
 
Results: Ninety publications were screened, 28 full-text papers reviewed, and 17 
analyzed.  Collectively, n = 627 SI culture-positive cases among n = 975 culture-
confirmed TB cases were reported.  Diagnostic yield of SI ranged from 35% to 95%. 
Pooled diagnostic yield was 74% (CI 65-81%), with significant heterogeneity (p<0.0001, 
I2=86%). There were no statistically significant differences in yield between sub-groups 
defined by HIV prevalence or age. Univariate analysis demonstrated that use of fiber-
optic bronchoscopy (FOB) as the comparator method was associated with 22% reduction 
(CI 2-42%) in diagnostic yield of SI. However, after adjustment for confounding, meta-
regression analysis showed that FOB usage (p=0.21) and saline concentration (p=0.31) 
were not independently associated with diagnostic yield. 
 
Conclusion: Sputum induction will detect approximately three-quarters of M. 
tuberculosis culture-positive cases under study conditions. Significant heterogeneity in 
diagnostic yield was not explained by HIV prevalence, age, or use of fiber-optic 
bronchoscopy as the comparator method. The use of a particular nebulized saline 





















Early diagnosis to reduce the period of infectivity is considered one of the most effective 
TB control strategies. However, isolation of M. tuberculosis is difficult in children, HIV 
co-infected people, and others with paucibacillary disease (1-3). Failure to confirm the 
presence of M. tuberculosis at first presentation may contribute to ongoing disease 
transmission. It follows that strategies to improve bacteriologic confirmation of 
pulmonary TB by optimization of sputum collection are of great importance for control of 
the epidemic.  
 
Gastric lavage and fiber-optic bronchoscopy (FOB) with lavage have been regarded as 
the optimal diagnostic procedures in persons with paucibacillary TB (4-7).  However, 
these methods are relatively invasive and not always accessible in TB-endemic settings 
(8). Sputum Induction (SI) is a non-invassive procedure that allows sputum to be obtained 
from patients who are unable to expectorate, or who produce insufficient sputum. SI has 
been reported to be as effective as, or superior to, gastric lavage or FOB for diagnosis of 
TB (9, 10).  Kawada et al found SI to be better than gastric aspiration in TB suspects (11).  
Anderson et al reported that the diagnostic yield of SI is as good as FOB for diagnosis of 
smear-negative pulmonary tuberculosis (PTB) (12).  Hatherill et al found the diagnostic 
yield of sputum induction in children to be equivalent to that of gastric lavage (13). 
Conde et al reported that SI was safe, with high diagnostic yield and substantial 
agreement with FOB, in both HIV seronegative and seropositive patients (14).  
 
Interpretation of the usefulness of SI in clinical and programmatic settings is difficult, due 
to the heterogeneous patient populations and wide variation in techniques that have been 
reported (15). Published SI guidelines have not tackled this methodological 


















in asthma, and recommendations vary widely - for example, the concentration of 
nebulized saline ranges from 0.9 to 7% (15-18). It follows that risk-benefit and cost-
benefit ratios for SI in a national TB control programme are difficult to estimate. We 
conducted a systematic review and meta-analysis of factors affecting the percentage 
diagnostic yield of SI (numerator M. tuberculosis SI culture-positive cases; denominator 




Search strategy  
We performed a systematic literature search to identify relevant studies in an electronic 
database; personal reference collections of experts; reference lists of papers of interest; 
working group reports; and published review articles.  Studies published in English or 
Spanish were searched for through PubMed. Search terms included “Sputum Induction”, 
“Induced Sputum”, “Inducción de Secresiones”, “Esputo Inducido” “Tuberculosis”, “TB” 
and “PTB”. All prospective diagnostic studies that compared SI using a saline (sodium 
chloride) solution, in addition to any of the following techniques were eligible for review: 
(1) routine expectorated sputum; (2) gastric lavage; (3) nasopharyngeal aspiration; or (4) 
FOB with bronchoalveolar lavage. Studies that used nebulized solutions other than saline; 
specialized induction devices (eg. Lung flute®) (19); studies that did not use SI or a 
comparative diagnostic technique in all patients; and studies that reported pulmonary 
infections other than tuberculosis, were excluded. 
 
Study selection and quality assessment 
Two authors (YG and MH) developed the search strategy and one author (YG) conducted 
the primary systematic search for all studies meeting the pre-determined inclusion 


















screened. Study quality assessment and data extraction were conducted if a study met all 
inclusion criteria and no exclusion criteria. Data were extracted using a standardized data 
collection tool and entered into a Microsoft® Access database. A second reviewer (MH) 
cross-checked study eligibility, quality assessment, and data extraction, for validity and 
consistency. Full-text papers of the identified citations were reviewed by both the primary 
and secondary reviewers to select the final study set. Disagreement between the two 
reviewers at each stage was resolved by discussion until consensus was reached.  
 
Data extraction  
The following data were extracted from each study: 1) first author, year of publication, 
and journal; 2) country where the study was conducted; 3) study design; 4) study 
population; 5) methodological details of the SI procedure (if available), including saline 
volume and concentration, and nebulizer output and duration; 6) complications of the SI 
procedure; 7) number of cases diagnosed by culture of M. tuberculosis using SI; and 8) 
total number of patients diagnosed by culture of M. tuberculosis using SI and/or any of 
the comparator techniques listed above. 
 
Data analysis 
Percentage diagnostic yield, defined as the number of tuberculosis cases diagnosed by SI 
(numerator), divided by the total number of culture-confirmed tuberculosis cases by any 
technique (denominator), with 95% confidence intervals, was calculated for each study. 
Cochran’s Q test was used to assess statistical heterogeneity in yield between studies, 
with p-value ≤ 0.1 indicating significant heterogeneity. Inconsistency across studies was 
quantified using the I-square statistic (20). Potential causes of heterogeneity were 
investigated by stratification into subgroups and by fitting a meta-regression model to 
explain heterogeneity in terms of study-level covariates. Sub-group stratification included 


















saline); HIV prevalence in the study population (high or low); and use of a bronchoscopic 
comparator technique (FOB with lavage). For the purposes of this analysis, study HIV 
prevalence ≥ 10% was defined as high (21). Diagnostic yields, statistical tests for 
heterogeneity, and Forest plots were analysed using StatsDirect Software, Version 2.7.8 
[StatsDirect Limited; http://www.statsdirect.com].  Considering the extent of variability 
between the studies, and based on the a priori assumption that each study estimated a 
different diagnostic yield  , a random effect (8)  meta-regression analysis was performed 
to assess independent associations with diagnostic yield of SI, after adjustment for 
potential confounding by saline concentration, HIV prevalence, age category, and FOB 




Literature search and study selection 
Figure 1 summarises the search strategy and selection of studies for inclusion in the 
meta-analysis.  A total of 78 citations were obtained from PubMed and 12 papers from 
other sources. Forty-eight papers which did not meet the inclusion criteria were excluded 
after screening of titles and abstracts and, of the remaining 42 publications, one published 
in Japanese was excluded. The full text of each of the 41 papers was reviewed, and 24 
were excluded on the basis of: (1) publication reporting extra-pulmonary TB; (2) use of 
nebulisation solutions other than saline; or (3) study design that did not incorporate a 
comparator technique.  The remaining 17 studies were included in the meta-analysis. 
 
All 17 studies were cross-sectional (Table 1) and recruited a total of 3,988 participants.  
Publication dates ranged from 1961 to 2009.  The studies differed in population (patient 
selection), sample size, and SI methodology.  Study sample sizes ranged from 28 to 1,869 














culture-positive TB ranged from 7 to 138 individuals (median n=20, IQR 15 – 48).
Twenty nine percent of studies were conducted in children and 47% were either
conducted in high HIV prevalence areas, or researchers reported a HIV sero-prevalence
greater than 10% among participants. The majority of studies (65%) were conducted in
low and middle income countries. SI was performed using saline concentrations ranging
from 3% to 20% (median 3%, IQR 3 - 10), using a variety of ultrasonic nebulizers or
conventional air compressors, and varying duration of saline nebulization (data
incomplete). Eight studies (47%) compared SI to gastric lavage(13, 22-26), six studies
(35%) to FOB(12, 14, 27-29), three studies (18%) to spontaneous expectorated
sputum(29-31), three studies (18%) compared SI to other invasive procedures, including
the string test, lymph node biopsy, and nasopharyngeal aspiration(32-34), and two studies
(12%) compared three diagnostic procedures (SI, spontaneous sputum, and FOB in one
publication (31); and SI, gastric lavage, and FOB in the other (9)). 
Diagnostic yield 
M. tuberculosis was isolated in 975 (24%) of the 3,988 participants. Microbiological
diagnosis of TB was established through SI in 627 cases (i.e. 64% of all culture-
confirmed TB diagnoses). Figure 2 shows the Forest plot of diagnostic yield with 95%
CI for each study, as well as the pooled diagnostic yield and 95% CI. Diagnostic yields
for SI ranged from 35% to 95% (median 79%), with pooled diagnostic yield of 74% (95%
CI 65 to 81%). However, there was substantial heterogeneity in study results: X2 (df=16)
= 115, P < 0.0001, I² 86% (95% CI 79% to 90%). Sub-group analyses of diagnostic yield
by age category, concentration of nebulized saline, HIV prevalence, and use of FOB as
the comparator method, are displayed in separate Forest plots in Figures 3-6, and


















Meta-Regression: Exploring sources of Heterogeneity 
Univariate regression analysis demonstrated no significant associations between 
diagnostic yield and HIV prevalence (p=0.37), or age category (p=0.35). Use of FOB as 
the comparator method was associated on average with 22% reduction in the diagnostic 
yield of SI (95% CI 2 – 42%), p=0.036, compared to studies that did not use FOB, in the 
univariate analysis. However, interpretation of this association was confounded by use of 
3% saline in the studies also using FOB as the comparator method (Figure 7). A meta-
regression analysis was conducted to adjust for potential confounding effects of FOB 
usage, saline concentration, HIV prevalence, and age category on diagnostic yield as the 
outcome variable. HIV prevalence and age category had no effect on the model and were 
excluded. The meta-regression model demonstrated that FOB usage (p=0.21) and saline 
concentration (p=0.31) were not independently associated with changes in diagnostic 




This meta-analysis of SI for diagnosis of pulmonary TB has shown that, although 
diagnostic yield in individual studies may range from 35% to 95%, SI is likely to detect 
between 65 – 81% of culture-confirmed TB cases under study conditions, regardless of 
age group or HIV prevalence in the study population. We might have expected the 
comparative diagnostic yield of SI to be greater among studies reporting paucibacillary 
disease, such as pediatric studies and those with high HIV prevalence in the study 
population, but no such effect was observed. We found that use of bronchoscopic lavage 
as a comparison method was associated with, on average, 22% lower diagnostic yield 
from SI, compared to studies that did not employ FOB; second, we observed that use of 


















However, we have demonstrated by meta-regression analysis that neither saline 
concentration nor FOB usage were independently associated with diagnostic yield from 
SI.   
 
This is the first reported meta-analysis of the diagnostic yield of SI and the strengths of 
the study include the comprehensive search strategy; duplicate and independent study 
selection; quality assessment and data extraction; and the use of meta-regression analysis. 
It is particularly important that potential sources of heterogeneity are examined in a meta-
analysis showing high levels of inconsistency in yield.  Sources of variability that could 
be attributed to within-study factors (eg. participant selection) and between-study factors 
(study design and conduct) are explored by meta-regression.  
 
The optimal saline concentration for SI is not known. It has been suggested that higher 
nebulized saline concentrations might have a greater osmotic effect on airway secretions 
(35), increasing the volume of the induced sputum sample, and thereby increasing the 
diagnostic yield. Our group has shown that nebulized 5% saline is both safe and tolerable, 
with minimal physiologic changes, when used for SI among adults investigated for PTB 
in an ambulatory setting (36).  However, others have suggested that higher nebulized 
saline concentrations might be associated with greater risk of airway reactivity and higher 
rates of adverse events during the procedure (37). The findings of this meta-analysis 
suggest that higher saline concentrations are not associated with better diagnostic yield in 
SI after adjusting for confounders. We suggest that the safety and diagnostic yield of low 
nebulized saline concentrations, perhaps even 0.9% saline, should be studied 
prospectively in an effort to minimize adverse events. 
 
Observed variability might also be explained by unreported differences in SI technique 


















particle size, such as nebulization devices (jet or ultrasonic nebulizer), might also, affect 
deposition of the saline solution in the tracheobronchial tree, and the diagnostic yield of 
the procedure. The selected studies used a broad range of nebulization devices and 
oxygen cylinders with different flow outputs, which would have directly affected 
nebulized particle size and airway deposition. Other potential sources of heterogeneity 
include severity of pre-existing lung disease, inclusion bias towards paucibacillary TB 
disease, and other patient-specific characteristics that might explain the presence of 
outliers in this analysis.  However, reporting of these important data was inconsistent, 
incomplete, and did not allow a more in-depth analysis. 
 
We have shown that the observed reduction in SI diagnostic yield in those studies using 
FOB as the comparator method is confounded by use of lower saline concentration (3%) 
in this group. Studies using invasive diagnostic techniques might be more likely to 
include smear-negative or sputum-unproductive individuals, leading to selection bias 
towards lower yield. It is also possible that, if FOB were better at detecting paucibacillary 
culture-positive TB cases than SI, the observed yield of SI relative to the total number of 
culture-confirmed cases would be lower in studies reporting FOB data. However, some 
studies have shown that the yield of sputum induction is equal to, or even better than that 
of FOB, which is consistent with our finding that FOB usage was not independently 
associated with lower diagnostic yield (9, 12, 14). 
 
Several limitations of this meta-analysis must be considered.  The search was restricted to 
three sources, including one electronic database, additional references recommended by 
experts in the field, and the published reference lists and reviews. One reviewer 
conducted the primary search to screen for citations, which might have introduced study 
selection bias, although two reviewers conducted the secondary search and quality 














this meta-analysis is the lack of a gold standard diagnostic comparator group in the
reported studies. Although some diagnostic methods, such as FOB, are believed to
provide better diagnostic accuracy than others, it is clear that none of the reported
comparator methods are sufficiently sensitive to define the population with true TB
disease with 100% accuracy. It follows that surrogate measures must be used to infer
sensitivity, as others have done using percentage diagnostic yield, which utilizes all
culture-confirmed TB cases as the denominator (13, 25). As noted above, few studies
documented key technical aspects of the SI procedure and reporting of this important
information was often inconsistent. Prospective, comparative studies of the diagnostic
yield of SI are needed, with rigorous definition of the study populations and
standardization of technique.
Conclusion: Sputum induction will detect approximately three-quarters of M.
tuberculosis culture-positive cases under study conditions, among children and adults,
regardless of HIV prevalence. However, the significant heterogeneity demonstrated in
this meta-analysis indicates that diagnostic yield in certain study populations may differ
significantly from this estimate. The observed variability in diagnostic yield cannot be
attributed to differences in HIV prevalence, or age category of the study population. Use
of FOB as the comparator method was associated with lower diagnostic yield in the
univariate analysis, but interpretation of this effect was confounded by use of lower
nebulized saline concentration in the same studies. FOB use and saline concentration
were not independently associated with diagnostic yield and therefore, the use of a
particular nebulized saline concentration cannot be recommended on the basis of
diagnostic yield. We suggest that additional technical, clinical, and epidemiologic factors
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Table 1: Detailed description of studies included in the meta-analysis.  



















Hensler , 1961 (22) US Adults SNEG/SUNPROD 28 0 10 GL 3 3 19 14 20 
Beck, 1962 (30) US Adults SNEG/SUNPROD 62 0 10 SS NS† NS† 8 3 10 
Yue , 1967 (23) US Adults SNEG/SUNPROD 189 0 10 GL NS† NS† 138 84 153 
Anderson , 1995 (12) Canada Adults SNEG/SUNPROD 92 0 3 FOB 1 1 20 19 26 
Zar, 2000 (24) SA Children All 142 70 5 GL 1 2 15 9 16 
Conde , 2000 (14) Brazil Adults All 251 17 3 FOB 1 1 94 103 143 
McWilliams, 2002 (27) NZ Adults All 129 0 3 FOB 3 1 26 1 27 
Zar , 2005 (25) SA Children All 250 38 5 GL 3 3 51 38 62 
Vargaz, 2005 (32) Peru Adults SNEG/SUNPROD 212 100 20 ST 1 1 9 15 15 
Iriso, 2005 (33) Uganda Children All 126 49 3 PLNB 1 1 30 6 36 
Brown, 2007  (9) UK Adults SNEG/SUNPROD 140 4 3 GL / FOB 3 3 / 1 42 37 54 
Schoch, 2007 (31) Switzerland Adults All 101 0 3 FOB / SS 2 1 / 2 27 28 33 
Owens, 2007  (34) UK Children SNEG/SUNPROD 94 47 3 NPA NS† NS† 19 21 24 
Ganguly, 2008 (28) India Adults SNEG/SUNPROD 52 0 3 FOB NS† NS† 7 5 20 
Morse, 2008 (26) Botswana Adults All 140 81 20 GL NS† NS† 48 13 57 
Hatherill, 2009 (13) SA Children All 1654 2 5 GL 2 2 108 127 194 
Bell, 2009 (29) Malawi Adults SNEG/SPRODUCT 111 68 3 FOB /GL/ SS NS† NS† 13 26 18 
 
Note: ‘Category of TB Suspect’ differentiates studies that only included TB suspects that were smear negative and sputum productive (SNEG/ SPRODUCT) or smear negative  and sputum unproductive (SNEG/SUNPROD) at 
pre-screening from studies that included all smear negative TB suspects.  ‘NS†’ Refers to included studies in which the total of samples per procedure was not clearly specified. 
Country Abbreviations:   SA South Africa; NZ New Zealand; UK United Kingdom; US United States. 














                  
 
 
Table 2:  Diagnostic yield of sputum induction by sub-group. 
 
Category  Pooled Estimate (%) 95% CI 
 
Adults vs. Children 
Adults 71 (60 -81) 
Children 79 (62-92) 
 
Saline Concentration 
Saline Concentration <5 73 (63-82) 
Saline Concentration ≥5 75 (59-89) 
 
HIV Prevalence 
High HIV Prevalence 78 (69-86) 
Low HIV Prevalence 69 (54-83) 
 
Use of Fiber-Optic Bronchoscopy (FOB) 
No use of FOB 81 (70-90) 
Use of FOB 58 (38-77) 
 
























Figure 1:  Flow chart of the study selection process.  
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Figure 2: Sputum Induction Diagnostic Yield – All Studies. 
 
Diagnostic Yield of SI among all the studies: Heterogeneity tests: Cochran Q = 115.29 (df = 16) P < 
0.0001 Moment-based estimate of between studies variance = 0.12 I² (inconsistency) = 86% (95% CI = 
79% to 90%).  Pooled proportion = 74 (95% CI = 65 - 81). 
 
0.0 0.2 0.4 0.6 0.8 1.0 
Combined 0.74 (0.65, 0.81) 
Bell (1) 0.72 (0.47, 0.90) 
Hatherill (1) 0.56 (0.48, 0.63) 
Morse [2008] 0.84 (0.72, 0.93) 
Ganguly [2008] 0.35 (0.15, 0.59) 
Owens [2007] 0.79 (0.58, 0.93) 
Schoch [2007] 0.52 (0.34, 0.69) 
Brown [2007] 0.78 (0.64, 0.88) 
Iriso [2005] 0.83 (0.67, 0.94) 
Vargaz [2005] 0.53 (0.27, 0.79) 
Zar [2005] 0.88 (0.77, 0.95) 
McWilliams [2002] 0.48 (0.29, 0.68) 
Conde [2000] 0.66 (0.58, 0.74) 
Anderson [1995] 0.77 (0.56, 0.91) 
Zar [2000] 0.94 (0.70, 1.00) 
Yue [1967] 0.90 (0.84, 0.94) 
Beck [1962] 0.88 (0.47, 1.00) 
Hensler [1961] 0.95 (0.75, 1.00) 














                  
 
 
Figure 3: Sputum Induction Diagnostic Yield: Adults vs. Children. 
 
 
Diagnostic Yield of SI by Subgroup Analysis according Age Groups:   Adults (a): Heterogeneity tests: 
Cochran Q = 73.36 (df = 11) P < 0.0001 Moment-based estimate of between studies variance = 0.13 I² 
(inconsistency) = 85% (95% CI = 75% to 90%) Pooled proportion = 71 (95% CI = 60 - 80).  Children 
(b): Heterogeneity tests: Cochran Q = 37.6 (df = 4) P < 0.0001 Moment-based estimate of between 
studies variance = 0.17 I² (inconsistency) = 89% (95% CI = 77% to 94%) Pooled proportion = 79 (95% 
CI = 61 - 92). 
Figure 3b. Sputum Induction in Children 
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Figure 3a. Sputum Induction in Adults 
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Figure 4: Sputum Induction Diagnostic Yield: Nebulized Saline Concentration. 
 
 
Diagnostic Yield of SI by Subgroup Analysis according to Salinity:  Saline Concentration <5% (a): 
Heterogeneity tests: Cochran Q = 56.55 (df = 9)  P < 0.0001 Moment-based estimate of between studies 
variance = 0.09 I² (inconsistency) = 84% (95% CI = 71% to 90%) Pooled proportion = 73 (95% CI = 63 
- 82). Saline Concentration ≥ 5%  (b): Cochran Q = 47.94  (df = 6)  P < 0.0001 Moment-based estimate of 
between studies variance = 0.19 I² (inconsistency) = 88% (95% CI = 76% to 92%)  Pooled proportion = 
75 (95% CI = 59 - 89). 
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Figure 4a. Sputum Induction with Saline Concentrations < 5% 
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Diagnostic Yield of SI by Subgroup Analysis according to HIV Prevalence:  High HIV prevalence (a): 
Heterogeneity Tests: Cochran Q = 21.97 (df = 7) P < 0.0026 Moment-based estimate of between studies 
variance = 0.05 I² (inconsistency) = 68% (95% CI = 12% to 83%).  Pooled proportion = 78 (95% CI = 
69 - 86). Low HIV prevalence (b): Heterogeneity Tests: Cochran Q = 89.93 (df = 8) P < 0.0001 
Moment-based estimate of between studies variance = 0.20 I² (inconsistency) = 91% (95% CI = 86% to 
94%)  Pooled proportion = 69 (95% CI = 54 - 82). 
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Figure 5b. Sputum Induction in Low HIV Prevalence Studies  
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Figure 6: Sputum Induction Diagnostic Yield: Use of Fiber-optic Bronchoscopy (FOB) as the  





Diagnostic Yield of SI by Subgroup Analysis according to the use of Fiberoptic Bronchoscopy.  Studies 
reporting no use of FOB (a): Heterogeneity Tests: 78.03 (df = 9) P < 0.0001; Moment-based estimate of 
between studies variance = 0.15; I² (inconsistency) = 89% (95% CI = 81% to 92.1%).   Pooled 
proportion = 81 (95% CI = 69 - 90). Studies reporting the use of FOB (b): Heterogeneity Tests: 
Cochran Q = 93.51 (df = 6) P < 0.0001; Moment-based estimate of between studies variance = 0.28; I² 
(inconsistency) = 93.6% (95% CI = 90% to 96%)   Pooled proportion = 58% (95% CI = 37 - 77). 
 
Figure 6b. Sputum Induction Studies in comparison to FOB 
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Figure 6a. Sputum Induction Studies without FOB 
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Figure 7: The Effects of Saline Concentration and FOB Use on Diagnostic Yield.   
 
 
All FOB studies reported using a 3% saline concentration. After the model is adjusted for FOB use, the 
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Running Head: Patient-specific infection control measures. 
ABSTRACT  
Context/Introduction:  Knowledge and acceptability of patient-specific infection 
control measures to reduce transmission of Mycobacterium tuberculosis has not been 
adequately studied in developing countries. 
















Design: Prospective questionnaire-based study to determine the knowledge and 
acceptability of patient-specific infection control measures after frequent contact 
with health care workers. 100 participants were consecutively interviewed (50 TB 
suspects; 50 newly diagnosed TB patients).  TB patients underwent a second 
interview at the end of treatment. 
Results: At baseline, patients on TB treatment, who had received TB education at 
diagnosis, did not show higher levels of TB knowledge and preventive measures, 
compared to TB suspects, who had not received any TB education at screening. 
Acceptability of patient-specific infection control measures to be conducted at health 
care facilities was higher compared to acceptability for measures to be conducted at 
home and at work, except for cohorting and/or isolation. At the end of TB treatment, 
TB patients increased their knowledge of TB and showed higher acceptability levels 
towards patient-specific infection control measures over time.  
Conclusion: Knowledge and acceptability of patient-specific infection control 
measures for TB increases over time with frequent contact with health care workers. 
In order to increase acceptability and adherence to patient-specific measures to 
reduce TB transmission, public health authorities must design and implement 
effective health education programmes for newly diagnosed TB patients. These 
programmes should focus on knowledge and empowerment of TB at diagnosis, the 


















Early diagnosis and treatment of tuberculosis (TB) infectious cases have been 
considered the most effective control strategies to reduce TB transmission [1-3]. 
However, efforts to improve TB case identification and treatment compliance, have 
only partially improved this major public-health problem [4, 5].  The burden of TB 
dramatically declined in industrialized countries during the past century, even prior 
to the introduction of TB chemotherapy [6]. This decline in TB rates was attributed 
to reduction in the degree of effective contact between individuals [7], in other 
words,  a decrease in the number of individuals in contact with each infectious case 
[7]. This reduction in effective contact was attributed to improvements in social 
conditions, nutrition, and isolation of infectious cases [7, 8]. 
Strategies to reduce TB transmission were further outlined in 1994 by the Centres for 
Disease Control and Prevention (CDC) [9]. Strategies such as patient isolation and 
cohorting, artificial ventilation, ultra-violet lighting, cough protocols, and respiratory 
protection for health care workers were implemented in industrialized countries to 
minimize air-bone TB contact bacilli, mainly in health care facilities [10, 11]. TB 
control efforts made considerable progress in countries in which rigorous 
implementation of measures to control infection, lowered the risk of tuberculosis 
among health care workers [12-14]. However, implementation of these same 
practices have not been feasible in developing countries due to financial constraints, 
and limited structural and human resource capacity [15]. 
 
South Africa has one of the highest TB notification rates in the world, with almost 
















formulated National Strategic Plan for TB control [17],  delay in starting TB 
treatment and low case-finding rates may contribute to on-going transmission in 
South Africa. Therefore, it is important to apply field-adapted infection control 
measures concurrently with chemotherapy. 
  
Patient-specific infection control measures have been suggested for resource-limited 
areas, including cough protocols; cohorting and/or isolation; improvement of 
ventilation at home; and, staying away from work until at least two weeks of 
treatment has been completed [2, 18]. However, the success of any infection control 
measures that rely on patient adherence hinges on the degree to which these 
measures are accepted by patients in the community.  Knowledge and acceptability 
of patient-specific measures to control TB transmission have not been studied in 
developing countries with high TB burden. 
 
The aim of this study was to determine baseline TB knowledge levels among TB 
suspects and newly diagnosed TB patients and establish which patient-specific 
measures for control of TB transmission were acceptable, in a South African 
community with high TB incidence rates; second, we aimed to determine if 
knowledge and acceptability of patient-specific infection control measures improved 
with on-going TB education over time.  
 
PATIENTS AND METHODS  
We conducted a prospective questionnaire-based study to determine knowledge and 
acceptability of patient-specific TB infection control measures, (October 2009 - May 
















Doorns, and Rawsonville TB clinics in the Breede River Valley. This region is 
located in the Western Cape province of South Africa and has a population of about 
134,271 people and an estimated TB prevalence of 1188 / 100 000 population [19].  
Participants were classified based on their status, as (i) TB suspects or (ii) TB 
patients. TB patients were defined as individuals who were newly diagnosed and 
starting treatment for pulmonary TB for the first time; moreover, TB patients had 
already received TB education from health care workers (at diagnosis). TB suspects 
were defined as individuals undergoing TB investigation and who had not received 
TB. Participants were eligible for inclusion if they were a TB suspect or a TB 
patient, status, aged ≥18 years old, and with the ability to give informed consent and 
to understand and complete the survey questionnaire. 
Data Collection 
A questionnaire was designed based on recommendations of local infection control 
specialists, and modified after the pilot study with TB suspects and TB. The 
questionnaire was based upon WHO recommendations for TB infection control in 
health-care facilities, congregate settings and households [2]. The questionnaire 
comprised questions about (1) core TB knowledge; and patient-specific  infection 
control measures at (2) health care facilities; (3) at home, and finally at (4) work 
settings. Participants’ TB knowledge was determined through six basic questions 
about the disease (TB cause; TB transmission; transmission mode[s]; 
chemoprophylaxis for children; TB treatment; and, TB infection control measures). 
The remaining sections of the questionnaire aimed to determine acceptability of 
patient-specific measures to help reduce TB transmission among TB patients and 
















patients and TB suspects were both interviewed at baseline. Subsequently, once TB 
patients had ended their treatment, a second interview was conducted.  
Data analysis 
The Chi-square test—or the Fisher’s exact when applicable—was used to compare 
proportions (TB suspects versus TB patients; TB patients at baseline versus TB 
patients at the end of treatment). A scoring system was used to assess levels of TB 
knowledge and acceptability. One point was accrued for every correct answer and 
none for an incorrect one. Spearman’s correlation analysis was applied to determine 
bivariate relationships between knowledge and acceptability scores. The level of 
statistical significance was set at 5%. Stata® 11 was used for data analysis. 
 
RESULTS 
Twenty-two percent of participants were IsiXhosa speakers (n = 22); 78% were 
Afrikaans speakers (n = 78). 47% of participants were women (n = 47), and 53% 
men (n = 53); 44% of participants, at the time that the first interview was conducted, 
were living with 5 or more people in their houses (n = 44); 74% of participants 
confirmed that there were more than two individuals per room (n = 74). 9% of 
confirmed TB patients were sharing a room with children under the age of 5 (n = 5); 
6% of them were sharing a room with children older than 5 years (n = 6), and 10% of 
TB patients were sharing a room with other adults and children altogether (n = 10). 
Only 18% of the participants slept alone (n = 18); 56% of our participants were 
working when the first interview was conducted (n = 56). At baseline, there were no 
important differences in terms of demographic characteristics between TB suspects 
and TB patients (See Table 1).  
 
















TB cause and transmission 
No major differences were found between TB suspects and patients in terms of core 
TB knowledge. However, in both groups, participants had poor to moderate levels of 
knowledge about TB. Only 57% of all respondents reported that they knew the cause 
of TB (n = 57), although only 25% of these respondents (n = 25) confirmed that TB 
was caused by a micro-organism. The remaining participants (n = 75) had 
misconceptions regarding the cause of TB. 5% of participants reported that TB was 
caused by drinking alcohol (n = 5); 5% attributed TB to uncleanliness (n = 5); 12% 
to smoking (n = 12); 4% to the use of drugs (n =  4); and, 6% believed that TB was a 
hereditary disease (n = 6). Surprisingly, more TB suspects (n = 19) knew that TB 
was a microbial disease as compared to TB patients (n = 6) (p –value 0.003). 95% of 
the participants reported that TB could be transmitted to other people (n =). TB 
patients (n = 50) as compare to TB suspects (n = 45) were more aware that TB 
follows a human-to-human transmission pattern (p-value 0.022). However, only 54% 
of all participants reported that they knew how TB was transmitted (n = 54). 
Participants confirmed that TB could be transmitted through sharing food utensils (n 
=9 ); by kissing (n = 10); and even by living in low-temperature areas (n =15 ). 
Only 20% and 26% of TB patients (n = 20) and TB suspects (n = 26), respectively, 
reported that TB was transmitted by being in close contact with a TB patient (See 
Table 2).  
 
TB treatment and TB transmission 
Less than half of the participants (n = 41) reported that TB transmission could be 
















patients nor TB suspects had a clear understanding of when TB chemotherapy starts 
to lower the bacillary load. 4% of participants (n = 4) responded that, a TB patient 
usually stops transmitting TB on the first day of treatment; 4% reported that TB 
treatment was effective in reducing M. tuberculosis transmission after 2 months on 
TB chemotherapy (n = 4), and 24% of participants (n = 24) said that TB transmission 
stops after treatment has been completed.  
 
Knowledge about infection control measures 
When participants were asked if they knew of any methods to reduce the 
transmission of M. tuberculosis, only 49% of the participants (n = 49) reported that 
they knew of measures to control TB. A higher proportion of TB suspects (30%; n = 
30) claimed to know of patient-specific measures to help reduce TB transmission (p-
value 0.028) compared to TB patients (19%; n = 19). However, answers regarding 
implementation of patient-specific measures such as: (1) use of facemasks during 
transportation to a hospital or clinic; (2) use of facemasks in a hospital or clinic; (3) 
covering the mouth at a health care facility; (4) covering the mouth at home or at 
work; (5) separation from other patients, (6) sleeping alone, or avoiding sleeping in a 
room with small children; (7) opening house windows to the outside air; and (8) the 
use of fans for moving air to the outside, showed no significant difference between 
TB suspects and TB patients. On the other hand, a greater proportion of TB suspects 
(n = 27) believed that by completing a course of anti-TB treatment, TB transmission 



















Acceptability of infection control measures  
 
Acceptability of infection control measures at health care facilities  
There was a high level of acceptability of patient-specific infection control measures 
among TB suspects and TB patients. For instance, all participants were willing to 
complete anti-TB treatment as a means to prevent TB transmission, and 89% of the 
participants (n = 89) were willing to use facemasks in health care facilities—more 
TB patients (n = 48) than TB suspects (n = 41) were willing to implement such 
measure (p-value 0.025). TB patients and TB suspects showed similar levels of 
acceptability for cough protocols while at a health care facility. The measure that 
many participants were reluctant to implement at health care facilities was isolation 
and/or separation from other patients.  TB suspects and TB patients who did not 
agree with the implementation of this measure reported that they would not like to be 
separated from other patients, and the fear of rejection or TB stigma influenced their 
decision (See table 3).  
 
Acceptability of infection control measures at home  
Measures to control TB transmission at home were in general, acceptable to most 
participants. Cough protocols, opening of house windows to improve ventilation, and 
isolation at home, were accepted by most participants. No significant differences 
were found between TB suspects and TB patients (See table 3). The use of 
facemasks at home (n = 54), the use of fans to increase ventilation (n = 59), as well 
as sleeping in a room by themselves or avoiding sleeping in a room with small 
children (n = 68) were less acceptable. TB patients (n = 33) were more accepting of 
















participants who were willing to use isolation at home as a method to reduce the 
transmission of M. tuberculosis to their families, reported that this was feasible in 
their homes, whereas 20% reported that even though they were willing to be isolated, 
isolation was not feasible at their homes. Only 15% of all participants reported that 
they were not willing to be isolated at home. 
 
Acceptability of infection control measures at work  
Infection control measures at work had a relatively high level of acceptability among 
participants at baseline. 65% of all participants would be willing to stop working 
until they have completed 2 weeks of treatment, or until smear microscopy was 
negative (n = 65). The majority of patients who did not agree with this measure 
stated that they would not receive any income (n = 18). TB and HIV stigma were not 
contributing factors to participants’ decision. 98% of participants stated that they 
would be more willing to cover their mouth with a handkerchief or tissue at work (n 
= 98), compared to 58% who would prefer to use a facemask at their workplace (n = 
58) (See table 3).  
 
TB Knowledge and acceptability of infection control measures at the end of 
treatment 
Among the initial group of TB patients who were interviewed at baseline, only 82% 
(n = 41) TB patients completed a second interview. Knowledge about TB and TB 
infection control measures increased significantly over time, between start and end 
of treatment, under research conditions. There was an increase from 23 to 36 in the 
















response rate of 32%), and a 41% increase in the total of participants who agreed that 
TB was caused by a micro-organism (6 to 25). 44% of respondents, who, at baseline, 
stated that they did not know how TB is transmitted, reported that they knew how a 
person can get TB, at the second interview (increase in response rate from 19 to 37 
individuals). When participants were asked to specify how TB was transmitted, an 
increase of 54% of participants reported that only by being in close contact with an 
infectious source, other individuals could get TB (14 to 36). At baseline most 
participants (n = 93) believed that children require IPT once exposed to M. 
tuberculosis, but there was no change over time. At the end of treatment, most 
participants also reported that they knew when a TB patient usually stops 
transmitting the disease. Measures such as using facemasks, cough protocols in 
health care facilities, opening house windows to improve ventilation and completing 
anti—TB treatment, were more often recognized as measures to reduce the 
transmission of TB at the end of participant’s follow-up, compared to baseline. A 
higher proportion of participants responded that these preventive methods helped to 
reduce TB transmission for health care workers (56%), home contacts (66%) and co-





We report the first study of knowledge and attitudes to TB in relation to the 
acceptability and implementation of patient-specific infection control measures 
(environmental and respiratory protection measures). After interviewing TB suspects 
and newly diagnosed TB patients, our study revealed limited basic knowledge about 
















immediately after individuals have had initial contact with health care providers. In 
our study, patients on TB treatment, who had received some TB education at 
diagnosis, did not reflect higher levels of TB knowledge and preventive measures, 
compared to TB suspects, who had not received any information or education. 
However, we have shown that with on-going education and experience, TB patients 
had increased knowledge of TB and infection control measures. Furthermore, we 
could observe that TB knowledge and acceptability of patient-specific infection 
control measures for TB increased over time (See figures 1 & 2). Similar to the 
findings of other authors who investigated levels of knowledge and practices among 
newly diagnosed TB patients [20-23], our study initially showed fairly low levels of 
knowledge regarding the disease and measures to reduce its transmission, coupled 
with moderate levels of acceptability of certain patient-specific measures. However, 
after contact with clinical research workers and personal on-going education, we 
could demonstrate that, the acceptability of these patient-specific measures increased 
in parallel with improvements in knowledge about TB. 
Turning to the results for attitudes towards patient-specific infection control 
measures for TB, at baseline we found that patients were much more comfortable 
and more willing to implement such practices at health care facilities compared to 
households and work settings. And although participants seemed to know that TB 
chemotherapy was a way to stop transmission and were eager to complete anti-TB 
treatment, they ignored when the infectiousness of TB patients declines. In addition, 
it was clear that measures involving cohorting or isolation at health care facilities 
were not acceptable for a vast proportion of participants. We could speculate that 
















experiences of stigmatization and social rejection. However, participants’ acceptance 
or perceptions on self-isolation (at home) increased over time. We also found that 
acceptability of measures that could “reveal” the TB status of patients such as the use 
of facemasks at home, increased significantly over time.  
As revealed in our evaluation of knowledge and acceptability of infection control 
measures at baseline, both groups, TB suspects and TB patients had similar levels of 
knowledge, even though TB suspects had not received any type of information from 
health care facilities. Yet, we could not evaluate the quality of information that 
health care staff from public health facilities might be providing to patients. 
Therefore, our findings (increased acceptability of some patient-specific measures as 
knowledge increased) might not be replicable in resourced-challenged health care 
settings. A study reporting knowledge, attitudes and practices among health care 
workers in Iraq, established that although TB knowledge among health care workers 
might be high, by contrast, infection control practices were poor [24]. Hashim et al 
showed that only 38.2% of health care workers from primary care centres in Iraq 
handled suspected TB cases correctly [24]. In this study, participants had frequent 
contact with health care providers under strict research conditions; this situation may 
therefore represent an ideal condition. However, this may not be achievable under 
programmatic conditions in many low-resourced health care settings. 
We were aware that social desirability bias is an important limitation of 
questionnaire-based studies and that it might have affected the validity of our 
research findings. Although we demonstrated that acceptability of patient-specific 
infection control measures increases in relation to improvements in knowledge about 














workers, and even though we tried to mitigate the effects of SDB, we acknowledged 
that some of our participants could have overreported “good behaviour” or
underreported “bad behaviour” in relation to the acceptability of patient-specific
infection control measures. 
One of the challenges in health education is that, the quality and amount of
information provided to patients depends on the knowledge, perceptions and 
attitudes of providers. In this case, information was provided by health care staff
from public health facilities and by clinical research workers under strict research
conditions. In both cases, these providers have been trained to educate patients. 
However, public health institutions in developing countries face overcrowding
conditions and in many cases, the quality and duration of interaction between health 
care providers may be insufficient for a complete and satisfactory educational 
dialogue.
However, this research presents an opportunity for TB control programmes to 
strengthen measures to decrease TB transmission. New policies emphasize the use of
isolation or even short term incarceration, as well as other “environmental” practices
to reduce TB transmission [25-27]. However, in resource-constrained areas, public
health authorities face (a) a lack of accurate diagnostic tools, which delays 
confirmation of infectious TB cases; (b) overcrowded health care facilities in which 
TB patients mix with other patients, increasing the risk of nosocomial TB
transmission to other patients and health care staff; and (c) lack of personnel in 
health care facilities, hampers the quality of information and educational support to 
















increase the possibility of developing TB disease, particularly for close contacts of 
TB patients and health care workers. 
The “National Infection Prevention and Control Policy for TB, MDR-TB and XDR-
TB” published by the South African Department of Health states that patients who  
are  identified   as TB  suspects at screening  must  be   given   advice   on respiratory 
hygiene/cough etiquette,  provided  with a  facemask  or  tissues  to   cover  their  
mouths  and  noses,    and   then  be  cohorted separately from other patients. Our 
findings showed that patients are reluctant to be isolated in health care facilities 
although they are more willing to be isolated at home.  Increased emphasis on home-
based care could help reduce nosocomial transmission of TB.  Clearly, the 
implementation of effective isolation at home must be followed by the 
implementation of other measures: firstly, health care institutions must promote 
adherence to TB chemotherapy; secondly, education about infection control 
measures must also be provided to family members and other community members 
to create a strong support network for TB patients. The risk of transmitting the 
disease to close contacts might also be reduced if patients are equipped with high 
efficiency (N95) masks to use at home, especially during the first weeks after 
treatment has been initiated.  
Conclusion 
Baseline knowledge about TB and TB infection control measures was poor to 
moderate among both TB suspects and TB patients, although the latter had received 
TB education after their diagnosis was confirmed. However, acceptability of patient-
specific infection control measures increases in relation to improvements in TB 
















control measures, public health authorities must design and implement early 
intensive TB education programmes to increase knowledge of TB and TB infection 
control measures. These educational resources should be accessible not only for TB 
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Table 1. Demographic Data 
 
 
Variable & Attribute (s) TB Suspects (%) TB Patients (%) Total P-Value 
Language: IsiXhosa 10 (20) 12 (24) 22 
0.629 
  Afrikaans 40 (80) 38 (76) 78 
Gender: Females 28 (56) 19 (38) 47 
0.071 
  Males 22 (44) 31 (62) 53 
Age (median)   33 years (18-54) 33 years (19 - 54) ─ 0.526 
Housing Conditions        
Total people in home:   ≥ 5 people 20 (40) 24 (48) 44 
0.42 
  < 5 people 30 (60) 26 (52) 56 
Total people/room (median) 2 people (2-9) 2 people (2-7) ─ 1.000 
Sleep alone   11 (22) 7 (14) 18 0.298 
Working Status:  Currently working 29 (58) 27 (54) 56 0.687 
  Working indoors 14 (48) 7 (26) 21 
0.084 


















Table 2. Baseline TB knowledge among TB suspects and newly diagnosed TB patients 
 
General Information on Tuberculosis 
TB Suspects (%)      
n = 50 
TB Patients (%) 
n = 50 
Total  
n = 100 P-Value 
Do you know the cause of TB?  32(32) 25(25) 57 0.157 
Germs 19(19) 6(6) 25 0.003* 
Do you think TB can be passed on to other people?  45(45) 50(50) 95 0.022* 
How a person does get TB?  29(29) 25(25) 54 0.422 
Do young children need chemoprophylaxis therapy once exposed to MTB?  44(44) 49(49) 93 0.112 
Do you know when a TB patient usually stops transmitting the disease?  18(18) 23(23) 41 0.309 
Do you know some measures to control tuberculosis?  30(30) 19(19) 49 0.028* 
Complete their course of anti—TB treatment  27(27) 14(14) 41 0.008* 

































TB Suspects (%) 
n = 50 
TB Patients (%) 
 n = 50 
Total       
n = 100 P-Value 
Infection Control Measures at Health Care Facilities     
Use facemask in health care settings? Y/N 41 (41) 48 (48) 89 0.025* 
Cover mouth when coughing and/and sneezing in a health care setting?  Y/N 48 (48) 50 (50) 98 0.495 
Complete a course of anti—TB treatment?  Y/N 50 (50) 50 (50) 100 - 
Be separated from other patients? Y/N 32 (32) 36 (36) 68 0.391 
Infection Control Measures at Home     
Cover mouth with a handkerchief/tissue when coughing and/and sneezing? 50 (50) 49 (49) 99 1.000 
Cover mouth with facial mask when coughing and/and sneezing? 21 (21) 33 (33) 54 0.016* 
Sleep in a room by oneself or avoid sleeping in a room with small children? 33 (33) 35 (35) 68 0.668 
Open house windows to the outside? 43 (43) 46 (46) 89 0.338 
Use fans if possible for moving air to the outside?  30 (30) 29 (29) 59 0.839 
Infection Control Measures at Work     
Stop working until you have completed 2 weeks of treatment, or longer?  32 (64) 33 (66) 65 0.834 
Cover mouth with a handkerchief/tissue when coughing and/and sneezing?  48 (96) 50 (100) 98 0.495 






















Table  4. Baseline TB knowledge among at the end of treatment 
 
 
Knowledge & Perceptions about Tuberculosis 
Baseline (%) 
n = 41 
End Treatment (%) 






Do you know the cause of Tuberculosis (TB)?  23 (56) 36 (88) 32 13.21 - 36.46 0.001* 
Do you think tuberculosis can be passed on to other people?  41 (100) 41 (100) ─ ─ N/A 
How a person gets TB? Y/N 19 (46) 37 (90) 44 24.51 - 48.66 <0.001* 
Do young children need treatment?   40 (98) 41 (100) 2 ─2.32 - 2.44 1.000 
Do you know when a TB patient usually stops transmitting the disease?  21 (51) 34 (83) 32 11.24 - 40.25 0.002* 
Do you know some measures to control tuberculosis? Y/N 16 (39) 33 (80) 41 18.41 - 52.98 <0.001* 
































n = 41 
End Treatment 






Infection Control Measures at Health Care Facilities      
Use facemask HC settings?   39 (95) 41 (100) 5 ─3.34 - 4.88 0.5 
Cover mouth when coughing and/and sneezing in a health care setting?   41 (100) 41 (100) - - N/A 
Complete a course of anti—TB treatment?  41 (100) 41 (100) - - N/A 
Be separated from other patients?  28 (68) 26 (63) 5 ─15.71 - 23.61 0.804 
Infection Control Measures at Home      
Cover mouth with a handkerchief/tissue when coughing and/and sneezing?  41 (100) 40 (98) 2 ─2.32 - 2.44 1.000 
Cover mouth with facial mask when coughing and/and sneezing?  26 (63) 35 (85) 22 2.89 - 30.49 0.023* 
Sleep in a room by oneself or avoid sleeping in a room with small children? 28 (68) 33 (80) 12 ─4.39 - 20.72 0.18 
Open house windows to the outside?  37 (90) 40 (98) 24 2.07 - 38.27 0.031* 
Use fans if possible for moving air to the outside?  23 (56) 32 (78) 22 4.68 - 26.71 0.012* 
Isolation at home?   37 (90) 39 (95) 5 ─5.97 - 9.63 0.625 
Infection Control Measures at Work      
Stop working until you have completed 2 weeks of treatment, or longer?  26 (63) 31 (76) 12 ─4.39 - 20.72 0.18 
Cover mouth with a handkerchief/tissue when coughing and/and sneezing?  41 (100) 41 (100) - - N/A 

























Figure 1. Relationship between baseline TB knowledge and acceptability of infection control measures among TB 
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Appendix 4: Submission of questionnaire and consent Form to the UCT Research Ethics
Committee
